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Intestinal iron absorption increases during pregnancy to support maternal and fetal 
iron demands. Although knowledge on non-heme iron absorption has advanced substantially 
since identification of the hormone hepcidin in 2000, the mechanisms of heme iron absorption 
remain elusive. Catabolism of senescent red blood cells releases 10-times more iron into the 
circulation daily than does iron absorption from the diet, yet the contribution of this 
endogenous maternal heme iron source to fetal iron transfer is unknown. The human placenta 
abundantly expresses an array of heme transporters but it is unclear whether these proteins 
play a role in placental heme utilization. The objective of this research was to explore the 
mechanism and regulation of heme and non-heme iron utilization in the duodenum and the 
placenta, the two major sites of iron flux during pregnancy. 
To address these questions, stable iron isotopes (57Fe and 58Fe) were used to measure 
duodenal heme and non-heme iron absorption in rats and placental transfer of iron derived 
from maternal red blood cell catabolism and from maternal diet in pregnant women. In 
Sprague Dawley rats, hepcidin up-regulation suppressed the absorption of both heme and non-
heme iron but the effect was more pronounced for non-heme. Hepcidin was inversely 
associated with iron transporters on the apical but not basolateral side of the duodenum, 
suggesting apical iron transport is the primary target of hepcidin action. The stable iron 
 isotope study in pregnant women (n=16, ages 17-35 years) indicated that iron derived from 
maternal red blood cells was transferred to the fetus, revealing the importance of maternal red 
cell iron stores in supporting fetal iron demands. In a cohort of pregnant adolescents (13-18 
years), placental protein expression of two putative heme transporters were associated with 
neonatal iron status, consistent with a role of these proteins in placental iron transport. Future 
research is needed to elucidate the roles of these transporters in the uptake and intracellular 
trafficking of heme in the placenta and to characterize the sources of heme iron in the 
circulation and inter-tissue heme trafficking pathways.   
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CHAPTER 1 
INTRODUCTION 
Literature review: Pregnancy and iron homeostasis1 
Introduction 
Iron deficiency (ID) and iron deficiency anemia (IDA) remain significant public health 
concerns both in the US and throughout the world (1). It is estimated that 2 billion women and 
children worldwide are ID (2). Pregnant women are particularly vulnerable to IDA due to the 
high iron (Fe) demands of pregnancy. Fe requirements increase markedly over pregnancy from a 
net savings early in pregnancy (due to the cessation of menstruation), to a maximum 3-8 mg of 
Fe per day during the third trimester of pregnancy (3). The net Fe cost of a singleton pregnancy 
has been estimated to range from 480-1,150 mg, of this nearly 300 mg is deposited in the fetus 
(3). Pregnancy often results in a depletion of existing maternal Fe stores, every 1µg of circulating 
ferritin represents 10 mg of storage Fe (4). To accommodate the Fe demands of pregnancy, 
women would need to enter pregnancy with approximately 500 mg of storage Fe, yet only 20% 
of reproductive aged women are estimated to have this reserve and approximately 40% of 
women worldwide enter pregnancy with no storage Fe (5). 
The large numbers of reproductive-aged women with pre-existing anemia coupled with 
the elevated Fe requirements of pregnancy make pregnant women particularly vulnerable to 
IDA. In the US, 30% of pregnant women have a total body iron (TBI) < 0 mg/kg in the third 
trimester of pregnancy, indicative of exhausted Fe stores (6). National data suggest that the 
prevalence of anemia is 21.55 per 1,000 women (7). Similar data from a largely minority 
                                                             
1 Cao C, O'Brien KO. Pregnancy and iron homeostasis: an update. Nutr Rev 2013;71(1):35-51. 
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population reports a prevalence of IDA of 27.4% in the third trimester of pregnancy (8). The 
prevalence of anemia is impacted by use of prenatal supplements and ranges from 14-52% in 
pregnant women that are not taking prenatal supplements, to 0-25% among pregnant women 
consuming Fe supplements (9).  
The magnitude and consequences of IDA during pregnancy are well appreciated yet 
many unresolved questions remain on the physiology of Fe absorption from all dietary sources of 
Fe (heme and non-heme), the impact of supplement type (prenatal vs. single or multiple 
micronutrient) on maternal and neonatal Fe status, the optimal timing and net amount of 
supplemental Fe needed across pregnancy and the full impact of Fe supplementation on birth 
outcomes. Appropriate Fe status indicators are needed in order to evaluate the impact of Fe 
supplementation on maternal Fe status yet assessment of Fe status during pregnancy is 
compromised by variability in maternal plasma volume expansion (PVE). Relationships between 
maternal Hb and adverse birth outcomes are often U-shaped with increased risk observed at both 
ends of the Hb spectrum (10, 11). The degree to which increased Hb may be a consequence of 
failure to expand plasma volume requires further study as increased Fe stores are not always 
evident in those with elevated Hb concentrations (12). At this time, there are no rapid or 
validated approaches that can be utilized to control for variability in PVE across pregnancy. 
Little attention has been focused on the impact of maternal Fe status during pregnancy on 
neonatal Fe status at birth due to challenges and concerns with routine blood sampling among 
healthy newborns. Recent studies are beginning to compile reference data on hematological 
status and Fe stores among healthy newborns using both venous and cord blood (13-15). The 
goal of this document is to review issues relevant to Fe utilization during pregnancy and its 
impact on the Fe endowment of the neonate at birth considering Fe availability from both 
 3 
maternal diet (heme and non-heme sources) and from endogenous maternal Fe reserves (Fe 
stores and red blood cell (RBC) catabolism). 
Fe supplementation across pregnancy 
Fe supplementation is routinely recommended for US pregnant women to help meet the 
increased Fe demands of pregnancy. In 2008, the American Congress of Obstetricians and 
Gynecologists (ACOG) recommended prenatal supplementation with an Fe-containing prenatal 
supplement for all US pregnant women (16). ACOG also advocates universal anemia screening 
with additional targeted Fe supplementation for pregnant women that are found to be anemic 
(16). Similarly, the EU guidelines, also recommend daily Fe supplementation during the second 
half of pregnancy (17). However, in the most recent National Institute of Clinical Excellence 
guidelines on antenatal care in the UK (18), universal Fe supplementation is not advocated for all 
pregnant women on the basis of inconsistent reports on the benefits of Fe supplementation on 
maternal and infant health as well as potential drawbacks including gastrointestinal side-effects, 
reduced absorption of non-heme Fe (19), and other minerals (20), as well as increased oxidative 
stress (8). According to the UK guideline, Fe supplementation should only be considered for 
women with Hb concentrations < 11 g/dL in the first trimester or Hb concentrations < 10.5 g/dL 
at 28 weeks of gestation (18). The belief that Fe supplementation is not warranted in all women 
is also evident by the lack of any pregnancy related increase in the reference dietary intakes for 
Fe in the UK (21) or EU (17). 
In contrast, the recent 2010 Dietary Guidelines for Americans emphasized the need for 
women of reproductive age to consume Fe-rich food sources and components that enhance Fe 
absorption in addition to foods containing heme Fe because it is more readily absorbed (22). 
These dietary guidelines also recommended that all pregnant women consume a daily Fe 
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supplement as recommended by their health care provider (22). While the 2010 Dietary 
Guidelines for Americans highlighted the intake of heme Fe sources because of their enhanced 
bioavailability, few data on mechanisms of heme absorption and utilization are available, 
especially among pregnant women. 
Many studies have reviewed the impact of maternal non-heme Fe supplementation on 
risk of anemia across pregnancy and found Fe supplementation to result in positive benefits for 
both maternal and neonatal outcomes (23-27). An updated Cochrane Review on effects and 
safety of daily Fe supplementation during pregnancy has been published and supports that an 
increase in maternal Hb concentrations and a decrease in the risk of anemia is evident in women 
receiving either intermittent or daily Fe/folate supplementation (24). In general, daily oral Fe 
(30-60 mg of elemental Fe) and folic acid (0.4 mg) supplementation have been found to reduce 
the risk of low birth weight infants, increase birth weight, and in some groups impact neonatal 
mortality (28-31). The positive impact on birth outcomes has been found to occur both with (28, 
30, 32), or without (29, 31) a significant impact on maternal Hb in the third trimester.  
In many settings, multiple micronutrient deficiencies exist and treatment with Fe alone 
may adversely impact absorption and status of other micronutrients that are limited in the diet. In 
particular, numerous studies in pregnant and non-pregnant females have found interactions 
between Fe and zinc absorption (33-36). In 1999, UNICEF and WHO suggested that 15 
additional micronutrients (at recommended nutrient intake levels) be added to a 30 mg Fe 
supplement in part to enhance the absorption and utilization of Fe (37). Recent reviews of 
randomized controlled trials evaluating the impact of multiple micronutrient supplements 
compared to Fe-folate supplements alone found that multiple micronutrient supplements 
containing Fe had no significant additional benefit on prevention of maternal anemia during the 
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third trimester when compared to Fe-folate supplements alone (27, 38, 39). There was, however, 
evidence of a reduction in risk of low birth weight (38), and small for gestational age births (27, 
39), compared to Fe-folate supplements alone.   
Maternal response to non-heme Fe supplementation across pregnancy is influenced by 
baseline Hb concentrations as highlighted in a recent Fe supplementation study (40). In this 
study, over 1200 pregnant women from Burkina Faso were randomized to receive either a 
standard Fe-folate supplement (60 mg of Fe and 400 µg of folic acid, n = 632) or a UNIMMAP 
multiple micronutrient supplement containing 30 mg of Fe and 400 of µg folic acid in addition to 
13 other micronutrients (n = 636) (40). The study uniquely examined treatment response as a 
function of Hb status at entry into the study (anemic vs. non-anemic). Among non-anemic 
women, Hb concentrations decreased across gestation irrespective of supplementation group. In 
contrast, Hb concentrations increased significantly across gestation in those that were anemic at 
baseline, such that by term the mean Hb was not significantly different between those that were 
anemic vs. non-anemic at baseline, nor did type of supplement ingested impact treatment 
response (40). Of interest, the risk of hemoconcentration (Hb > 13 g/dL) was associated with 
micronutrient intake in the cohort as a whole, but was independent of supplementation group or 
initial maternal Hb concentration. This study highlighted the adaptable physiology of Fe 
absorption during pregnancy and the ability of maternal Fe status to impact utilization of Fe from 
supplemental, non-heme Fe sources during pregnancy. The study also highlighted the 
physiological decrease in Hb that occurs over pregnancy. Even with Fe supplementation, 51% of 
women remained anemic at term, highlighting the regulation of Fe utilization in response to 
maternal needs. More data is needed to understand the risk of hemoconcentration and the 
physiological determinants of this process in women taking Fe supplements.  
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The majority of Fe supplementation studies have provided inorganic, non-heme Fe   
supplements which are known to be tightly regulated in response to maternal Fe stores and 
circulating hepcidin concentrations (33, 41). Far less is known about the relative bioavailability 
or efficacy of heme Fe during pregnancy. To date, only one published randomized controlled 
study has evaluated the impact of a supplemental heme Fe source on Fe stores in a group of 90 
pregnant women (42). Women were randomized to receive ferric fumarate alone (27 mg with 
ascorbic acid), ferric fumarate and heme Fe (24 mg of ferric fumarate with 3 mg of heme Fe as 
Hemofer®) or a placebo. Supplements were ingested from week 20 of pregnancy through 24 
weeks postpartum. Fe supplementation over the second half of pregnancy was associated with a 
significant improvement in Hb compared to the placebo group. However, the heme group had 
significantly better Fe stores at the end of pregnancy compared to the placebo and heme intake 
appeared to protect against depletion of maternal Fe stores at 24 weeks postpartum compared to 
the placebo or ferric fumarate group alone (42). 
Few studies on maternal Fe intake have differentiated non-heme from heme Fe and little 
is known about the effect of heme Fe intake on maternal and fetal health. In a recent survey in 
1,274 British pregnant women, intake of non-heme, but not heme Fe, was positively associated 
with infant birth weight (43). Median heme Fe intake in these women during the first trimester 
was 0.3 mg/day, which was lower than that reported among a recent US pregnant cohort (0.8 
mg/day) (43). In this US cohort, the risk of gestational diabetes mellitus increased in those with 
higher heme intake in early pregnancy even after controlling for consumption of red and 
processed meats, saturated fat, and cholesterol (43). More large-scale studies among pregnant 
women are needed to examine the impact of dietary heme Fe intake on other aspects of maternal 
and neonatal health as well as on Fe status. 
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Genome-wide association studies have recently been utilized to identify the proportion of 
variation in common Fe status markers that is explained by genetic determinants. Using this 
approach, genetic variants in the HFE and transferrin genes explain roughly 40% of the genetic 
variation in serum transferrin (44, 45). Significant, but much smaller associations have been 
found between single nucleotide polymorphisms in TPMRSS6 (Matripase-2) and serum Fe, 
transferrin saturation and erythrocyte mean cell volume (44). Matripase-2 is involved in the 
regulation of Fe homeostasis via its ability to suppress the stimulation of hepcidin transcription 
as mediated by bone morphogenic protein (46). A recent stable Fe isotope absorption study in 
mother-toddler pairs found that only approximately 50% of non-heme Fe absorption was 
explained by Fe status and known dietary factors and a highly significant relationship was 
observed between individual mother-toddler pairs after controlling for known confounders (47). 
Based on these observations, the authors speculated that much of non-heme Fe absorption was 
driven by inheritance or by an unknown factor in the shared environment of the mother and her 
child (47). As this field evolves, it may be possible to identify and target those at increased risk 
for anemia so that appropriate interventions or increased anemia surveillance can be 
implemented among pregnant women at increased risk for anemia. 
Assessing maternal Fe status during pregnancy 
A number of common biomarkers are utilized to characterize anemia and/or maternal Fe 
status across pregnancy including; Hb (Hb) and hematocrit (Hct), serum ferritin (SF), serum 
soluble transferrin receptor (sTfR), and total body iron (TBI). A list of common indicators and 
their reference ranges are presented in Table 1.1. At present, Hb and Hct are the most widely 
used indicators to assess anemia during pregnancy. Measures of Hb and Hct drop from early to 
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mid-pregnancy as a result of pregnancy-associated hemodilution, i.e. a smaller increase in RBC 
mass (~25%) relative to that of plasma volume (~50%) (48).  
Table 1.1. Cut-off values for ID, and normal ranges of Fe status indicators in pregnant women 1 
Indicator First trimester  Second 
trimester  
Third 
trimester  
Hb cut-off (g/dL) 
   Cut-off used to define anemia < 11.0 < 10.5 < 11.0 
   Cut-off used for anemia in black women < 10.2 < 9.7 < 10.2 
   Cut-off used for anemia in cigarette smokers < 11.3 < 10.8 < 11.3 
   Cut-off used for anemia in those living at high 
altitude 
< 11.2–13.0 < 10.7–12.5 < 11.2–13.0 
   Reference range 11.6–13.9 9.7–14.8 9.5–15.0 
Hct cut-off (%) 
   Cut-off used to define anemia < 33.0 < 32.0 < 33.0 
   Cut-off used for anemia in black women < 31.0 < 30.0 < 31.0 
   Cut-off used for anemia in cigarette smokers < 34.0 < 33.0 < 34.0 
   Cut-off used for anemia in those living at high 
altitude 
< 33.5–39.0 < 32.5–38.0 < 33.5–39.0 
   Reference range 31.0–41.0 30.0–39.0 28.0–40.0 
SF (µg/L) < 12.0 
   Reference range 6.0–130.0 2.0–230.0 0–116.0 
Serum sTfR (mg/L) > 4.4 or > 8.5 
sTfR/SF > 300.0 
sTfR-F index (sTfR/log SF) > 1.8 
TBI (mg/kg) < 0 
    Reference range 5.6–7.3 3.4–5.0 0.8–2.0 
Serum Fe (µg/dL) < 40.0 
Transferrin saturation (%) < 16.0 
TIBC (µg/dL) > 400.0 
ZnPP (µmol/mol heme) > 70.0 
1 Cut-offs and ranges were taken from the following references: Mei et al. (6), ACOG (16), Suominen 
et al. (49),  Abbassi-Ghanavati et al. (50), CDC (51), Carriaga et al. (52), and van den Broek et al.(53). 
Reference ranges are values between the 2.5 and 97.5 percentiles of the reference populations. 
Because of the considerable interpersonal variation in the degree of hemodilution and 
PVE (54), pregnant women with the same RBC mass may have very different Hb and Hct 
values. Factors that have been shown to impact PVE in humans or animals include: preeclampsia 
(55), chronic hypertension (56), idiopathic fetal growth restriction (57), ID (58), food restriction 
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(59), and low protein intake (60). The impact of these conditions on the Fe status indicators 
should be kept in mind when interpreting biochemical data across pregnancy.   
The have published Hb and Hct thresholds indicative of gestational anemia based on the 
5th percentile of the distributions of these two variables and cutoff values for anemia for pregnant 
women during the first, second and third trimester (61). Several population-based studies have 
shown optimal pregnancy and birth outcomes in women with Hb concentrations between 9.5-
11.0 g/dL (62-65), raising the possibility that the current CDC norms for Hb may be set too high 
(66). In addition, high Hb concentrations ( > 13 g/dL) have also been shown to confer an 
increased risk of low birth weight and pre-term delivery and this U-shaped relationship between 
Hb and adverse birth outcomes has been observed in pregnant populations from many diverse 
demographic backgrounds (10, 11, 62-64). This association has been suggested to be in part due 
to shared pathologies including hypertensive disorders and preeclampsia (67). 
While Hb/Hct measures are diagnostic of anemia, a large proportion of anemia is due to 
causes other than ID such as folate or vitamin B12  deficiencies, hematological disorders, and 
chronic inflammation (68). More specific Fe status indicators are necessary to determine whether 
the anemia noted is a consequence of ID. SF is one such indicator that is commonly used to 
estimate storage Fe  because of its close correlation with both total mobilizable tissue Fe reserves 
(69), and Fe stores in bone marrow (70). The WHO has identified SF as the best indicator of the 
effectiveness of Fe intervention trials, and proposed the use of a SF value < 12-15 µg/L to 
indicate absent Fe stores in adults (61). Most studies in pregnant women have adopted the lower 
end of this range, i.e. 12 µg/L, to account for the physiologic decline in SF due to PVE (6, 71). 
This cut-off (SF < 12 µg/L) is also one of the discriminatory criteria set by the Institute of 
Medicine for prescribing Fe supplements during the first and second trimester of pregnancy (72).   
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However, similar to other Fe status indicators in blood, SF is subject to the impact of 
hemodilution and is further limited by its poor sensitivity to true Fe depletion due to its large 
within-person variation (73), and the Fe-independent rise this acute phase protein exhibits as a 
consequence of inflammation. This inflammatory response has been shown to mask ID in 
individuals with heightened inflammatory status (74, 75). Pregnancy itself is an inflammatory 
state with many studies detailing elevations in inflammatory markers such as C-reactive protein 
(CRP) (76, 77), GM-CSF (78, 79), leptin (80), and T-helper 2 cell cytokines (interleukin-4, 
interleukin-6 and interleukin-10) (81, 82). Early pregnancy and parturition are thought to be pro-
inflammatory states, while mid-gestation is thought to be an anti-inflammatory state (83, 84). 
Thus, a concurrent measurement of SF with other acute phase reactants such as CRP and alpha 
1-acid glycoprotein is generally recommended to control for possible effect of inflammation 
(61). Body mass among non-pregnant women has been linked with suboptimal Fe stores and 
elevated CRP even after adjusting for Hb concentrations (85). This is thought to be a 
consequence of down-regulation of Fe absorption from elevated hepcidin concentrations that 
occur due to adiposity associated inflammation (85). The ability of pregnancy itself, and/or 
pregnancy associated weight gains to impact systemic inflammatory markers, hepcidin and Fe 
status is poorly studied.   
While SF is an indicator of body Fe stores, sTfR yields information about cellular Fe 
demands and the erythropoietic proliferation rate. Circulating sTfR is derived primarily from the 
detachment of the receptor from developing erythroblasts and serum concentration of this 
indicator rises when Fe supply to the erythron is limited due to exhausted Fe stores (86). In the 
absence of erythropoietic disorders, serum sTfR identifies mild tissue Fe insufficiency with high 
sensitivity (87). In contrast to SF levels, serum sTfR exhibits low intra-personal variability (73), 
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and is less affected by acute phase phenomenon (86, 88); therefore, serum sTfR is particularly 
useful in identifying ID in individuals with normal to high SF during inflammation (88). Serum 
sTfR concentrations remain stable in the first trimester of pregnancy and increase progressively 
from late pregnancy to term, a phenomenon often attributed to increased erythropoiesis and 
higher occurrence of tissue ID as gestation progresses (71, 89, 90). Studies that have evaluated 
the utility of serum sTfR in pregnant women reported a sensitivity of 70%-78% and specificity 
of 46%-100% of high sTfR concentration in detecting ID as diagnosed by other Fe indices (71, 
89, 91). In adults, a serum sTfR > 8.5 mg/L is indicative of tissue ID as determined by 
quantitative phlebotomy (87). This cut-off has been shown to be highly specific to Fe depletion 
during pregnancy (52), and has been used by most published literature on sTfR during pregnancy 
(89, 92). However, a recent publication using National Health and Nutrition Examination Survey 
data (2000-2006) used 4.4 mg/L as the upper reference level for sTfR in pregnant women based 
on the manufacturer’s reference range in 261 women without ID or anemia (6). The overall 
prevalence of ID defined by sTfR > 4.4 mg/L (17.4%) was significantly lower than that 
identified when using SF < 12 µg/L (25%) and this difference remained evident when examined 
within each trimester (6). However, when ID was evaluated in reference to absent TBI (< 0 
mg/kg), this sTfR cutoff was shown to be able to identify a similar number of ID cases with 
reasonable sensitivity (64.0%) and high specificity (92.8%). There is a large amount of 
variability observed between different commercial TfR immunoassays (93), but a new WHO 
reference standard, prepared from recombinant TfR, is now available for data harmonization 
purposes (94).  
Assessment of both SF and sTfR may better capture the full spectrum of tissue Fe 
homeostasis and when expressed as a ratio (sTfR/SF), may avoid correct for PVE differences 
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and thus provide a more accurate reflection of Fe status during pregnancy. The sTfR/SF ratio as 
a measure of ID was first proposed by Skikne et al. in 1990 (87). This measure has been tested 
against bone marrow aspirates in a group of anemic pregnant women and showed 85% 
sensitivity and 79% specificity when the cutoff was set at 300 (53). Use of both sTfR and SF 
data also allows for an estimation of TBI using the logarithm developed by Cook et al. which 
was calibrated by quantitative phlebotomy in healthy adults to provide a continuous, numerical 
description of Fe status from surplus to deficit (93). It should be noted that because TBI is 
expressed on a weight basis, the expected increase in body weight during pregnancy may 
underestimate the true body Fe stores in pregnant women when comparing the values to non-
pregnant populations. Although the validity of TBI cannot be tested by phlebotomy in pregnant 
populations, this model of Fe status assessment has been utilized in several pregnancy studies (6, 
12, 93), including the recent National Health and Nutrition Examination Survey (1999-2006) (6). 
The cut-off of TBI for tissue ID is set at 0 mg/kg in pregnant women as in other adult 
populations (6, 93). 
Hepcidin, the key Fe-regulatory hormone secreted by the liver, negatively affects 
systemic Fe homeostasis by blocking both non-heme Fe absorption from the diet and Fe 
mobilization from macrophages and hepatocytes (95). Hepcidin production is induced by Fe 
stores and inflammation and is suppressed by erythropoietic activity and hypoxia (96). Due to 
the lack of standardized quantification methods and the scarcity of large population-based studies 
to derive reference ranges (97), hepcidin assays performed to date are restricted to research 
situations and this measure has unknown diagnostic utility among pregnant women. One recent 
pregnancy-specific, reference study for serum hepcidin was published in a group of 116 Fe-
replete pregnant women at term (98). The reported 95% CI ranged from undetectable (< 5 
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ng/mL) to 58.6 ng/mL, with a median of 10.7 ng/mL. This study also included 75 pregnant 
women with low Fe stores (SF < 12 µg/L) but did not attempt to determine cut-offs of hepcidin 
for use in ID diagnosis. The utility of urinary hepcidin has also been examined in 190 pregnant 
Bangladeshi women and was found to be strongly associated with SF (99). We recently explored 
the role of hepcidin in regulating absorption of heme and non-heme Fe in a small sample of 
pregnant and non-pregnant women (41). Heme Fe absorption was significantly higher than that 
observed for non-heme Fe in both pregnant and non-pregnant women (41). Of interest, serum 
hepcidin only became a significant predictor of non-heme Fe absorption when data from the 
pregnant and non-pregnant participants were combined, explaining 24% of the variation in non-
heme Fe absorption, a value similar to that we previously reported for non-pregnant women 
(100). This raises the question of whether hepcidin provides additional information about Fe 
status when compared to the existing panel of Fe status indicators in individuals absent of 
pathologies, and if yes, whether this additional information would offset the high analytic cost of 
the test. It is worth noting that although the stimulatory effect of inflammation on hepcidin is 
well characterized (101), different inflammatory markers seem to exhibit differential 
relationships with hepcidin during pregnancy (102), which may be reflect the differences in the 
temporal response to the induction of inflammation of these acute phase proteins. This illustrates 
the need for future research to identify biomarkers that are most useful in the interpretation of Fe 
status measures known to be affected by inflammation. Also, due to methodological differences 
in the analytical approaches currently available for hepcidin measurement, widely different 
absolute values are obtained which limits the comparability of data. A recent review of analytical 
differences indicates that while absolute differences exist, relative differences are comparable 
between the existing hepcidin quantification methods (103). Furthermore, there is conflicting 
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evidence as to whether urinary hepcidin is a better estimate of hepcidin production than serum 
hepcidin (104-106). Serum hepcidin measures have lower variability (96), and would not be 
impacted by pregnancy associated alterations in glomerular filtration rate, urine production and 
do not need to be corrected for creatinine. More pregnancy data are needed to assess the 
diagnostic utility of hepcidin in relation to the existing panel of Fe status indices across gestation.  
Placental Fe transport  
All the Fe required for fetal growth and development is actively transported from the 
mother to the fetus by the placenta. Early radiotracer studies in animals with hemochorial 
placentas (like the human which has a hemochorial placenta), suggest that Fe is rapidly moved 
from the maternal circulation to the fetus against a concentration gradient (107-109). Studies in 
the rabbit (107), and rhesus monkey (110), have injected 59Fe radiotracer directly into the fetus in 
vivo. Lack of measurable radioactivity in maternal plasma (110), or non-dosed littermates (107), 
suggest that the transfer of Fe to the fetus is unidirectional and that little to no recycling of Fe 
occurs. Kinetic studies using perfused human placenta lobules also support the in vivo animal 
data and indicate that this transfer is unidirectional (111). However, recently the heme export 
protein, Feline Leukemia Virus subgroup C Receptor (FLVCR)1, was identified and found to be 
most abundantly expressed in the human placenta when compared to other body tissues (112). 
This may suggest a reverse flow of heme Fe from the placenta to the maternal circulation that 
perhaps functions to protect the feto-placental unit from Fe toxicity. In erythroid cells export of 
heme Fe by FLVCR1 is an important mechanism utilized to prevent cellular heme toxicity and 
ensure cell survival (112). The presence of FLVCR1 in the placenta, and recent data linking this 
protein to maternal Fe status (113), suggest that this protein may serve a similar role in the 
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placenta. More experimental evidence is needed to assess the role of FLVCR1 in relation to 
placental Fe transport.   
While data on the mechanisms of transport are evolving over time, it is known that a net 
flux of roughly 270 mg of Fe is transferred across the placenta to be accumulated by the 
developing fetus, most of which is occurs over the last 10 weeks of gestation (114). During late 
pregnancy, an average of 5.6 mg of Fe per day from dietary or endogenous maternal sources is 
trafficked across the placenta to meet fetal demands (3). The magnitude of this placental Fe flux 
during late gestation is nearly 6-times higher than the amount of Fe typically absorbed across the 
enterocyte from dietary sources in non-pregnant women, and represents nearly 30% of the 20 mg 
of Fe that is typically catabolized daily from senescent RBCs. The Fe delivered to the fetus is 
obtained either from three primary sources as detailed in Figure 1.1: 1) dietary Fe sources (heme 
and non-heme Fe); 2) liver Fe stores; or 3) Hb in RBCs. 
 
 
Figure 1.1. Fetal Fe sources during pregnancy 
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Placental non-heme Fe transport   
The majority of research on cellular Fe trafficking has focused on the enterocyte. It is 
assumed that the placental syncytiotrophoblast employs a similar Fe trafficking system to that of 
the duodenal epithelium but trafficking mechanisms in placental tissue are less well 
characterized. Several lines of evidence, including the identification of placenta-specific 
ferroxidase necessary for basolateral Fe efflux (115), and the demonstration of the redundancy of 
divalent metal transporter 1 (DMT1) in mouse placenta (116), cast doubt on this claim and 
support the notion that the placenta may have a distinct cellular Fe process that uniquely 
responds to the local and systemic maternal and fetal regulatory signals. Furthermore, the 
placenta, unlike the enterocyte, cannot rid excess intracellular Fe by sloughing of senescent crypt 
cells into the lumen of the gastrointestinal tract every 3 days. To avoid excess Fe transfer to the 
fetus the placenta must restrict uptake into the syncytiotrophoblast, store unwanted Fe within the 
tissue until parturition, or export excess intracellular Fe back into maternal circulation if not 
needed by the developing fetus. Fe stable isotopic data suggests that once transferred to the fetus 
there is no recycling of non-heme Fe from fetal to maternal circulation based on data that find no 
association between days post-dosing and enrichment of the neonate at birth (117-120). Unlike 
the enterocyte that responds only to systemic maternal signals, the placenta may regulate 
expression of proteins in response to both maternal and fetal signals. The fetus begins producing 
hepcidin in the first trimester of gestation (121), and neonatal hepcidin concentrations are 
regulated independently of maternal hepcidin concentrations (98). Further work assessing 
relative associations between placental transport proteins and both maternal and neonatal Fe 
status at birth is needed to elucidate this process.  
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While many steps in the trans-placental Fe trafficking await further characterization, 
initial uptake of Fe from the circulation into placental tissue is relatively well defined. Classic 
thought holds that the majority if not all fetal Fe is derived as inorganic Fe from maternal 
diferric-transferrin (122-124). The serum diferric-transferrin binds to placental transferrin 
receptor (TfR) which is abundantly expressed on the apical side of placental syncytiotrophoblast, 
leading to the endocytosis of the vesicle containing the transferrin-TfR complexes. Acidification 
of the vesicle facilitates the dissociation of Fe from transferrin. The released Fe is reduced to its 
ferrous state by a recently identified family of ferrireductases, Steap 1, 2, 3, 4 (125), and 
transported out into the cytoplasm through a protein channel by DMT1, though there is evidence 
of an DMT1-independent Fe exit pathway functioning in the placenta (116). Both the Steap 3 
and 4 ferrireductases are highly expressed in the placenta and may exhibit functional redundancy  
to maintain Fe flow to the fetus (125). Once in the cytoplasm, Fe is either incorporated into its 
storage form (ferritin), or is delivered to transferrin in the fetal circulation via concerted action of 
the Fe exporter, ferroportin (FPN) and the placental ferroxidases such as Zyklopen (115).  
Research from both human and animal models has revealed several steps in the placental 
Fe transfer pathway that may be subject to regulation by maternal and fetal Fe status. Previous 
research from our laboratory has shown that the amount of dietary non-heme Fe transported 
across the placenta is increased in women with ID, suggesting that Fe transport apparatus in the 
placenta is able to adapt to maternal Fe supply (117, 118). In rats fed a low Fe diet, 
compensatory changes in the placental Fe transport pathway were seen with increased activity of 
copper oxidase as well as enhanced expression of TfR and the iron-responsive element (IRE)-
regulated DMT1 but not FPN (126). These authors further demonstrated a commensurate rise in 
radio-Fe uptake with increased TfR mRNA expression in cultured BeWo cells, suggesting that 
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the up-regulation of proteins involved in placental Fe transfer is partly responsible for the 
functional increase in Fe transfer during deficiency (126). The few available human data also 
confirm this feedback control of placental Fe transfer by demonstrating an inverse relationship 
between maternal Fe stores and placental expression of TfR (127) and ferritin (128). 
The importance of fetal signals in controlling placental Fe transport is an evolving area of 
research. In a series of experiments in rats, Gambling et al. (121) identified the fetal liver Fe as 
the key fetal determinant of placental Fe transfer. A strong inverse association between fetal liver 
Fe and placental expression of TfR was evident suggesting that fetal hepcidin may be a key 
mediator of this regulation (121). Interestingly, the authors found no relationship between 
hepcidin and the expression of its ligand FPN in the placenta and suggested that the classic 
interaction between hepcidin and FPN observed in other tissues may not be operative in the rat 
placenta (121). Our data in pregnant teenagers also found a significant inverse association 
between neonatal SF and placental TfR protein expression even after controlling for maternal SF 
(127). 
Placental heme Fe transport  
Several diverse types of placentas, across many species (carnivores in particular) have 
paraplacental structures on the margins of the placenta which are referred to as hemophagous 
organs (129). Within the hemophagous organ maternal erythrocytes are ingested by phagocytic 
trophoblast cells and the heme Fe released is utilized to meet fetal Fe demands (129). In some 
species, such as the dog, these areas stain bright green due to the magnitude of Fe accumulated at 
this site (130). Humans have a hemochorial placenta; most species with this type of placenta are 
believed to rely primarily on uptake of transferrin-bound Fe to meet fetal Fe requirements (129). 
However, the human placenta also exhibits an abundant expression of many proteins involved in 
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heme Fe uptake and utilization including proton coupled folate transporter (PCFT) (131, 132), 
FLVCR1, and FLVCR2. The FLVCR1 protein functions as a heme export protein (113, 133), 
while FLVCR2 may serve as a heme influx protein (134). In humans, expression of FLVCR1 is 
the highest in the placenta when compared to all other body tissues (112, 135), perhaps as noted 
above this is suggestive of a putative use of maternal heme as source of fetal Fe during 
pregnancy. The human placenta also contains the necessary scavenger receptors for heme- and 
Hb-complexes (136, 137). Much of daily RBC catabolism occurs extravascularly in the liver and 
spleen (releasing non-heme Fe for subsequent use by tissues) but 10-20% of RBC catabolism is 
thought to occur intravascularly which would release 1-2 mg Fe into the circulation as free Hb 
and heme (138). These substances are highly reactive and are quickly bound to their respective 
blood carriers haptoglobin (Hp) and hemopexin (Hx) (139), to be ferried to target tissues 
(hepatocytes and reticuloendothelial macrophages) known to express scavenger receptors for the 
Hb- and heme-carrier complexes. Interestingly, the scavenger receptors for Hb (the Hp-Hb 
complex binds to CD163) (137), and heme (Hx-heme complexes bind to lipoprotein-related 
protein 1 (LRP1)) (136), are also abundantly expressed in the human placenta, supporting the 
notion that the placenta may be capable of utilizing heme Fe sources. Heme Fe may also be 
obtained from dietary absorption. The mechanisms by which heme Fe is absorbed and exported 
across the enterocyte have not yet been determined. It was initially thought the PCFT was the 
elusive heme transporter but this protein was subsequently identified as a proton coupled folate 
transporter and its affinity for folate was found to be more than two orders of magnitude greater 
than its reported affinity for 55Fe-hemin (132). The heme export protein (FLVCR1) is also 
abundantly expressed in the human duodenum (112). A summary of the proteins involved in 
heme and non-heme Fe utilization by the placenta and enterocyte are depicted in Figure 1.2. 
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Figure 1.2. Fetal Fe sources and mechanisms of placental Fe transfer 
Whether the presence of the heme transport and catabolic proteins in the human placenta 
indicate this organ can utilize dietary or maternal endogenous heme sources remains largely 
unknown. Consistent with the hypothesis of heme Fe utilization in the placenta, we have recently 
reported an inverse association between placental expression of the heme exporter FLVCR1 and 
maternal SF in teens with depleted Fe at delivery, suggesting that heme Fe may participate in 
placental Fe trafficking, especially when fetal Fe demands peak in third trimester of pregnancy 
(113). We have also recently found preferential fetal uptake of maternally ingested heme Fe 
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source compared to placental uptake of Fe from a dietary non-heme Fe source, which suggests 
there may be a preferential ability of the placenta to use dietary Fe of heme-origin (118).  
Impact of other nutrients on Fe metabolism during pregnancy 
Many nutrients can interact with Fe to influence Fe bioavailability at the level of the gut 
and/or at the systemic level to impact regulation of whole body Fe homeostasis. Dietary factors 
that are known to enhance non-heme Fe absorption include vitamin C (140), and animal tissues 
(141), while other dietary factors (such as phytates (142) and calcium (143)) inhibit non-heme Fe 
absorption. These associations that are often evident in single-meal studies are not always found 
when looking at relationships based on habitual dietary intakes. For example, while calcium 
intake can reduce non-heme Fe absorption if ingested in the same meal (143), calcium 
consumption does not appear to have a significant impact on Fe balance as indicated by several 
population surveys that found no association between dietary calcium intake and SF 
concentrations (145;146). Absorption of heme Fe, in contrast, appears to be little impacted by 
known dietary inhibitors or enhancers of non-heme Fe. There is some evidence that both meat 
(144), and soy proteins (145) increase the bioavailability of heme, possibly by preserving heme 
in the monomeric state (146).  
Many processes involved in systemic Fe metabolism are dependent upon the status of 
other nutrients. Copper deficiency is thought to cause systemic ID and anemia by lowering the 
level and activity of two copper-containing ferroxidases (hephaestin and ceruloplasmin) which 
are essential for Fe export from the intestine (147), and from Fe stores (148). In rats, dietary 
copper deficiency during pregnancy was associated with reduced fetal Fe stores, suggesting a 
role for copper in placental Fe transport (149). This association may be mediated by the recently 
identified multi-copper ferrioxidase, Zyklopen, which is enriched in the placenta compared to 
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other tissues such as the heart and kidney (115). Zyklopen has also been observed to be up-
regulated in response to cellular copper deficiency in human placental trophoblast-like BeWo 
cells (115). 
Zinc supplementation trials in human adults have demonstrated adverse effects of dietary 
zinc on Fe homeostasis as evidenced by its ability to decrease Fe absorption (20), and by 
findings of lower serum Fe in zinc-supplemented pregnant women compared to the non- or Fe-
supplemented groups (33). Although the mechanisms underlying these effects remain unclear, 
there is evidence for a direct stimulatory effect of zinc on intestinal expression of DMT1 and 
FPN (150), and for a common transport pathway in the liver possibly mediated by Zip14 (151).   
Another micronutrient deficiency frequently associated with anemia during pregnancy is 
vitamin A deficiency (152). Vitamin A affects multiple aspects of Fe metabolism including 
absorption (156), RBC production, and mobilization from tissue Fe stores (153). Intervention 
studies in anemic pregnant women showed that concurrent supplementation of both vitamin A 
and Fe is more effective at improving Hb levels than either vitamin A or Fe alone, suggesting a 
synergistic relationship of these two nutrients in promoting erythropoiesis during pregnancy 
(154, 155). 
Maternal ID and its consequences on the neonate  
For many years, little attention was focused on the impact of maternal Fe status on 
neonatal Fe stores at birth since it was thought that the fetus functioned as a “perfect parasite” 
and would be able to acquire sufficient Fe even in the face of mild to moderate maternal anemia.  
Many new developments on regulation of Fe physiology and neonatal Fe status have challenged 
this assumption. An increasing body of literature supports the premise that fetal Fe needs will be 
compromised when maternal Fe stores are suboptimal (25, 114, 156, 157). There is also a 
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growing body of literature that suggests that altered or limited Fe supply in utero, during key 
windows of development, may lead to adaptive responses that permanently impact metabolic or 
developmental programming and the developing brain (158, 159). The timing at which ID occurs 
in utero has been found to impact subsequent outcomes in the offspring (160, 161). Suboptimal 
Fe stores at birth are associated with long-term, irreversible cognitive deficits in the offspring 
(162, 163). Of note, cord SF concentrations < 76 µg/L have been associated with impaired 
language ability, tractability and fine motor skills in children subsequently studied at 5 years of age 
(164). The Fe endowment at birth is also critical in insuring that the neonate maintains Fe stores 
over early infancy because the neonatal gut is developmentally immature and may not regulate 
Fe absorption in response to Fe stores until 6-9 months of age (165, 166). 
Greater attention on relationships between maternal Fe status and neonatal Fe stores is 
needed based on new findings including data indicating that infants whose mothers were anemic 
during pregnancy have been found to be more than 2-times as likely to have an abnormal 
laboratory indicator of Fe status at 9 months of age in comparison to infants born to non-anemic 
women (167). Assessment of Fe status in neonates is challenging as there are few normative data 
because universal screening for anemia is considered unwarranted (168), and venipuncture is not 
routinely undertaken among healthy newborns. 
Assessing Fe status in newborns  
Existing reference data define anemia in infants born after 34 weeks of gestation as a 
central venous Hb < 13 g/dL or a capillary Hb < 14.5 g/dL (169). Efforts to establish references 
ranges for Hb in neonates have been hindered by the technical difficulty in obtaining 
venipuncture specimens (170), high variability in previously used measurement approaches (13, 
171), and the small sample sizes of most reference value studies (172-174). 
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Using archived records of a large number of neonatal patients with minimal hematology-
related pathologies, a series of recent publications sought to establish reference ranges (5th and 
95th percentiles) for commonly measured hematologic parameters in preterm to term infants (13, 
15, 175). With these data, the reference ranges of Hct and Hb for term neonates were set at 42-
62% and 14-22 g/dL respectively, which are, on average, 10% and 3.3 g/dL higher than those for 
neonates born before 28 weeks of gestation (15). Additional challenges are evident in the 
assessment of neonatal Fe  status because both Hb and Hct increase slightly during the first few 
hours after birth and then decline linearly such that by 28 days after birth values are lower than 
observed at birth (13). Because most hematologic parameters are impacted by postnatal age and 
also vary considerably with advancing gestation (171), both gestational-and-postnatal-age-
specific reference ranges are needed to fully interpret population and individual data among 
newborns. An additional challenge in interpretation occurs because the mode of blood collection 
(e.g., venous, arterial, capillary) is not always recorded and can impact values obtained.  Due to 
poor perfusion of a neonate’s extremities, capillary Hb and Hct are about 5-25% higher than 
those obtained simultaneously from venous or arterial blood (171).  
National data on neonatal Fe status does not exist as 1-2 year-olds are the youngest age 
group monitored for anemia prevalence by National Health and Nutrition Examination Survey. A 
recent report from American Academy of Pediatrics (AAP) emphasized the importance of 
screening infants and young children for ID due to its potential adverse effects on neuro-
development (5). As noted by this report and others, no single screening test is available that will 
capture the full spectrum of Fe status in pediatric populations and measurements of Fe  status in 
addition to Hb must be determined before ID is diagnosed (5). The AAP suggests two options for 
IDA screening: Hb < 11 g/dL and measurement of 1) SF and CRP, or 2) reticulocyte Hb 
 25 
concentration. To identify ID without anemia, the use of SF, CRP, and reticulocyte Hb 
concentration is recommended (5). The usefulness of these measures in the assessment of Fe 
status during early infancy or at birth has not been fully evaluated. In addition, many core 
clinical laboratories do not have the instrumentation needed to measure reticulocyte hemoglobin 
concentration limiting the utility of this index as a measure of neonatal Fe stores. Normative 
ranges for many neonatal Fe status indicators that have been used in the literature are presented 
in Table 1.2. 
Table 1.2. Normal ranges of hematological values in cord blood and capillary blood 
from term neonates1 
 Cord blood Capillary blood  
(1–3 days of age) 
Hb (g/dL) 13.5–19.5 14.5–22.5 
     Anemia cut-off  < 13.0 < 14.5 
Hematocrit (%) 42–60 45–67 
Erythrocyte count (1012/L) 3.9–5.5 4.0–6.6 
Mean corpuscular volume (fL) 98–118 95–121 
Mean corpuscular Hb (pg) 31–37 31–37 
Mean corpuscular Hb concentration (g/dL) 30–36 29–37 
SF (µg/L) 40–309  
    Tissue Fe depletion < 34  
1 Cut-offs and ranges as published in Siddappa et al. (176), Brugnara (169), and 
Siddappa et al (14). All reference ranges are central 95% intervals of the reference 
populations except for SF, which consists of the central 90% of the reference population. 
Cord clamping and neonatal Fe status 
Delaying the time at which the umbilical cord is clamped post-delivery has a significant 
impact on the net amount of blood, and hence Fe stores, transferred to the neonate at birth. On 
average, delaying clamping until the cord has stopped pulsing translates to an additional 30% 
more blood volume in the neonate which would could contribute up to 60% more RBC (177-
179). Delayed cord clamping has also been linked to persistent benefits on early Fe homeostasis 
as evidenced by better Fe stores (ferritin) at 6 months of age (178, 180, 181). Concerns with this 
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practice have to do with a possible link with an increased risk of postpartum hemorrhage in the 
mother and neonatal jaundice in the newborn. A recent Cochrane review of this topic did not 
support any increased risk to the mother (on either postpartum or severe postpartum hemorrhage) 
but did find that delayed cord clamping resulted in significantly higher Hb levels in the neonate 
at birth and higher SF concentrations at 6 months (182). However, the need for early 
phototherapy for jaundice was slightly increased in those with late cord clamping (182). 
Because cord clamping practices are not standardized and may be highly variable as a 
consequence of medical beliefs and birth/delivery circumstances, it is perhaps not surprising that 
data on relationships between maternal and neonatal Fe status are often conflicting.   
Vulnerable maternal and neonatal groups 
There are several high risk maternal groups for which gestational anemia screening or 
assessment of neonatal Fe status at birth may be warranted. Since most Fe is obtained during the 
third trimester of pregnancy, infants that are born preterm have a limited window of opportunity 
to accrue in utero Fe stores. Since maternal ID itself increases the risk of preterm birth, low birth 
weight infants that are born preterm may be particularly vulnerable. The AAP highlights both 
prematurity and low birth weight as risk factors for ID and IDA at 1 year of age (5). Additional 
risk factors for ID and IDA that were highlighted by the AAP include: exclusive breastfeeding 
beyond 4 months of age without supplemental Fe, weaning to whole milk diet low in Fe and 
among those with poor growth, low socioeconomic status and children with medical concerns 
that lead to feeding problems (5). Several other common pregnancy related complications or 
population groups may also be at increased risk for anemia over the course of pregnancy 
including; women with gestational diabetes mellitus, women carrying multiples, pregnant 
adolescents and women with inflammatory or infectious conditions across pregnancy.   
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Gestational diabetes 
Gestational diabetes mellitus is a common problem among pregnant women affecting 
approximately 7% of pregnancies in the US (183). Gestational diabetes increases the risk of 
neonatal macrosomia, respiratory distress syndrome, and hypoglycemia and has also been linked 
to abnormal Fe acquisition by the developing fetus (184-188). Mechanisms responsible for the 
limited maternal-fetal Fe transfer are thought to involve a combination of chronic fetal 
hypoxemia and increased erythropoiesis leading to impaired Fe stores (156). Placental up-
regulation of TfR occurs likely as a regulatory response to accommodate the increased fetal Fe 
demand (187), but this up-regulation may insufficient to fully compensate for fetal Fe deficits 
because TfR has been found to be hypergylcosylated in diabetic pregnancies (185). When net Fe 
delivered to the developing fetus is limited, Fe may be prioritized to support fetal RBC 
production over other fetal tissues and Fe storage compartments. Net Fe content of the brain, 
liver and heart have been found to be decreased by 40-90% in autopsy studies of infants born to 
diabetic women when compared to control infants matched for gestational age at birth (188). The 
dysregulated maternal-fetal Fe homeostasis in diabetic pregnancies has been linked to functional 
consequences for the neonate/child as evidenced by impaired auditory recognition memory 
processing at birth (176), and altered explicit memory performance in children from diabetic 
pregnancies at 3.5 years of age (189). 
Adolescent pregnancy 
Recent figures from the Centers for Disease Control and Prevention (CDC) indicate that a 
total of 1,100 adolescents give birth each day in the US; 1 in 10 new mothers is an adolescent 
and teen childbearing costs US taxpayers more than 9 billion dollars per year (190). Few studies 
have specifically focused on pregnant adolescents to characterize the magnitude, determinants 
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and potential adverse health consequences associated with anemia in this age group. Minority 
adolescents may be particularly vulnerable as they are at higher risk for both early childbearing 
and anemia. Data from 1,141 African-American adolescents receiving care at a prenatal 
maternity clinic in Baltimore, Maryland found that while 9-13% of pregnant adolescents were 
anemic during early gestation, this prevalence increased to 57- 66% by the third trimester of 
pregnancy (191). Even after adjusting the normal Hb range downwards to 9.0-10.5 g/dL, to 
account for the 0.8 g/dL lower Hb observed among blacks (191), maternal anemia in adolescents 
was associated with a nearly 2-fold increased risk of low birth weight and preterm birth (10). In a 
longitudinal study of 80 minority teens, teens with a TfR/SF ratio > 300 in the second trimester 
were 12-times more likely to be classified with IDA during their third trimester of pregnancy, 
and 31% of teens had a TBI < 0 mg/kg in late gestation (12). While teens with low Fe reserves 
have been found to up-regulate placental TfR to meet fetal Fe demands, 9% of babies born to 
adolescent mothers were found to have ferritin stores ≤  34 µg/L at birth (127). This may have 
functional consequences as ferritin concentrations ≤ 34 µg/L have been associated with brain ID, 
impaired auditory recognition memory, and lower psychomotor development scores (176). 
Multiple births  
 Multiple births in the US are rapidly increasing in large part due to assisted reproductive 
technologies. From 1980-1999 alone, the rate of triplet births increased by more than 400% and 
twin births by more than 50% (192). Recent data indicate that multiple births now comprise 3-
4.5% of all births in the US (193). Women carrying multiples are at increased risk for premature 
birth; nationally the average gestational age at delivery for those carrying twins is 37 weeks and 
for those carrying triplets it is 33 weeks (194). Preterm birth is a known risk factor for early 
anemia screening as emphasized by the AAP (5). Women carrying multiple fetuses may be at 
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even greater risk of ID due not only to the high Fe costs required by multiple fetal/placental 
units, but also due to their high gestational weight gains which could potentially increase 
systemic inflammatory mediators such as interleukin-6 (IL-6). The US currently has no specific 
nutritional recommendations for women carrying multiples, nor are there specific screening 
recommendations for their neonates to insure the Fe stores at birth are adequate. Obtaining 
normative data on Fe status in women carrying multiples will identify the degree to which Fe 
insufficiency is present in this group. Should anemia and/or low neonatal Fe stores be prevalent, 
subsequent screening and intervention approaches can be developed to target this high-risk 
group.    
Conclusion 
 Many women enter pregnancy with insufficient Fe reserves and lack access to foods rich 
in Fe or Fe supplements. Recent reviews have highlighted the positive impact of maternal Fe 
supplementation on maternal birth outcomes, preterm birth and low birth weight but questions 
remain on how Fe supplementation influences maternal Fe stores at parturition, neonatal Fe 
status at birth and subsequent health outcomes in the child. In spite of the known associations 
between maternal anemia and adverse outcomes, more research is needed to design effective 
interventions to prevent or minimize maternal anemia. Additional work is needed to assess 
relative benefits of single vs. multivitamin mineral supplements on maternal status across 
pregnancy. To date, the majority of attention on Fe intake and pregnancy outcomes has focused 
on non-heme Fe. Heme Fe is independently regulated and has greater bioavailability in the 
mother. New data suggests there may be differential use of Fe from non-heme or heme sources 
during pregnancy. Similarly, while the placenta has some of the highest expression of heme 
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trafficking proteins of all tissues in the human body, the role, regulation and functions of these 
proteins in the placenta are poorly described in relation to maternal and neonatal Fe status.  
To fully assess benefits and drawbacks to Fe supplementation, research and analytical 
approaches are needed to understand the physiological anemia of pregnancy that occurs due to 
hemodilution. In women with insufficient plasma volume expansion, more research is needed to 
identify biomarkers of this process in order to account for this measure in interpretation of 
circulating Fe status indicators. Additional work is also needed to identify the mechanisms 
responsible for hemoconcentration during pregnancy and the role of Fe intake in this process.  
Hepcidin is now known to be a systemic Fe regulatory hormone, but questions remain on 
the role of this hormone on maternal, placental and neonatal Fe status. The fetus independently 
produces its own hepcidin early in gestation; the degree to which fetal hepcidin regulates 
placental Fe trafficking proteins in response to fetal Fe needs merits further attention. Because 
hepcidin explains only 20-30% of the variability in Fe absorption, additional data are needed to 
identify other genetic and environmental factors that impact maternal and neonatal Fe 
homeostasis. 
Fe status in utero may program the fetus and impact brain development and subsequent 
neurobehavioral and cognitive outcomes. Animal studies have indicated that critical windows of 
development may exist across gestation and additional work is needed to explore if similar 
relationships exist in humans and if the timing and type of Fe supplementation given impacts 
outcomes in the offspring. Universal anemia screening is recommended in infants at 1 year of 
age but assessment at this late date may miss infants at increased risk for early ID. Given the 
explosion in multiple births, the continued problem of teen pregnancy, and the increase in risk of 
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obesity and gestational diabetes mellitus, these groups may benefit from additional neonatal 
screening to insure that Fe status in the neonate at birth is optimal.   
Limited normative data are available on Fe status indicators among healthy neonates. 
Birth practices such as cord clamping can markedly impact Fe stores in the neonate and 
confound exploration of relationships between maternal and neonatal Fe status. The impact of 
neonatal Fe status at birth on acute and long-term functional outcomes is a growing area of 
interest. Many new approaches are available to assess functional outcomes in the neonate; 
continued application of these approaches among at-risk cohorts will allow for better targeting 
and intervention of neonates with suboptimal Fe reserves at birth.  
The 1997 review by Allen (122) on pregnancy and ID ended with the statement: “It is 
possible that efforts to improve the situation, and compliance by mothers, might be improved if 
adverse impacts of ID during pregnancy were better documented. Conversely, if the impacts are 
minimal, it may be more appropriate on a global scale to focus on severe anemia and to view 
pregnancy as a situation of temporary anemia and iron depletion that does not require 
intervention in every woman.” Many advances have been made over the past 15 years of 
research on this topic yet many unresolved issues remain. The impact of Fe supplementation 
during pregnancy extends beyond the pregnant women to her developing fetus. Additional focus 
on the role of Fe in promoting optimal maternal and neonatal outcomes is needed at these key 
life stages. 
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Research Overview and Specific Aims 
Data from National Health and Nutrition Examination Survey indicate that the prevalence 
of iron deficiency (ID) among children age 1-2 years has more than doubled over the past 
decade, reaching 15.9% in 2008 (195). ID during infancy delays the development of the central 
nervous system and results in cognitive, social-affective, and psychomotor impairments. At 
present, there are no nutritional screening programs for ID in infants < 12 months (196). In 
addition, the regulatory capacity of the enterocyte may not be fully developed during early 
infancy and may not adequately modify iron (Fe) absorption in response to Fe status (197). For 
this reason low Fe stores at birth are a major risk factor for infant ID (198). A better 
characterization of the major factors involved in the establishment of neonatal Fe stores will help 
formulate effective prenatal strategies to maximize the birth Fe endowment and minimize 
adverse effects of postnatal Fe insufficiency.  
Fe in the diet exists in two forms: non-heme Fe and heme Fe. Heme Fe only represents 
10% of total dietary Fe intake but accounts for one-third of absorbed Fe due to its high 
bioavailability (199). In contrast to the relatively well-defined mechanisms of non-heme Fe 
absorption, the specifics of heme Fe absorption remain uncertain. Over the past decade, several 
heme Fe transporters have been identified in the intestine yet their role in Fe absorption remains 
unexplored. Despite extensive evidence for the importance of maternal diet in insuring adequate 
fetal Fe supply, little is known about endogenous maternal Fe sources and their contributions to 
fetal Fe. It is well recognized that dietary Fe alone is not enough to meet the high fetal demands 
during the third trimester of pregnancy and nearly 30% of women enter pregnancy with no Fe 
stores (6). Endogenous Fe obtained from the degradation of senescent RBCs constitutes the 
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largest single Fe influx into the circulation (20 mg Fe/day) (200), and may represent a potentially 
important Fe source of heme and non-heme iron for the fetus. However, virtually no information 
is available on the utilization of this Fe source during pregnancy. The majority of Fe derived 
from RBC breakdown is recycled back into maternal circulation as non-heme Fe but a small 
portion is thought to be released as heme or hemoglobin (Hb) (139). The human placenta 
contains all known receptors and catabolic enzymes involved in heme Fe utilization (201). At 
present, questions remain as to whether any of these proteins play a role in placental Fe transfer 
and how they are regulated in response to maternal and fetal signals. Recent data in rats 
highlights the ability of the fetus to regulate placental Fe transfer via the action of the fetal 
systemic Fe regulatory hormone, hepcidin (121). This hypothesis has yet to be validated in 
humans. Furthermore, while the fetus may have some capacity to regulate Fe transfer, the 
relative importance of maternal versus fetal hepcidin in regulating placental Fe transfer remains 
to be determined. 
To address gaps in intestinal and placental Fe transport and the regulation of Fe 
homeostasis during pregnancy, we undertook a series of animal and human studies with the 
following five specific aims:  
 
Aim 1: To review literature on Fe utilization during pregnancy  
Current status: A review on various aspects of Fe related topics in pregnancy including Fe 
supplementation, mechanisms of placental Fe transport, assessment of maternal and neonatal Fe 
status was published in Nutrition Reviews in 2013. The review is included in Chapter 1 as the 
background for this doctoral work.   
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Aim 2: To determine the impact of hepcidin on intestinal heme Fe absorption in rats with 
induced Fe overload  
Hypothesis: 1) Fe loading in rats will increase liver hepcidin production and strongly suppress 
duodenal expression of non-heme Fe transporters and non-heme Fe absorption; and 2) Heme Fe 
absorption and duodenal heme Fe transporters will be less impacted by hepcidin up-regulation.  
Current status: The manuscript is presented in Chapter 2 and is undergoing second round of 
review at the Journal of Nutrition as of July 2014.  
 
Aim 3: To measure placental expression of heme Fe transporters and identify the 
determinants of their expression 
Hypothesis: Placental expression of two heme transporters (LRP1 and PCFT) will be associated 
with maternal and neonatal Fe status and the Fe regulatory hormone, hepcidin. 
Current status: The manuscript on placental LRP1 expression is in press at Reproduction. The 
manuscript on placental PCFT expression has been written and will be submitted to the Journal 
of Nutrition by the end of July. Both manuscripts are presented in Chapter 3.  
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Aim 4: To assess the relative contributions of maternal RBC catabolism and dietary Fe 
absorption to fetal Fe stores in human pregnancy 
Hypothesis: 1) A greater fraction of Fe derived from maternal RBCs will be transported to the 
fetus when compared to relative amounts of Fe transferred to the fetus from maternal diet during 
the third trimester of pregnancy; and 2) Placental transfer of both maternal Fe sources will be 
negatively regulated by neonatal hepcidin.  
Current status: A total of 16 participants have been recruited since August, 2012 and 12 women 
have completed the study. Sample collection from all participants will be finished in October 
2014, laboratory analysis will be completed by December 2014, and the manuscript will be 
submitted for review by January 2015. Preliminary results are presented in Chapter 4.  
 
Aim 5: To determine the impact of pre-pregnancy obesity and excessive gestational weight 
gain on maternal hepcidin and neonatal Fe status in pregnant adolescents   
Hypothesis: Maternal obesity and excessive gestational weight gain will be associated with 
elevated inflammation as measured by interleukin 6 and hepcidin and this will be associated with 
deficits in neonatal Fe status at birth. 
Current status: The manuscript is presented in Chapter 5 and is currently under review at the 
Journal of International of Obesity as of July 2014.  
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CHAPTER 2 
DUODENAL ABSORPTION AND TISSUE UTILIZATION OF DIETARY HEME AND 
NON-HEME IRON IN A RAT MODEL OF IRON OVERLOAD2 
Abstract 
Dietary heme contributes to Fe intake yet regulation of heme absorption and tissue 
utilization of absorbed heme remain undefined. In a rat model of Fe overload, we utilized stable 
Fe isotopes to examine heme and non-heme Fe absorption in relation to liver hepcidin and to 
compare relative utilization of absorbed heme and non-heme Fe by erythroid (RBC) and Fe 
storage tissues (liver and spleen). Twelve male Sprague Dawley rats were randomized to 
injections of either saline or Fe dextran (16 mg or 48 mg of Fe over 2 weeks). After Fe loading, 
rats received oral stable Fe in the forms of 57Fe-ferrous sulfate and 58Fe-labeled hemoglobin. 
Expression of liver hepcidin and duodenal Fe transporters and tissue stable Fe enrichment were 
determined 10 days post-dosing. High Fe loading increased hepatic hepcidin by 3-fold and 
reduced duodenal expression of divalent metal transporter1 by 76%. Non-heme absorption was 
2.5-times higher than heme Fe absorption. Absorption of both forms of Fe were inversely 
correlated with hepatic hepcidin expression but hepcidin had a stronger impact on non-heme Fe 
absorption (p=0.04). Significantly more 57Fe was recovered in RBC and more 58Fe was 
recovered in the spleen. Elevated hepcidin significantly decreased heme and non-heme Fe 
absorption but had a greater impact on non-heme Fe absorption. Differential tissue utilization of 
heme vs. non-heme Fe was evident between erythroid and Fe storage tissues, suggesting some 
heme may be exported into the circulation in a different form than non-heme Fe. 
                                                             
2 Cao C, Thomas CE, Insogna KL, O’Brien KO. In revision at Journal of Nutrition July 2014. 
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Introduction 
Fe is an essential micronutrient for humans and plays a critical role in a variety of 
processes such as oxygen transport and energy production. Because humans have no regulated 
mechanism of Fe excretion, Fe balance relies primarily on tight regulation at the level of 
intestinal Fe absorption (1). Dietary Fe is present in two distinct forms: heme Fe (animal 
products) and non-heme Fe (plants, animal products and supplements). The absorption of non-
heme Fe is tightly controlled by body Fe status and the liver-derived peptide hormone, hepcidin, 
the hormone that responds to body Fe reserves to regulate Fe homeostasis (2). Hepcidin is 
thought to affect Fe absorption by inducing the degradation of the basolateral Fe transporter 
ferroportin (FPN), thus limiting Fe export into the circulation (3). However, this classic model of 
hepcidin action has been challenged by accumulating cell culture and animal data showing 
mixed results regarding the relationship between hepcidin and duodenal FPN (4-7). Recent 
studies in mice and Caco-2 cells further suggest that the brush boarder Fe transporter, divalent 
metal transporter 1 (DMT1), not FPN, is the primary target of hepcidin regulation (5). Clearly, in 
vivo experiments that explore the interrelationships between hepcidin, intestinal Fe transporter 
expression, and non-heme Fe transport are needed to clarify the complex mechanisms by which 
hepcidin modulates absorption of dietary heme and non-heme sources of Fe.   
Heme Fe constitutes ~10% of total dietary Fe intake in a typical western diet but is 
thought to provide nearly one-third of absorbed Fe because of its substantially higher absorption 
and bioavailability (8). Despite the importance of heme in Fe nutrition, the mechanisms 
responsible for heme Fe absorption remain largely uncharacterized. In contrast to non-heme Fe, 
heme Fe absorption is less stringently regulated in response to Fe status and dietary inhibitors 
and enhancers. Apical heme uptake is thought to occur either via receptor mediated endocytosis 
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(9), or may in part be mediated by a low affinity heme importer, proton coupled folate 
transporter (PCFT) (10), or to an as yet identified heme importer. It is believed that once in the 
enterocyte, the majority of heme Fe is converted to inorganic Fe and enters a common 
intracellular Fe pool with non-heme Fe to be exported out to the circulation by FPN. An 
alternative heme enterocyte export pathway has been described in guinea pigs whereby heme is 
exported intact into the plasma (11). The presence of the heme exporter, feline leukemia virus C 
receptor 1 (FLVCR1), in the human duodenum supports this hypothesis (12). Little is known 
about the relative impact of hepcidin on heme versus non-heme Fe absorption and the degree to 
which Fe overload differentially influences duodenal and tissue expression of heme and non-
heme Fe transporters. 
The goal of this study was to utilize a rat model of Fe overload and labeled heme and 
non-heme Fe to examine the impact of hepcidin on heme vs. non-heme Fe transport across the 
enterocyte in vivo and to evaluate associations between Fe loading and hepcidin expression on 
duodenal, hepatic and splenic expression of proteins involved in the transport of heme [PCFT, 
heme oxygenase (HO)-1] and non-heme Fe [DMT1, FPN, duodenal cytochrome b (Dcytb)]. We 
hypothesized that Fe loading would elevate liver hepcidin production and result in parallel 
reductions in duodenal FPN and non-heme Fe absorption and that Fe loading would have a 
substantially larger ability to down-regulate non-heme Fe trafficking proteins and absorption.  
We further hypothesized that heme and non-heme Fe absorption would be differentially 
impacted by hepcidin expression. 
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Methods 
Animals and treatments 
Twelve adult male Sprague Dawley rats (8-10 weeks of age) were maintained on a 
standard rodent diet (Fe content: 36 ppm; AIN93-G, Harlan Teklad, Indianapolis, IN) for a week 
before being randomized to one of three groups: high Fe loading, moderate Fe loading, or control 
group. Animals in the high and moderate Fe groups received a total of 48 mg and 16 mg Fe 
administered through intra-peritoneal injections of Fe dextran twice a week for two weeks from 
Day 0 to Day 13. A relatively mild regimen of Fe overload was chosen (~0.03 and 0.1 mg Fe/g 
body weight) when compared to other Fe loading rodent protocols (0.2-1.5 mg/g body weight) 
(13-16) to better characterize relationships between Fe absorption and hepcidin under more 
physiological conditions. Animals in the control group were injected with phosphate buffered 
saline (PBS) at the same time points during the same period. All study procedures were approved 
by the Yale Institutional Animal Care and Use Committee.  
Isotope preparation 
Stable Fe isotopes (57Fe at 95% enrichment and 58Fe at 93% enrichment) were purchased 
from Trace Sciences International (Richmond Hill, Canada). The 57Fe isotope was converted into 
ferrous sulfate solution by Anazao Health Corporation (Tampa, FL) using the method of 
Kastenmayer et al (17). The 58Fe isotope was converted into ferrous citrate and injected into a 
piglet to intrinsically label porcine RBC as described elsewhere (18). The 58Fe enrichment of the 
labeled porcine RBC was 17.3 ± 0.01% as determined by magnetic sector thermal ionization 
mass spectrometer (ThermoQuest Corp., Bremen, Germany). 
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Iron absorption studies 
Absorption of heme and non-heme Fe were measured 2-weeks after Fe loading using 
orally administered stable Fe isotopes. Oral stable Fe tracers containing similar amounts of total 
Fe (25.4 µg 58Fe as porcine 58Fe-Hb, total Fe from the Hb dose: 145.0 µg; 172.1 µg 57Fe as 
57FeSO4; total Fe from the FeSO4 dose: 181.0 µg) were administered by oral gavage on two 
separate days using a randomized cross-over design so that half of the rats received the heme Fe 
tracer on Day 14 and non-heme Fe tracer on Day 17 and the remaining rats received these two 
forms of Fe in the reverse order. Fe tracer doses were separated by 3 days to allow sufficient 
time for the intestinal epithelium to renew in order to minimize any impact of the first tracer dose 
on absorption of the second tracer dose. Absorption of the heme and non-heme tracers was 
assessed by RBC enrichment 10 days after the administration of the second tracer since prior Fe 
tracer studies in rats have established that RBC incorporation of injected Fe is complete within 6 
days of administration (19, 20). Rats were sacrificed 10-days post-dosing, and whole blood was 
collected by cardiac puncture. Serum was separated and stored at -80ºC. Liver, kidney, spleen, 
heart, and duodenal tissue were harvested, flash frozen in liquid nitrogen, and stored at -80ºC 
prior to analysis for Fe isotopic enrichment by TIMS as detailed below. 
Blood and tissue Fe isotopic enrichment measurement 
Samples of whole blood, liver, and spleen were digested with 4 mL HNO3 in 
polytetrafluoroethylene beakers and evaporated to dryness after the solutions were clear. 
Samples were dissolved in 2 mL 6N HCl and Fe was extracted by anion exchange 
chromatography as described previously (21). The eluate was dried and reconstituted in 50µl 3% 
HNO3. Extracted Fe samples (8 µL) were loaded onto rhenium filaments (H Cross Co, 
Weehawken, NY) with 4 μL silica gel (Sigma-Aldrich, St Louis, MO) and 4 μL phosphoric acid. 
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Isotopic ratios (57/56Fe and 58/56Fe) were measured using TIMS. The natural abundance values 
used were 0.02317 for 57/56Fe and 0.00308 for 58/56Fe. Relative SDs averaged 0.025% and 0.30% 
for 57/56Fe and 58/56Fe, respectively. All acids used were ultrapure (Ultrex; JT Baker, Phillipsburg, 
NJ).  
Calculation of tissue isotope incorporation  
The net amount of 57Fe and 58Fe incorporated in RBC was determined by multiplying 
RBC enrichment of the two tracers by the total RBC Fe mass assuming a blood volume for male 
Sprague Dawley rats of 68.6 mL/kg (22), and an Fe content of Hb of 3.47 g/kg (23). A similar 
approach was used to calculate the net amount of 57Fe and 58Fe in liver and spleen using the 
measured tissue 57Fe and 58Fe enrichment, tissue Fe concentration, and an estimated tissue 
weight for male Sprague Dawley rats derived from equations developed based on the age of the 
animal (24).  
Calculation of Fe absorption 
Fe absorption was calculated as the total amount of tracer recovered in RBC, liver and 
spleen as a fraction of the oral dose. Due to inadequate liver sample and nickel contamination in 
some spleen and liver samples which interfered with 58Fe enrichment measures, data on total 
recovered 57Fe and 58Fe were only available for 11 and 9 of the 12 rats, respectively. From the 
animals with complete tissue enrichment data, we determined that 80.5% and 71.3% of the total 
recovered 57Fe and 58Fe were found in RBC. This allowed us to make assumptions about RBC 
incorporation of heme and non-heme Fe tracers for the 3 rats that did not have complete tissue 
enrichment data. We also calculated absorption based on 80% RBC incorporation frequently 
used in human studies to estimate heme and non-heme Fe absorption. This method did not 
change the relationships between heme/non-heme Fe absorption with hepcidin.  
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Calculation of Fe absorption and tissue Fe uptake  
The oral Fe tracer has two primary fates once absorbed across the enterocyte: it is either 
utilized by RBC for Hb synthesis or delivered to storage sites (primarily the liver and spleen) 
(Figure 2.1). Absorption of heme and non-heme Fe was calculated as the total amount of heme 
(58Fe) or non-heme (57Fe) tracer recovered in RBC, liver, and spleen as a fraction of the total oral 
tracer dose administered. Tissue utilization of absorbed tracers was assessed using 3 approaches. 
The first approach presented the delta percent excess of each isotope, which reflects the degree to 
which the natural abundance of isotope in each tissue was increased as a result of tissue tracer 
uptake. The second approach estimated the net quantity (µg) of each Fe tracer recovered in the 
RBC pool, liver, and spleen. The third measure assessed the relative distribution of absorbed 
tracer in RBC, liver, and spleen by expressing the amount of tracer in each tissue as a proportion 
of the total tracer recovered.  
 
 
Figure 2.1. Calculation of duodenal absorption and tissue distribution of dietary heme 
and non-heme Fe isotopes 
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Tissue Fe determination 
Tissue Fe concentration was measured using a graphite atomic absorption 
spectrophotometer (Perkin-Elmer 370, Norwalk, CT). Bovine liver standard 1577 (National 
Bureau of Standards) was analyzed in the same manner to insure accuracy of the Fe 
measurements.   
Western blotting of tissue Fe proteins and serum ferritin  
Protein was extracted from liver, spleen, and duodenum by homogenizing tissues in lysis 
buffer containing protease inhibitors (Sigma Aldrich, St. Louis, MO). Proteins (30 µg) were 
solubilized in Laemmli buffer and boiled for 5 min at 95°C before SDS-PAGE and subsequent 
transfer onto polyvinylidene difluoride (PVDF) membranes. Membranes were blocked in 
Odyssey Blocking Buffer (Li-Cor, Lincoln, NB) for 1 hour and incubated with primary 
antibodies overnight at 4oC. Antibodies and the concentrations used were as follows: anti-FPN 
(MTP11-A, Alpha Diagnostics, San Antonio, TX) at 1:1000 dilution; anti-TfR1 (No. 136800, 
Life Technologies, Grand Island, NY) at 1:5000 dilution; anti-PCFT (ab25134, Abcam, Boston, 
MA) at 1:1000 dilution; anti-HO1 (SPA-869, Enzo Life sciences, Farmingdale, NY) at 1:500 
dilution; anti-ferritin (ab55077, Abcam, Boston, MA) at 1:1000 dilution. After incubation with 
the primary antibodies overnight at 4°C, membranes were washed five times and then incubated 
with appropriate infrared secondary antibodies (1:5000 dilution; Li-Cor, Lincoln, NE) at room 
temperature for 1 hr. Blots were visualized using the Odyssey Infrared Imaging System (Li-Cor, 
Lincoln, NE) and the expression of target proteins were normalized to β-actin (sc47778, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) and expressed as a ratio relative to the control group. 
Six duodenal lysates from six rats appeared to be partially degraded as indicated by substantially 
lower β-actin levels compared to other analyzed duodenal lysates. These lysates were excluded 
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from western blot analysis of duodenal Fe transporters. The degradation likely reflects the known 
presence of high concentrations of proteases in duodenal tissue. 
Serum ferritin was analyzed by western blotting in serum samples collected on the day of 
sacrifice. Serum (5 µL) was diluted with DI H2O, separated on a 12.5% SDS-PAGE gel, and 
transferred to a PVDF membrane. After blocking, the membrane was incubated with a ferritin 
antibody (ab55077, Abcam, Boston, MA; 1:1000), probed with an infrared secondary antibody, 
and analyzed using the Odyssey imaging system as described above. 
Quantitative reverse-transcription polymerase chain reaction (qPCR) 
Total RNA was extracted from duodenal enterocytes and liver using TRIzol reagent 
(Invitrogen, Carlsbad, CA), followed by purification using the RNeasy Mini Kit (Qiagen, 
Valencia, CA). The cDNA was synthesized using the iScriptTM cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA) and reversed transcribed using a PTC-100 PCR machine (MJ Research, Inc., 
Waltham, MA). qPCR was performed using TaqMan assays for the following targets: Dmt1 
(Rn00565927_m1), Dcytb (Rn01484657_m1), TfR1 (Rn01474701_m1), hepcidin 
(Rn00584987_m1), Pcft (Rn01471182_m1), hephaestin (Rn00515970_m1), and Fpn 
(Rn00591187_m1) (Applied Biosystems, Foster City, CA). β-actin was used as the endogenous 
reference (Rn00667869_m1; Applied Biosystems). The PCR reactions were run using an iQ2 
Optical System (Bio-Rad, Hercules, CA) with the following protocol: 95°C for 10 min, 40 cycles 
at 95°C for 20 sec, and 60°C for 1 min. Relative quantification of target genes was calculated 
using the comparative CT method. 
Statistical analysis 
Statistical analyses were performed in JMP 10.0 (SAS, Cary, NC). Differences between 
treatment groups were compared using one-way ANOVA and Tukey’s post-hoc test. Differences 
 64 
in isotopic enrichment between liver, spleen, and blood were analyzed in a regression model 
coding rat ID as a random effect. Heme and non-heme Fe absorption were compared by paired t 
test. Simple linear regression was used to examine relationships between hepcidin, RBC Fe 
incorporation, Fe transporter expression, and tissue isotopic enrichment. An interaction term 
between Fe form (heme vs. non-heme) × hepcidin was used to test whether the effect of hepcidin 
on Fe absorption differed between heme versus non-heme Fe. Data are expressed as Mean ± 
SEM unless otherwise indicated. Statistical significance was defined when P < 0.05. 
 
Results 
Impact of Fe loading on tissue Fe content, hepcidin, and tissue Fe transporter expression 
Two weeks of Fe loading with a total of 16 mg or 48 mg did not significantly influence 
body weight or Hb levels between the Fe loaded and control groups. Rats in the high Fe group 
had elevated tissue Fe concentrations (mg/g dry weight) in liver and spleen while those in the 
moderate Fe group only exhibited significant increases in the Fe content of the spleen. Fe loading 
significantly increased liver hepcidin mRNA in the high Fe group (Figure 2.2); the increase in 
the moderate Fe group did not reach significance (p = 0.2). Hepcidin correlated in logarithmic 
proportion to liver Fe concentrations (r = 0.95, p < 0.0001). Serum ferritin did not differ between 
the 3 treatment groups (p = 0.1) but was significantly higher in the combined high and moderate 
Fe group when compared to the controls (p = 0.03) (Figure 2.2).  
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Figure 2.2. Effect of Fe injections on hepcidin and tissue Fe transporter expression in rats. (A) 
Liver hepcidin mRNA in rats injected with either PBS, 16 mg or 48 mg of Fe. Values represent 
mean ± SEM (n=4). Bars with different letters are significantly different. (B) Serum ferritin 
protein expression determined by western blotting. (C) Liver expression of genes involved in Fe 
metabolism. (D) Expression of proteins involved in Fe metabolism in the spleen.  
 
 
Expression of genes involved in Fe metabolism in the liver was determined by qPCR 
(Fpn and TfR1) and western blotting (FPN, TfR1, HO-1, and ferritin) (Figure 2.2). Fe injections 
significantly suppressed hepatic TfR1 but had no impact on hepatic Fpn mRNA. Similar 
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treatment responses were noted for hepatic protein expression of TfR1 and FPN. Hepatic protein 
expression of ferritin and HO-1 in the high Fe group tended to be higher than the moderate and 
control groups but differences observed were not statistically significant. Expression of Fe 
proteins in the spleen was assessed by western blotting (Figure 2.2). Only HO-1 was 
significantly increased in response to moderate and high Fe injections. Together, these results 
indicate the high Fe dextran treatment produced the classic phenotype of Fe overload while the 
moderate Fe regimen only mildly elevated Fe stores in the spleen without significantly affecting 
hepcidin production or expression of tissue Fe transporters.  
Impact of Fe loading on Fe absorption and duodenal Fe transporter expression 
Average absorption efficiencies of heme and non-heme Fe in the control animals 
averaged 19.8 ± 3.3% (mean ± SD) and 45.2 ± 12.1% (mean ± SD), respectively. Heme and non-
heme Fe absorption were strongly correlated within animals (r = 0.79, p = 0.002). In contrast to 
the significantly higher heme vs. non-heme Fe absorption that is known to occur in humans, the 
mean heme Fe absorption observed in all rats (n=12) was 60% lower than observed for non-
heme Fe absorption (n=12, p = 0.0007). Injections of moderate and high doses of Fe dextran 
suppressed non-heme Fe absorption by 46% (24.1% vs. 45.2%, p = 0.01) and 78% (10.0% vs. 
45.2%, p = 0.0004), respectively when compared to the control group. Percent heme Fe 
absorption was similarly decreased in the moderate (7.5% vs. 19.8%, p =0.0002) and high Fe 
group (4.7% vs. 19.8%, p<0.0001) when compared to the control group (Figure 2.3). Although 
the degree of suppression of heme and non-heme Fe absorption was greater with the 48 mg load 
as compared to the 16 mg load, these differences did not reach statistical significance (p = 0.08 
for non-heme Fe and p = 0.3 for heme Fe absorption). 
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Figure 2.3. Fe absorption and duodenal Fe transporter expression in rats after Fe 
loading treatment. (A) Heme and non-heme Fe absorption expressed as total 
heme and non-heme Fe isotopes recovered in RBC, liver, and spleen as a 
percentage of oral doses administered. (B) Duodenal mRNA expression of genes 
involved in Fe transport relative to the control group. Bars without a shared letter 
are significantly different. (C) Western blotting of genes involved in duodenal Fe 
transport (n = 2/group). 
 
Next we examined duodenal expression of genes involved in heme and non-heme Fe 
trafficking (Dmt1, Dcytb, Fpn, hephaestin, Pcft) and explored possible associations with heme 
and non-heme Fe absorption. Transcript levels of Dmt1 and Dcytb decreased significantly in the 
high Fe group (Figure 2.3) and both were significantly negatively correlated with heme and non-
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heme Fe absorption. However, no significant differences in mRNA expression of Fpn, 
hephaestin, or Pcft were evident in Fe loaded rats when compared to the control group. We also 
performed western blotting on selected heme and non-heme Fe proteins (FPN, PCFT HO-1, and 
ferritin) in duodenal lysates from 6 animals (Figure 2.3). Consistent with the mRNA results, 
there were no significant differences in FPN and PCFT protein expression between Fe loaded 
and control rats. Although only analyzed in two samples the expression of HO-1 and ferritin was 
higher in the high Fe group in both cases. 
Effect of hepcidin on Fe absorption and tissue Fe transporter expression  
Linear regression analysis showed that liver hepcidin mRNA correlated inversely with 
absorption of both heme (r = - 0.77, p = 0.003, n = 12) and non-heme Fe (r = - 0.80, p = 0.002, n 
= 12). The effect of hepcidin on Fe absorption differed significantly between the heme and non-
heme Fe tracers with every unit increase in hepcidin expression reducing heme absorption by 4.1 
% and non-heme absorption by 10.0% (p = 0.04). The interaction between dietary Fe (non-heme 
vs. heme Fe) and hepcidin is shown in Figure 2.4. 
 
 
Figure 2.4. Correlations of liver hepcidin mRNA with heme and non-heme Fe absorption 
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To investigate the molecular basis for the observed difference in the impact of hepcidin 
on heme and non-heme Fe absorption, duodenal heme and non-heme Fe transporter expression 
was examined in relation to liver hepcidin transcript expression. Hepcidin was inversely 
associated with Dmt1 (r = - 0.61, p = 0.04) and Dcytb mRNA (r = - 0.72, p = 0.009). There was a 
non-significant negative correlation between hepcidin and Fpn mRNA (p = 0.13). Hepcidin 
transcript expression did not correlate with duodenal Pcft mRNA expression. In the 6 rats with 
evaluable duodenal lysates, hepcidin protein levels were not associated with any of the Fe 
proteins examined (FPN, HO-1, PCFT, ferritin) except for a correlation with ferritin, which was 
not significant (r = 0.68, p = 0.09).  
Tissue utilization of ingested heme and non-heme Fe 
To explore whether there were potential differences in tissue utilization of absorbed heme 
and non-heme Fe, the relative recovery of the two tracers in RBC, liver, and spleen was 
evaluated (Table 2.1). A significantly higher percentage of non-heme Fe tracer was recovered in 
the RBC mass than that recovered for heme Fe (80.5% vs. 71.3%, p = 0.02). A reverse 
relationship was evident in the spleen, such that significantly more heme Fe tracer was recovered 
compared to the relative recovery of the non-heme Fe tracer (7.5% vs. 2.7%; p = 0.01). No 
significant difference in relative recovery of each form of Fe was noted in the liver. There was 
also a differential effect of hepcidin on tissue utilization of absorbed heme and non-heme Fe. In 
the RBC pool, the net amount of both 57Fe and 58Fe tracer recovered was inversely correlated 
with liver hepcidin (r = - 0.75, p = 0.005; r = - 0.76, p = 0.005, respectively). Hepcidin was not 
related to the net amount of either the heme or non-heme Fe tracer recovered in the liver or the 
spleen. 
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Table 2.1. Enrichment of 58Fe-heme and 57Fe-non-heme in blood, liver, and spleen in rats1 
 Non-heme (57Fe) Heme (58Fe) P-value 
Blood    
% Fe excess 8.6 ± 1.6 3.8 ± 0.5 0.0007 
Net tracer amount (µg) 34.9 ± 6.2 1.9 ± 0.3 0.0001 
% recovered tracer 80.5 ± 2.4 (n = 11) 71.3 ± 4.7 (n = 9) 0.02 
Liver    
% Fe excess 9.5 ± 3.3 (n = 11) 3.5 ± 1.3 (n = 10) 0.002 
Net tracer amount (µg) 6.8 ± 1.1 (n = 11) 0.41 ± 0.04 (n = 10) 0.0005 
% recovered tracer 16.8 ± 2.0 (n = 11) 21.2 ± 3.7 (n = 9) 0.15 
Spleen    
% Fe excess 1.6 ± 0.5 1.2 ± 0.5 (n = 10) 0.4 
Net tracer amount (µg) 0.9 ± 0.2 0.13 ± 0.03 (n = 10) 0.002 
% recovered tracer 2.7 ± 0.6 (n = 11) 7.5 ± 1.8 (n = 9) 0.01 
1 Values are mean ± SEM; n < 12 indicates lack of tissue sample or nickel contamination that 
interfered with 58Fe determination 
Discussion 
Few studies have simultaneously assessed the impact of hepcidin on heme and non-heme 
Fe absorption and tissue utilization in relation to key Fe transport proteins and hepcidin 
expression. In the rat model of Fe loading, hepcidin was found to have a significantly greater 
ability to regulate absorption of non-heme Fe when compared to heme Fe, a difference that was 
accompanied by significant differences in expression of DMT1 and Dcytb. Differential tissue 
utilization of orally ingested heme versus non-heme Fe was also evident, with the RBC 
preferentially utilizing Fe derived from a dietary non-heme Fe source while the spleen 
preferentially utilized dietary Fe ingested in the form of heme Fe.     
Moderate Fe loading resulted in a 3-fold increase in liver hepcidin and a 4-fold reduction 
in non-heme Fe absorption. These changes were accompanied by a marked down-regulation in 
duodenal Dmt1 mRNA while duodenal Fpn mRNA showed only a slight, but non-significant, 
decrease in response to Fe injection and increased hepcidin production. Similar findings of an 
inverse association between hepatic hepcidin expression and duodenal Fe transporter mRNA 
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have been observed in both Fe-loaded mice (25) and rats (4, 26). These changes are thought to 
occur in response to rises in intracellular Fe, which could reduce transcript stability via the iron 
regulatory element/iron regulatory protein system (27), or inhibit transcription by interfering 
with hypoxia inducible factor-2 signaling (28). We found that transcript levels of Dmt1 and Fpn 
were highly correlated with their functionally associated ferrireductase/ferroxidase, Dcytb and 
hephaestin, suggesting a coordinated regulation of these genes in the duodenum (29, 30). 
Contrary to the classic hepcidin-dependent down-regulation of FPN protein observed in the 
macrophage, both FPN protein and transcript expression in the duodenum were unrelated to 
hepcidin and non-heme Fe absorption. This is in line with recent studies in Caco-2 cells and 
rodents showing no impact of hepcidin treatment on duodenal FPN and basolateral Fe transport 
(5, 7, 31). Our results support the accumulating evidence that DMT1, and not FPN, is a primary 
target for hepcidin regulation in the duodenum. It has been suggested that hepcidin may 
indirectly affect duodenal FPN protein by down-regulating DMT1 and thus decreasing 
intracellular Fe concentrations and hence Fpn transcripts (5). This may explain the low FPN 
protein levels in mice with sustained hepcidin expression (5). It is worth noting that hepcidin 
remained a significant determinant of non-heme Fe absorption after accounting for variation in 
duodenal Dmt1 mRNA, suggesting the presence of other absorptive components that mediate the 
suppression of Fe absorption by hepcidin.  
In this study, absorption of Fe from a dietary heme Fe source was on average 60% lower 
than Fe absorption from non-heme, ferrous sulfate. Our finding of a preferential absorption of 
non-heme over heme Fe has been previously documented in early radiotracer studies in Sprague 
Dawley rats where a 70-90% lower retention of Fe from heme Fe sources (Hb (32, 33), 
myoglobin (34), and beef (35)) was noted compared to Fe retention from non-heme Fe sources. 
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However, these data are in direct contrast to human studies that consistently show a 2-5 fold 
greater relative Fe absorption from heme vs. non-heme Fe (36-38). The physiological basis for 
this species difference in differential heme vs. non-heme Fe utilization is unknown and perhaps 
reflects adaptation to habitual diets of primarily animal- vs. plant-based Fe sources. Despite the 
relative differences in heme versus non-heme Fe absorption, cellular mechanisms of heme and 
non-heme Fe absorption are thought to be similar between these two species (39). There is also 
ample evidence to suggest that rats respond similarly to dietary and physiological factors known 
to affect heme Fe absorption in humans including meat proteins and body Fe stores (40). 
Because of these qualitative similarities, rat models offer important insights on the mechanisms 
and regulation of heme Fe absorption in humans although species differences must be considered 
when making inferences.  
Both heme and non-heme Fe absorption were suppressed by Fe overload and both were 
inversely correlated with liver hepcidin. Liver hepcidin expression explained 59% and 63% of 
the variation in heme and non-heme Fe absorption but had a greater relative impact on non-heme 
Fe absorption. Liver total Fe concentrations were found to be an equally strong predictor of the 
absorption of heme and non-heme Fe. These relationships closely resemble those observed 
between heme absorption and serum ferritin in humans (36, 38), confirming that heme Fe 
absorption is responsive to changes in body Fe status, though to a lesser extent than non-heme 
Fe. The inhibitory effect of Fe status on heme Fe absorption did not seem to be mediated by 
duodenal PCFT and HO-1, as neither was changed by Fe injection or hepcidin. Interestingly, 
there was a strong inverse relationship between heme absorption and duodenal Dmt1 mRNA. 
This may reflect their shared regulation by body Fe status or a role of Dmt1 in transporting 
heme-derived inorganic Fe from the endosome after apical endocytosis of heme (9). 
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The use of stable Fe isotopic techniques provided a unique opportunity to simultaneously 
compare tissue utilization of these two types of dietary Fe in the same animals in response to 
body Fe stores. Differential tissue utilization of dietary heme versus non-heme Fe was evident 
with more non-heme Fe intake being utilized for RBC synthesis while a greater proportion of 
dietary Fe was delivered to the spleen when ingested as heme Fe. The relative distribution of 
absorbed non-heme Fe tracer between the liver, spleen, and RBC was similar to prior findings 
obtained following intravenous injection of radio-Fe salts in mice (41) and rats (42, 43). Few 
such data are available for heme Fe. While the majority of absorbed heme was recovered in the 
RBC Fe pool, the fraction of heme tracer recovered in RBC (71.3%) was significantly lower than 
that observed for non-heme Fe tracer (80.5%). The variable utilization of these two forms of Fe 
evident in the RBC was supported by the significantly 2-fold higher enrichment of heme-Fe in 
the spleen when compared to enrichment of non-heme Fe (7.5% vs. 2.7%). There was also a 
trend for greater uptake of heme Fe in the liver (21.2% vs. 16.8%) but this difference did not 
reach significance. The differential tissue utilization of absorbed heme versus non-heme Fe may 
suggest that a portion of absorbed heme exits the enterocyte in a form distinct from non-heme 
Fe. If heme is exported intact as heme using the FLVCR1 protein found on the basolateral 
membrane in enterocytes, it should share the same metabolic fate as plasma heme and be taken 
up by cells that express the heme receptor protein lipoprotein-receptor related protein 1 such as 
hepatocytes and macrophages in the liver and spleen (44). It has been shown in rats that more 
than 90% of intravenously injected heme-hemopexin is recovered in liver within 2 hours of 
tracer injection (45). This is consistent with our finding that a greater proportion of absorbed 
heme was delivered to the spleen and liver compared to relative tissue utilization of non-heme 
Fe.  
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In conclusion, moderate Fe loading in rats significantly increased tissue Fe content and 
hepatic hepcidin expression without impacting serum ferritin or hemoglobin concentration. 
Increased hepatic hepcidin expression was associated with significantly lower duodenal 
absorption of both heme and non-heme Fe absorption. The suppressive effects of hepcidin on 
non-heme and heme Fe absorption were mediated by DMT1 and were not associated with 
changes in FPN. Hepcidin more potently down-regulate non-heme absorption than heme Fe 
absorption in rats. There were significant differences in tissue deposition of the absorbed heme 
and non-heme Fe tracers suggesting some heme may be exported into the circulation in a 
different form from non-heme Fe. The cellular and molecular mechanisms underlying this 
difference will require further study. 
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CHAPTER 3 
PLACENTAL EXPRESSION OF HEME IRON TRANSPORTERS IN RELATION TO 
MATERNAL AND NEONATAL IRON STATUS 
Study1:  Placental heme receptor LRP1 correlates with the heme exporter FLVCR1 and 
neonatal iron status3 
Abstract 
LDL receptor-related protein 1 (LRP 1) is a transmembrane receptor highly expressed in 
the human placenta. It was recently found to be the receptor for heme and its plasma binding 
protein hemopexin (Hx) and is integral to systemic heme clearance. Little is known about 
systemic concentrations of hemopexin during pregnancy and whether maternal Hx and placental 
LRP1 contribute to fetal Fe homeostasis during pregnancy. We hypothesized that placental LRP1 
would be up-regulated in maternal/neonatal Fe insufficiency and would be related to maternal 
circulating Hx. Placental LRP1 expression was assessed in 57 pregnant adolescents (14 -18 y) in 
relation to maternal and cord blood Fe status indicators (Hb, SF, sTfR), the Fe regulatory 
hormone hepcidin and serum Hx. Hemopexin at mid-gestation correlated positively with Hb at 
mid-gestation (r = 0.35, P = 0.02) and Hx at delivery correlated positively with cord hepcidin (r 
= 0.37, P = 0.005). Placental LRP1 protein expression was significantly higher in women who 
exhibited greater decreases in serum Hx from mid-gestation to term (r = 0.28, P = 0.04). 
Significant associations were also found between placental LRP1 protein with cord hepcidin (r = 
- 0.29, P = 0.03) and placental heme exporter FLVCR1 (r = 0.34, P = 0.03). Our data are 
consistent with a role for placental heme Fe utilization in supporting fetal Fe demands.  
                                                             
3 Cao C, Pressman EK, Cooper EM, Guillet R, Westerman M, and O’Brien KO. Accepted for 
publication at Reproduction. June 2014. 
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Introduction 
The placenta serves as the sole conduit for the transfer of maternal nutrients to the fetus 
across pregnancy. It is believed that most, if not all, of the iron (Fe) delivered to the placenta is 
supplied as non-heme Fe. It is unclear whether plasma heme obtained from either intravascular 
red blood cell (RBC) catabolism (1), or from macrophage heme export (2), might also be utilized 
to support fetal Fe demands.  
 Hemopexin (Hx) is a plasma protein with high affinity for heme and contributes to 
systemic Fe homeostasis by delivery heme to the liver for storage (1). Decreases in serum Hx 
reflect a discharge of heme into the circulation and Hx is commonly measured along with the 
plasma hemoglobin (Hb) scavenge protein, haptoglobin (Hp), to assess the severity of 
intravascular hemolysis (3). Few data are available on Hx concentrations in pregnant women and 
it is unclear whether Hx is related to Fe status.  
The LDL receptor-related protein 1 (LRP1) is a trans-membrane protein expressed in a 
variety of cell types including macrophages, hepatocytes, and neurons (4). Of interest, LRP1 is 
highly expressed in human placenta (5, 6) and has been suggested to play a role in placental lipid 
transport (7). Recently, Hvidberg et al. identified LRP1 as the receptor for the Hx-heme complex 
and revealed a novel role of LRP1 in systemic heme recycling (8). These authors suggested that 
the high expression of LRP1 in the human placenta may enable Fe recovered from maternal 
circulating heme to be delivered to the fetus (8) but no studies have examined this hypothesis. 
Fe efflux from the placenta to the fetus is thought to be mediated by the only known 
mammalian cellular non-heme Fe exporter, ferroportin (FPN) (9, 10). Consistent with its role in 
Fe export, FPN is localized to the basolateral side of human placental syncytiotrophoblast (11). 
FPN is under tight control by the hormone hepcidin, which binds and induces degradation of 
FPN protein and thus limits cellular Fe export. Whether this FPN-hepcidin model in 
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macrophages applies to the human placenta and whether placental FPN is related to expression 
of heme Fe transporters remain unknown.  
The objectives of this study were: 1) to evaluate placental expression of the heme 
transporter LRP1 and the Fe export protein FPN in pregnant adolescents delivering at term and 
2) to investigate the relationships between placental LRP1 and FPN with placental heme Fe 
exporter FLVCR1, maternal and neonatal Fe status, and changes in maternal Hx across gestation.  
 
Methods 
Subjects 
Pregnant adolescents in this study were enrolled in a larger prospective study addressing 
the relationship between maternal and fetal mineral status. All participants were recruited from 
the Rochester Adolescent Maternity Program in Rochester, NY between 2007 and 2011. 
Characteristics of this study cohort have been described elsewhere (12, 13) and data on placental 
expression of Fe and vitamin D-related proteins have been published (14-16). The Institutional 
Review Boards at Cornell University and the University of Rochester approved all study 
procedures and written informed consent was obtained from all participants. A maternal blood 
sample was taken at mid-gestation (~26 wks) and at delivery (~40 wks) at which time cord blood 
and placental tissue were also obtained. Placental tissue used in this study was from a subset (n = 
57) of the 113 teens who delivered term infants. 
Biochemical analysis   
Blood Hb was measured using a Cell Dyn 4000 hematology analyzer (Abbott 
Laboratories, Abbott Park, IL). Serum was separated and stored at −80°C prior to analysis. 
Serum Hx and Hp were determined by sandwich ELISAs from Genway Biotech (Genway 
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Biotech, San Diego, CA) and ALPCO (ALPCO Diagnostics, Salem, NH), respectively. Serum 
Hp lower than the normal range (0.3-2.0 g/L) was considered indicative of hemolysis (3). Serum 
ferritin (SF) and serum soluble transferrin receptor (sTfR) were measured using commercially 
available ELISA kits (Ramco Laboratories Inc., Stafford, TX). Total body iron (TBI) was 
calculated from SF and sTfR concentrations using the equation developed by (17): TBI (mg/kg) 
= - [log10 (sTfR/SF) –2.8229]/0.1207. Maternal ID was defined as either SF < 12 µg/L, sTfR > 
8.5 mg/L, or TBI < 0 mg/kg (18, 19). Because the Hb distribution for African Americans is 
shifted to the left of that for the Caucasians, we adjusted the Hb cutoffs downward by 0.8 g/dL to 
define anemia in African American teens as recommended by IOM for black populations (20). 
Specifically, anemia in whites was defined as Hb < 10.5 g/dL in the second trimester and Hb < 
11.0 g/dL in the third trimester and anemia in blacks was defined as Hb < 9.7 g/dL in the second 
and Hb < 10.2 g/dL in the third trimester. Neonatal anemia was defined when cord blood Hb was 
< 13.0 g/dL (21). C-reactive protein (CRP) was measured using Immulite 2000 immunoassay 
system (Seimens Diagnostics, Los Angeles, CA). Intrinsic LifeSciences (La Jolla, CA) measured 
serum hepcidin using a competitive ELISA specific for the mature peptide. The lower limit for 
detection of this assay is 5 µg/L. Serum hepcidin concentration below the limit of detection was 
given a value of 2.5 µg/L for data analysis purposes as previously described for this variable 
(22).  
Placental sample collection  
Placentas were collected immediately after delivery. Placental weight and dimensions 
were recorded. Multiple (4–5) placental samples were collected from different quadrants of the 
placenta, the maternal and fetal membranes removed and the samples then each cut into quarters 
and then randomly distributed into aliquots. These aliquots were either flash frozen (for western 
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blot analyses) or placed into RNAlater (Ambion, Austin, TX) and kept at -80°C. Placental 
protein lysates were prepared as previously described (14, 15) and protein concentrations of 
lysates were determined using Bio-Rad dye reagent (Bio-Rad, Hercules, CA). Lysates were 
diluted in SDS-PAGE sample buffer and stored at −80°C until analysis. 
Placental tissue Fe content 
Total tissue Fe content of the placental tissue was determined using atomic absorption 
spectrophotometry as detailed before (14) and expressed as µg Fe/g placental dry weight. 
Real-time quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) 
The expression of placental LRP1 mRNA was measured in 42 placentas with quality 
RNA. Total RNA was extracted from the placental tissue samples using the RNeasy Microarray 
Tissue Mini Kit (Qiagen, Valencia, CA). The extracted RNA was quantified and verified for 
integrity by the Experion automated electrophoresis system (Bio-Rad, Hercules, CA). RNA 
purity was checked by the ratio of absorbance at 260 and 280 nm on a Nanodrop 
spectrophotometer (Thermo Scientific, Wilmington, DE). A total of 1 µg RNA was reverse-
transcribed into cDNA with a transcriptor cDNA synthesis kit (Roche Applied Sciences, 
Indianapolis, IN). All qRT-PCR reactions were set up in a 10 μL reaction mixture containing 2 
μL of the cDNA template, 5 µL of SYBR Green I Master reaction mix, and 0.7 μM of primers 
and run in triplicate in 384-well plates on a LightCycler 480 instrument (Roche Applied 
Sciences, Indianapolis, IN). The cycling conditions included an initial denaturation step at 95°C 
for 5 min, followed by 45 cycles at 95°C for 10 sec, annealing at 60°C for 10 sec, and extension 
at 72°C for 10 sec. Specificity of amplifications was verified by melt curve analysis after PCR 
cycles. A single peak was consistently observed in all samples. Relative LRP1 mRNA expression 
was normalized to β-actin and compared to that obtained from a control placenta sample using 
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the 2-ΔΔCt method using the following equations: ∆Ct = Ct(LRP1) - Ct(β-actin); ∆∆Ct = 
∆Ct(sample) - ∆Ct(control placenta); and Fold Change = 2-∆∆Ct. The primers were designed using 
the ProbeFinder software from Roche Applied Science using the NCBI sequence ID 
(NM_002332 for LRP1 and NM_001101 for β-actin) and purchased from Integrated DNA 
Technologies (Coralville, IA). Sequences of the primer-pairs were as follows: LRP1, Forward: 5’ 
– GAT GAG ACA CAC GCC AATC TG - 3’, Reverse: 5’- CGG CAC TGG AAC TCA TCA – 3’; 
β-actin, Forward: 5’– CCA ACC GCG AGA AGA TGA –3’, Reverse: 5’ CCA GAG GCG TAC 
AGG GAT AG – 3’.  
Western blot analysis 
Western blot was performed to determine placental protein expression of LRP1 and FPN. 
Placental lysates were separated by SDS-PAGE using a triple-wide electrophoresis unit (CBS 
Scientific, Del Mar, CA) and electro-transferred to polyvinylidenedifluoride membranes 
(Millipore, Billerica, MA). Membranes were blocked in Odyssey Blocking Buffer (Li-Cor, 
Lincoln, NB) for 1 hr and incubated overnight at 4oC with antibodies against the following 
targets: mouse anti-LRP1 (1:3000 dilution; ab28320, Abcam, Cambridge, MA), rabbit anti-FPN 
(1:500 dilution; MTP-11A, Alpha Diagnostics, San Antonio), and β-actin (rabbit anti β-actin: 
1:5000 dilution: Abcam, Cambridge, MA or mouse anti β-actin: 1:2000 dilution: Santa Cruz 
Biotechnology, Santa Cruz, CA). Blots were then incubated with appropriate fluorescence-
coupled secondary antibodies (Li-Cor, Lincoln, NE) for 1 hr at room temperature. After washing, 
fluorescence of the protein bands was quantified by with the Odyssey IR imaging system (Li-
Cor, Lincoln, NE). A band at 85 kDa corresponding to the LRP1 β-chain was observed in human 
placenta and rat liver (Figure 3.1). A band of a lower molecular weight was evident in the 
placental lysates and may represent differential phosphorylation of the LRP1 β-chain (23), as 
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similar patterns have been observed in human placenta (24). The combined fluorescence of the 
upper and lower bands and that of the upper band was highly correlated (r = 0.96) thus the latter 
was used for data analysis. The use of combined signal of the upper and lower band did not 
change study findings. A control placenta sample was loaded in the left, middle, and right part of 
the gel and the CV for the 3 samples was 2.6% indicating minimal influence of the sample 
location on band intensity. A representative image of FPN western blot is shown in Figure 3.1.  
 
 
Figure 3.1. (A) Western blot of LRP1 in human placenta. Rat liver was used as a 
positive control for LRP1. (B) Western blot of FPN in human placenta. The left 
panel depicts human placental lysates with high and low expression of FPN. 
Antibody specificity was confirmed by the absence of the FPN band in the blot 
incubated with a FPN blocking peptide specific to the FPN antibody. 
Detailed western blotting methods for the determination of placental FLVCR1 expression 
in this cohort were previously published (14). Existing data on placental FLVCR1 were used in 
the present study to explore its relationship with placental LRP1 and FPN. 
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Statistical analysis 
Non-normally distributed variables were transformed to achieve normality prior to data 
analysis. Paired t-tests were used to compare serum Fe status indicators and Hx between mid-
gestation and delivery. Pearson’s correlation was used to examine associations between 
expression of placental LRP1, FPN, and FLVCR1, and serum Fe status indicators. Multivariate 
analysis was used to study associations while controlling for other variables. Multiple linear 
regression was used to model dplacental LRP1 expression. P values < 0.05 were considered 
significant. Data were reported as the means ± SDs unless otherwise stated. 
 
Results 
Subject characteristics 
General characteristics of the study participants are presented in Table 3.1. Average age 
at enrollment was 17.1 y and the majority of adolescents were African American and non-
Hispanic. Approximately 19.3% of the adolescents were obese prior to pregnancy and 61.4% 
gained than the IOM gestational weight gain recommendations. Of the 57 adolescents, five 
delivered by Caesarean section. Eleven infants were born small for gestational age and two were 
large for gestational age. 
Maternal Fe status and Hx concentrations across pregnancy 
Suboptimal Fe status in this adolescent cohort was evident (Table 3.2). Prevalence of 
anemia was 4.3% at mid-gestation and increased significantly to 10.2 % at term. Serum Hx 
decreased significantly by 9.9% from mid-gestation to delivery (p = 0.005). Mid-gestation Hx 
was positively associated with maternal Hb (r = 0.35, p = 0.02) and CRP (r = 0.30, p = 0.03) at 
mid-gestation and with maternal hepcidin (r = 0.29, p = 0.03) at delivery. Delivery Hx correlated 
with maternal hepcidin (r = 0.28, p = 0.04) at mid-gestation.  
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Table 3.1. Characteristics of study participants (n = 57) 
Characteristics Mean ± SD (Range) 
Age at enrollment (y) 17.1 ± 1.1 (14.0 – 18.7) 
Parity ≥ 1 (%) 11 
Pre-pregnancy BMI (kg/m2) 25.1 ± 6.0 (17.2 – 43.5) 
Gestational weight gain (kg) 17.6 ± 7.7 (-2.1 – 43.2) 
Race (%)  
African American 61 
Ethnicity (%)  
Non-Hispanic 75 
Delivery mode (%)  
Vaginal delivery 91 
Placental weight (kg) 0.61 ± 0.11 (0.35 – 0.86) 
Birth weight (kg) 3.30 ± 0.45 (2.50 – 4.71) 
Infant gender (%)  
Male 60 
 
 
 
Table 3.2. Fe status indicators in 57 pregnant adolescents and their neonates1 
Variable Mid-Gestation Delivery Cord Blood 
Hb (g/dL) 11.4 ± 0.8 (47) a 11.8 ± 1.3 (49) a 13.7 ± 2.7 (36) b 
SF (µg/L) 22.2 ± 19.1 (57) a 22.6 ± 12.9 (57) a 133.0 ± 79.4 (57) b 
Serum sTfR (mg/L) 5.6 ± 5.9 (57) a 5.4 ± 2.7 (57) a 8.3 ± 2.5 (57) b 
TBI (mg/kg) 3.2 ± 3.8 (57) a 3.6 ± 3.6 (57) a 8.0 ± 2.6 (57) b 
Serum hepcidin (µg/L) 28.0 ± 19.9 (57) a 36.2 ± 28.4 (57) a 131.8 ± 88.8 (57) b 
Serum Hx (g/L) 1.0 ± 0.2 (57) a 0.9 ± 0.3 (54) b 0.3 ± 0.2 (47) c 
Serum Hp (g/L) 0.9 ± 0.5 (57) ND ND 
Serum CRP (mg/L) 6.6 ± 6.9 (55) a ND 2.2 ± 10.8 (44) b 
1Data are presented as Mean ± SD (sample size); Sample sizes are different due to missing 
assay (Hb) or sample availability (serum Hx and CRP); ND, not determined; Values with 
different subscripts (a, b, c) are significantly statistically different. 
 
Both mid-gestation Hx (r = 0.50, p = 0.002) and delivery Hx (r = 0.52, p = 0.002) 
correlated strongly with cord Hb and remained positive predictors of cord Hb after controlling 
for maternal Hb at the respective blood sampling point. Higher maternal Hx at delivery was 
related to better neonatal Fe status as evidenced by its association with high cord hepcidin (r = 
0.37, p = 0.005) and low cord sTfR (r = - 0.27, p = 0.046). There was a non-significant positive 
correlation between the decrease in Hx from mid-gestation to delivery and the time elapsed 
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between the two blood sampling points (r = 0.26, p = 0.06). Greater decreases in Hx across 
gestation were seen in women with lower mid-gestation hepcidin (r = - 0.27, p = 0.046) and in 
neonates with lower hepcidin (r = - 0.30, p = 0.03). These relationships remained significant 
after controlling for time interval between the mid-gestation and delivery measures. Using all the 
variables obtained, a multivariate model that included weeks elapsed between the biochemical 
assessments made at mid-gestation and delivery, maternal hepcidin at mid-gestation, and 
maternal TBI at delivery was found to capture 23.3% of the variation in changes in Hx from mid-
gestation to delivery (p = 0.004).  
Serum Hp was assessed as an additional indicator of hemolysis in maternal mid-gestation 
blood samples. Serum Hp did not correlate with Fe status indexes in the maternal or neonatal 
circulation. Four of the 57 teens had low Hp levels (< 0.3 g/L) suggestive of hemolysis but there 
were no differences in Fe status indicators or hepcidin between these 4 teens and the rest of the 
cohort. Correlation analysis revealed significant positive associations between serum Hp with 
serum CRP (r = 0.31, p = 0.02) and Hx (r = 0.33, p = 0.01) at mid-gestation. 
Neonatal Fe status and Hx concentrations 
Neonatal hematological data are presented in Table 3.2. Nearly one third of the neonates 
were anemic at birth (cord Hb < 13 g/dL). Neonatal serum Hx was 74% lower than (p < 0.0001), 
and moderately correlated with maternal Hx at mid-gestation (r = 0.29, p = 0.046) but not at 
delivery. Cord Hx was not related to cord Fe status indicators or hepcidin.  
Associations between placental LRP1 and FPN with Fe status and Hx concentrations 
Expression of LRP1 and FPN in the placenta was not related to maternal race, ethnicity, 
gestational age at delivery, delivery mode (vaginal delivery, C-section), placental weight, or 
infant weight. Placental LRP1 protein expression correlated positively with suboptimal neonatal 
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Fe status as indicated by low cord hepcidin (r = - 0.29, p = 0.03; Figure 3.2) and high cord sTfR 
(r = 0.36, p = 0.006; Figure 3.2). Greater decreases in Hx from mid-gestation to delivery were 
associated with higher placental LRP1 protein expression (r = 0.28, p = 0.04; Figure 3.2). In the 
41 adolescents with data on placental FLVCR1 protein, there was a positive correlation between 
placental LRP1 and FLVCR1 (r = 0.34, p = 0.03; Figure 3.2). Placental LRP1 mRNA was not 
significantly correlated with LRP1 protein (p = 0.14). Greater LRP1 mRNA tended to be 
associated with higher placental weight (r = 0.28, p = 0.08) and birth weight (r = 0.26, p = 0.09). 
None of the maternal or neonatal Fe status variables were significantly associated with placental 
LRP1 mRNA.  
 
Figure 3.2. Significant correlates of placental LRP1 protein expression in pregnant adolescents 
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Placental FPN protein expression was insignificantly negatively correlated with maternal 
serum hepcidin (r = - 0.23, p = 0.08) and TBI at mid-gestation (r = - 0.23, p = 0.09). No 
significant relationship was found between placental FPN with neonatal hepcidin or other Fe 
status indicators. Similarly, there were no significant relationships between placental FPN and 
neonatal hepcidin when data were examined in adolescents who were ID or non-ID. Placental Fe 
content was positively correlated with placental FPN protein expression (r = 0.37, p = 0.01). 
Neither LRP1 nor FLVCR1 was correlated with FPN protein expression in the placenta.  
 
Discussion 
During late pregnancy, Fe flux across the placenta reaches a maximum of 3-8 mg per day 
(25), a magnitude several times higher than the amount absorbed from the diet. The high Fe 
transport capacity of the placenta is partly explained by the abundant presence of TfR on the 
syncytiotrophoblast (26) and it is believed that transferrin-bound inorganic Fe is the predominant 
form of Fe utilized by the placenta to support fetal requirements (27, 28). Recently, attention has 
been focused on the presence of multiple heme transport proteins in the human placenta (29), 
which suggests that this organ may be an alternate site of heme clearance and/or utilization. In a 
group of healthy pregnant adolescents, we assessed maternal and neonatal serum Hx in relation 
to placental expression of the heme-Hx receptor LRP1, the heme exporter FLVCR1, and the non-
heme Fe exporter FPN. We documented for the first time a significant positive correlation 
between two heme transporters LRP1 and FLVCR1 in the human placenta. In addition, placental 
LRP1 protein expression was higher in neonates with suboptimal Fe status and in women who 
experienced greater decreases in serum Hx from mid-gestation to delivery. Finally, we report 
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novel associations between maternal Hx with neonatal Hb and hepcidin, adding to the biological 
plausibility of a role for plasma heme in maintaining Fe homeostasis during pregnancy. 
Circulating Hx and liver LRP1 facilitate plasma heme clearance and protect against 
heme-associated oxidative damage. The importance of Hx in the resolution of hemolysis is 
evident from knockout studies showing that mice lacking Hx are more sensitive to both induced 
hemolysis (30) and heme overload (31). In addition to systemic heme scavenging, Hx and LRP1 
may mediate localized heme clearance in the brain during cerebral hemorrhage (32). Functional 
analyses have demonstrated the Hx-heme binding activity of LRP1 purified from human placenta 
(8), but few studies have examined the potential role of placenta as a site of Hx-heme clearance. 
In our study, placental protein expression of LRP1 was positively associated with that of 
FLVCR1, a plasma membrane heme exporter essential for erythroid cell survival and 
macrophage heme Fe recycling (33). It is possible that placental heme uptake (mediated by 
LRP1) and heme export (mediated by FLVCR1) are coordinately regulated to allow for 
sequestration of circulating heme while preventing accumulation of intracellular heme as 
depicted in Figure 3.3.  
Little is known about the cellular regulation of LRP1 expression by systemic Fe status. 
Studies in mouse hepatoma cells have found that Fe deprivation doubled the number of LRP1 
and increased heme uptake, indicating that LRP1 may be negatively regulated by Fe availability 
(34). Consistent with this reciprocal Fe regulation of LRP1 in the liver, we found that high 
placental LRP1 was associated with suboptimal neonatal Fe status, which may represent a 
compensatory mechanism to increase placental heme uptake during Fe insufficiency in support 
of fetal demands.  
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Figure 3.3. Proposed pathway of heme Fe utilization in the placenta 
Knockout experiments and localization studies provide convincing evidence that FPN is 
the protein that mediates Fe exit from placenta to the fetal circulation (10, 11, 35). At this time it 
is unclear whether levels of FPN protein in the placenta are controlled by hepcidin in a similar 
way to that found in macrophages. Our study, and previous research in rodents (36-38) and 
humans (39), suggests that placental FPN protein is not regulated by maternal or neonatal Fe 
status. These data support the notion that FPN-mediated Fe export may not be the rate-limiting 
step for placental Fe transfer (37). However, it still may be possible that changes in FPN 
subcellular location may inhibit Fe export without increased proteolytic degradation.  
The Hx concentrations observed in maternal and neonatal circulation were within the 
ranges previously established for healthy adults (3) and term infants (40). Similar to previous 
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reports (41, 42), cord Hx concentrations were 74% lower than those observed in maternal 
circulation, a phenomenon that has been suggested to be a consequence of low fetal Hx 
production (43).  
Kinetic studies demonstrated that extracellular Hx enhances heme export from human 
macrophages, supporting an emerging role of Hx in systemic heme trafficking (2). It has been 
suggested that the high serum concentration of Hx, which is comparable to that of the non-heme 
Fe transporter transferrin, is supportive of the importance of Hx in macrophage heme recycling 
under physiological conditions (33). Consistent with a role of Hx in systemic Fe balance in 
pregnancy, we observed associations between maternal Hx with cord Hb and hepcidin. Few 
studies have examined possible relationships between Hx and Fe status. In diabetic patients and 
healthy volunteers (n = 213), serum transferrin was a weak predictor of serum Hx while serum 
tri-acylglyerol and the diabetic state accounted for the majority of the variation (44). It is 
possible that the positive association between maternal Hx with maternal and cord Hb is 
representative of a greater capacity of maternal heme recycling and transport in support of fetal 
erythropoiesis. 
The major strength of this study is the concurrent measurement of placental expression of 
LRP1 and FLVCR1 protein expression with serum Hx in a group of pregnant adolescents with 
well-characterized Fe status. Due to the observational nature of this study, we could not 
determine cellular processes underlying the associations between LRP1, Hx, and Fe status and 
mechanistic studies are needed to assess the heme transport activity of placental LRP1 and 
determine whether this process is responsive to changes in maternal/neonatal Fe status.  
In summary, this study extends the current discussion of heme utilization to the placenta 
by documenting a relationship between placental LRP1 with maternal and neonatal Fe status in 
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pregnant adolescents with term delivery. Because of the observational nature of this study, 
further research is needed to elucidate the mechanisms underlying these associations and 
examine the significance of placental heme scavenging in supporting fetal Fe demands. 
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CHAPTER 3  
PLACENTAL EXPRESSION OF HEME IRON TRANSPORTERS IN RELATION TO 
MATERNAL AND NEONATAL IRON STATUS 
Study 2: Maternal obesity has no impact on placental folate transporter expression and 
cord folate concentrations in pregnant adolescents4  
Abstract 
Negative effects of maternal obesity during pregnancy may be mediated in part by the 
impact of increased circulating leptin on placental folate transport. The determinants of folate 
transporter expression in the placenta are not well defined. The role of the cellular folate and 
heme transporter, proton-coupled folate transporter (PCFT), in the placenta unknown. We 
assessed placental expression of three major folate transporters (proton coupled folate transporter 
(PCFT), reduced folate carrier (RFC), and folate receptor α (FRα)) in relation to maternal 
obesity, circulating leptin and Fe and folate status indicators in 49 pregnant adults and 
adolescents with term deliveries. Folate and Fe status indicators (Hb, serum folate, hepcidin, SF, 
and erythropoietin) and serum leptin were assessed in late pregnancy (28.8 ± 5.0 wks) and at 
delivery in the mother and the neonate. Placental folate transporter protein (PCFT and RFC) and 
transcript (PCFT, RFC and FRα) expression was assessed. Nearly one third of the participants 
were obese prior to pregnancy but maternal ppBMI or GWG did not impact placental folate 
transporter expression. A trend for higher cord folate in neonates born to obese mothers 
approached significance (p=0.06). Circulating leptin in late pregnancy was positively associated 
placental mRNA expression of RFC and FRα. Unlike RFC and FRα, placental PCFT was not 
                                                             
4 Cao C, Pressman EK, Cooper EM, O’Brien KO. Submitted to Journal of Nutrition July 2014. 
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correlated with cord folate concentration but was positively associated with serum hepcidin and 
erythropoietin in the neonate. Maternal obesity and increased leptin concentrations did not 
significantly impact cord serum folate concentrations or placental folate transporter expression in 
healthy pregnant adolescents at term. The association between PCFT and cord Fe status suggests 
a possible role of PCFT in placental Fe transport.  
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Introduction 
During pregnancy, folate demands increase by 5- to 10-fold to ensure adequate supply for 
DNA synthesis, cell proliferation, placental development and fetal growth (1). Maternal folate 
deficiency is associated with various negative pregnancy and neonatal outcomes including 
preterm delivery, low birth weight, congenital abnormalities, and neural tube defects (NTDs) (1-
3).  
The placenta transports folate from the maternal circulation to the fetus against a 
concentration gradient (4). This process is thought to be facilitated by the polarized distribution 
of folate transporters in the syncytiotrophoblast (5). Folate receptor alpha (FRα), a 
glycosylphosphoinositol-linked protein highly polarized to the maternal side of the human 
placenta (6, 7), mediates the uptake of folate from the maternal circulation while reduced folate 
carrier (RFC) is responsible for basolateral folate export into the fetal circulation (6, 8). This 
classic model of placental folate transport has been updated to incorporate the recently identified 
cellular folate transporter, proton-coupled folate transporter (PCFT) (9). Loss-of-function 
mutations in PCFT result in systemic folate deficiency (9, 10) and are the molecular basis for 
hereditary folate malabsorption in humans. In addition to folate, PCFT also exhibits some 
affinity for heme Fe and has been suggested to play a role in intestinal heme absorption (11). In 
human intestinal Caco-2 cells, transfection of PCFT enhances heme uptake (11, 12) while 
inhibition of PCFT reduces heme uptake (12, 13). The human placenta abundantly expresses 
PCFT (9) but the role of PCFT in this organ is much less understood. In the human 
syncytiotrophoblast, PCFT co-localizes with FRα on the maternal-facing membrane (6, 7), 
suggesting an involvement of PCFT in placental folate uptake. However, no PCFT-mediated 
folate transport activity could be demonstrated in human placental villous membranes when 
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studied under physiological pH conditions (14), which is consistent with the low pH optimum 
required for PCFT function (9). In addition, unlike Frα −/− and Rfc−/− mice that die early in utero 
(15, 16), Pcft −/− animals survive through embryonic development (10), which indicates a 
redundant role of PCFT in placental folate transport.   
It has been suggested that maternal obesity may negatively affect placental folate 
transport (14) and contribute to the higher incidence of neural tube defects observed among 
obese pregnant women (17). This effect may be mediated by obesity associated hyperleptinemia, 
as supported by experiments in human trophoblast BeWo cells (18). Human studies are needed 
to assess possible associations between placental folate transporters and maternal and neonatal 
folate status and to examine the impact of maternal pre-pregnancy BMI (ppBMI) and gestational 
weight gain (GWG), and adipokines on placental folate transport and cord folate and Fe 
concentrations.  
The purpose of this study was to assess placental expression of all known folate 
transporters (PCFT, RFC, and FRα) in relation to maternal and neonatal folate and Fe status, and 
to explore the possible impact of maternal obesity and circulating leptin on placental folate 
transporter expression and cord serum folate concentrations in a group of healthy pregnant 
participants delivering term infants. 
 
Methods  
Subjects 
Placental tissue (n=49) utilized in this study was obtained from two studies examining 
relationships between maternal and neonatal nutritional status and placental transporter 
expression during pregnancy. Pregnant adults (≥ 20 y) and adolescents (13-19 y) were recruited 
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from the University of Rochester Medical Center Midwifery Group and the Rochester 
Adolescent Maternity Program and in Rochester NY. Females were eligible to participate if they 
were otherwise healthy and carrying a single fetus. Exclusion criteria included HIV infection, 
diabetes, and malabsorption diseases. Both studies were approved by the Institutional Review 
Boards at Cornell University and the University of Rochester and informed consent was obtained 
from all participants. Data on maternal and fetal bone growth and calcitropic hormones (19, 20), 
placental expression of vitamin D metabolic enzymes (21) and Fe transporters (22-24), and 
maternal Fe absorption and placental Fe transfer (25, 26) have been previously published. 
The study design and sample collection of the two parent studies are detailed elsewhere 
(20, 22). In brief, information on maternal race, ethnicity, height, pre-pregnancy weight, and 
cigarette smoking was self-reported upon study entry. Weight at delivery was recorded by 
clinical staff using standard procedures and gestational weight gain was calculated by subtracting 
pre-pregnancy weight from delivery weight. Maternal blood samples (10 mL) were obtained 
during pregnancy (28.8 ± 4.9 wks) and at delivery (39.9 ± 1.0 wks). Cord blood samples were 
also obtained at delivery. Placentas were processed immediately after delivery and placental 
weight and dimensions were recorded. Multiple (4–5) tissue samples were collected from 
different quadrants of the placenta, the maternal and fetal membranes removed and the samples 
each cut into quarters and randomly distributed into aliquots. These aliquots were either flash 
frozen (for western blot analyses) or placed into RNAlater (Ambion, Austin, TX) and kept at -
80ºC until analysis. Placental tissues used in this paper were obtained from a subset (n = 49) of 
the 97 participants with both term deliveries (> 37 wks of gestation) and quality placental RNA 
and protein available. 
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Biochemical analysis  
Hemoglobin (Hb) was measured by the clinical laboratory at the Strong Memorial 
Hospital (Cell Dyn 4000 hematology analyzer; Abbott Laboratories, Abbott Park, IL). Serum 
ferritin (SF) and serum soluble transferrin receptor (sTfR) were measured using ELISA kits 
(Ramco Laboratories Inc., Stafford, TX). Total body iron (TBI) was calculated using the 
equation developed by Cook et al: TBI (mg/kg) = - [log10 (serum sTfR/SF) –2.8229]/0.1207 (27). 
Maternal ID was defined as either SF < 12 µg/L, sTfR > 8.5 mg/L, or TBI < 0 mg/kg (28, 29). 
Anemia in Caucasian participants was defined as Hb values < 10.5 g/dL in the second trimester 
or < 11.0 g/dL in third trimester (30). For African American participants, the Hb cutoffs for 
anemia were adjusted down by 0.8 g/dL based on IOM recommendations (31). Neonatal anemia 
was identified when cord blood Hb was < 13.0 g/dL (32). 
Serum folate, vitamin B12 and erythropoietin (EPO) were measured using the Immulite 
2000 immunoassay system (Seimens Medical Solutions Diagnostics, Los Angeles, CA). Due to 
limited sample volume in maternal delivery and cord blood samples, serum folate and B12 were 
only assessed in 31 of the 49 women and 39 of the 49 neonates at delivery. Folate deficiency was 
defined as a serum folate concentration < 6.8 nmol/L and vitamin B12 deficiency was identified 
as a serum concentration < 148 pmol/L (33). Serum leptin concentrations were determined by 
ELISA (Millipore, Billerica, MA). Intrinsic LifeSciences (La Jolla, CA) and serum hepcidin was 
measured using a competitive ELISA specific for the mature hepcidin peptide (34). The lower 
limit for detection of this assay is 5 µg/L. Hepcidin concentrations below the limit of detection 
were given a value of 2.5 µg/L for data analysis purposes as previously reported (23). 
 
 
 106 
Real-time quantitative polymerase chain reaction (qPCR) 
Total RNA was extracted from the placental tissue using the RNeasy Microarray Tissue 
Mini Kit (Qiagen, Valencia, CA). Extracted RNA was quantified and verified for integrity by the 
Experion automated electrophoresis system (Bio-Rad, Hercules, CA). RNA purity was checked 
by the absorbance ratios at 260 and 280 nm on a Nanodrop spectrophotometer (Thermo 
Scientific, Wilmington, DE). A total of 1000 ng RNA was reverse-transcribed using a 
transcriptor cDNA synthesis kit (Roche Applied Sciences, Indianapolis, IN). The reaction mix 
was incubated for 10 min at 25°C, followed by 30 min at 55°C and 5 min at 85°C. The cDNA 
sample were then stored at -20°C until qPCR analysis. The qPCR primers were designed through 
Roche Applied Science Universal Probe Library using the NCBI sequence ID (NM_016725 for 
Frα, NM_194255 for Rfc, NM_080669 for Pcft, NM_001101 for β-actin) and purchased from 
Integrated DNA Technologies (Coralville, IA). The primer sequences were as follows: Ffα, F: 5’ 
- CTGAGCCAGACGGAGAGC - 3’, R: 5’- CTGTGTTGTCATCCGCTGAG - 3’; Rfc, F: 5’- 
CAGTTCCTCGTGCCCATC - 3’, R: 5’- GGCAAAGAACGTGTTGACC - 3’; Pcft, F: 5’- 
CATCCCGGCTGTTCTGAT- 3’, R: 5’- CTGCTGGAACTCGAGGTGA - 3’; β-actin, F: 5’-
CCAACCGCGAGAAGATGA - 3’, R: 5’- CCAGAGGCGTACAGGGATAG - 3’. The qPCR 
reactions were prepared in a 10 µL reaction mixture (2 µL of cDNA template,  5 µL SYBR 
Green I Master reaction mix, 0.35 µL of 20 µmol/L primers, and 2.3 µL of H2O) and run in 
triplicate in 384-well plates on a LightCycler 480 instrument (Roche Applied Sciences, 
Indianapolis, IN). The cycling conditions included a denaturation step at 95°C for 5 min, 45 
cycles of 95°C each for 10 sec, annealing at 60°C for 10 sec, and extension at 72°C for 10 sec. A 
no-reverse transcriptase control and a no-template control were used in all qPCR experiments to 
detect DNA contamination in RNA samples and PCR reagents. To ensure the purity of the 
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amplification product, a melt curve was generated for each PCR reaction by holding the 
temperature at 95°C for 5 sec then 65°C for 1 min followed by a gradual increase in temperature 
to 97°C at a rate of 0.11°C/sec. Melt curves were consistent with a single gene product in each 
reaction. Relative mRNA expression of Frα, Rfc and Pcft was normalized to β-actin and 
compared to that obtained from a control placental sample using the 2-ΔΔCt method and the 
following equation: ∆Ct = Ct (Frα, Rfc or Pcft) – Ct (β-actin); ∆∆Ct = ∆Ct (sample) – ∆Ct 
(control placenta); and Fold Change = 2-∆∆Ct.  
Western blot analyses 
Protein lysates for western blot experiments were prepared by homogenizing placental 
tissue in hypertonic lysis buffer containing protease inhibitor cocktail (Sigma-Aldrich, St. Louis, 
MO) as previously described (25, 26). Protein concentrations of the lysates were determined by 
the Bradford dye-binding method (Bio-Rad, Hercules, CA). Placental lysates were diluted in 
SDS sample buffer and stored at −80°C until analysis  
Due to the lack of suitable commercially available FRα antibody, western blot was only 
performed for PCFT and RFC. Protein samples were separated by 10% SDS-PAGE, electro-
transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA), and blocked in 
Odyssey Blocking Buffer (Li-Cor, Lincoln, NB). The blots were then incubated overnight at 4°C 
with rabbit anti-PCFT (1:1000; ab25134, Abcam, Cambridge, MA) or rabbit anti-RFC (1:1000; 
sc-98970, Santa Cruz Biotechnology Inc., Santa Cruz, CA). β-actin was used as the loading control 
(1:5000 dilution; sc-47778; Santa Cruz Biotechnology Inc.) and was probed simultaneously with 
the folate transporter protein targets. Protein targets were detected with IR800 goat anti-rabbit 
IgG (1:5000; Li-Cor, Lincoln, NE) and quantified by the Odyssey infrared imaging system (Li-
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Cor). Human small intestine and rat kidney were used as the positive controls for PCFT and 
RFC, respectively. 
Dietary nutrient intake 
Frequency of prenatal supplement use was self-reported at study enrollment. In the 37 
subjects participating in the bone health study, information on dietary folate and Fe intake was 
also obtained by 24-h dietary recall and analyzed by a registered dietitian using the Nutrition 
Data System for Research (University of Minnesota, Minneapolis, MN).  
Statistical analysis 
All statistical analyses were performed using JMP Pro 10 (SAS Institute, Cary, NC). 
Non-normally distributed variables were transformed before further analysis. Two tailed t-tests 
were performed to compare placental transporter expression between ppBMI and GWG 
categories. Pearson’s correlation was used to assess the relationships between placental folate 
transporters with ppBMI, GWG, serum leptin, and folate and Fe status indicators. Forward 
stepwise regression was utilized to identify significant determinants of placental expression of 
folate transporters and cord folate concentrations. Significance was set at 0.05 and p values < 0.1 
were considered as trending toward significance. Data are reported as the means ± SDs unless 
specified otherwise. 
 
Results 
General characteristics of the study participants are shown in Table 3.3. This study 
included 6 pregnant adults (21.7 ± 2.7 yrs) and 43 pregnant adolescents (17.2 ± 1.2 yrs). There 
were no significant differences between the adult and adolescent participants in ppBMI, GWG, 
leptin, and maternal and neonatal Fe status indicators (Hb, SF, sTfR, TBI, EPO, and hepcidin). 
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More than half of the participants (55%) entered pregnancy overweight or obese while 69% 
experienced excessive weight gain across gestation based on ppBMI. Fully 55% of participants 
were taking prenatal supplements every day during pregnancy while 41% reported a frequency 
of 1-5 times/week. Women who reported daily supplement use tended to have higher serum 
folate concentrations in late gestation than those who consumed supplements with lower 
frequency (34.7 vs. 44.5 nmol/L, p=0.1). Of the 37 participants with data on dietary nutrient 
intake, 27% and 59% did not meet the estimated average requirement (EAR) for folate (520 
µg/day) (38) and Fe (23 mg/day) (39), respectively. However, there was no significant difference 
in maternal and cord serum folate concentrations between the participants whose folate intake 
was below EAR compared with those with intakes above the EAR.  
Table 3.3. Characteristics of pregnant subjects (n=49) 
Characteristics Mean ± SD 
Age at enrollment (y) 17.7 ± 2.1 
Gestational age at delivery (wk) 39.9 ± 1.0 
Parity ≥ 1 (%) 20 
Pre-pregnancy BMI (kg/m2)  26.6 ± 5.9 
Gestational weight gain (kg)  17.2 ± 7.4 
Cigarette use during pregnancy (%) 10 
Daily prenatal supplement use (%) 55 
Dietary folate intake (µg/day) a 840 ± 392 
Dietary Fe intake (mg/day) a 20.1 ± 7.6 
Race (%)  
      African American 61 
      Caucasian  39 
Ethnicity (%)  
      Hispanic  33 
      Non-Hispanic  67 
Placenta weight (kg)  0.61 ± 0.10 
Infant weight (kg) 3.31 ± 0.41 
a Available for 37 of the participants in the maternal and fetal bone 
health study 
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Maternal and neonatal folate status and maternal obesity 
This study cohort exhibited low Fe status but normal folate status (Table 3.4). Anemia 
was evident in 10.4% of the participants at delivery and 20.4% of the participants had depleted 
Fe stores (TBI < 0 mg/kg). All participants had normal B12 concentrations in late gestation while 
19% (6/31) were B12 deficient at delivery. None of the participants had folate deficiency in late 
gestation or at delivery. Cord serum folate was 1.6-times higher than (p<0.0001, n=26), and 
strongly correlated with maternal serum folate at delivery (r=0.66, p=0.003).  
Table 3.4. Fe and folate status in 49 pregnant participants and their neonates1 
Variable 
Late gestation 
(28.8 ± 4.9 wks) 
Delivery 
(39.9 ± 1.0 wks) 
Cord Blood 
Hb (g/dL) 11.2 ± 0.8 a 11.5 ± 1.3a 14.2 ± 2.9b 
SF (µg/L) 21.8 ± 20.3a 25.5 ± 17.0a 144.7 ± 97.9b 
Serum sTfR (mg/L) 5.5 ± 5.3a 6.0 ± 3.2a 8.1 ± 2.5b 
TBI (mg/kg) 2.7 ± 4.4a 3.3 ± 4.0a 8.3 ± 2.6b 
Serum EPO (mIU/mL) 36.8 ± 21.2 36.4 ± 24.1 40.7 ± 35.5 
Serum hepcidin (µg/L) 22.1 ± 19.3a 34.1 ± 36.5a 141.8 ± 101.7b 
Serum folate (nmol/L) 39.9 ± 20.0a 43.0 ± 16.9a 70.2 ± 26.0b 
Serum vitamin B12 (pmol/L) 319.0 ± 123.7a 257.3 ± 114.1b 746.5 ± 454.3c 
Serum leptin (ng/mL) 33.1 ± 20.5a 42.7 ± 22.0a 11.6 ± 9.3b 
1Data are presented as Mean ± SD. Values with different subscripts (a, b, c) are 
significantly different 
 
Women who were obese prior to pregnancy had significantly higher serum folate than the 
non-obese participants at delivery (53.8 ± 19.2 vs. 39.3 ± 14.7 nmol/L, p=0.04). This difference 
remained significant after adjusting for dietary folate intake. In addition, neonates born to obese 
mothers tended to have higher serum folate than those born to non-obese mothers (p=0.06). 
Maternal serum leptin in late gestation was significantly higher in obese mothers and tended to 
be positively associated with cord serum folate (r=0.31. p=0.07).  
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Determinants of placental folate transporter expression  
None of the placental folate transporters (transcript or protein) were related to maternal 
age, ethnicity, race, parity, infant weight, frequency of supplement use, or adequacy of dietary 
folate and Fe intake. The five participants who self-reported smoking during pregnancy had 
significantly higher placental RFC protein expression compared with the non-smokers (p=0.02). 
Placental RFC mRNA levels tended to decrease with advancing gestational age (p=0.1). There 
was a trend for a positive association between placental PCFT mRNA and placental weight 
(p=0.08). Male infants tended to have higher placental FRα mRNA expression than female 
infants (p=0.06).  
We examined the interrelationships between the expression of the three folate 
transporters in the placenta and their individual relationships with maternal and cord folate 
concentrations. Placental FRα mRNA expression was positively correlated with both RFC 
mRNA (r= 0.52, p=0.0001) and PCFT mRNA (r=0.39, p=0.007). There was no relationship 
between placental RFC and PCFT at the mRNA or protein level. Cord serum folate 
concentrations were positively associated with placental mRNA expression of FRα (r=0.32, 
p=0.048) and RFC (r=0.32, p=0.045), but not with PCFT mRNA (p=0.75) or PCFT protein 
(p=0.83). Placental RFC protein expression tended to be inversely associated with maternal 
serum folate in late gestation (r= -0.28, p=0.06).  
Associations between serum leptin and placental folate transporters  
We explored the relationships between placental folate transporter expression and 
obesity-related variables including ppBMI, GWG, and maternal and cord serum leptin. Pre-
pregnancy BMI did not impact placental mRNA or protein expression of the three folate 
transporters. Placental RFC mRNA was positively correlated with GWG (r=0.35, p=0.01) and 
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was 1.7-times higher in women who experienced excessive GWG compared with those who 
gained within or under the recommended range (p=0.002). Serum leptin in late gestation was 
positively correlated with placental mRNA expression of FRα (r=0.52, p=0.0002) and RFC 
(r=0.42, p=0.003). Maternal leptin in late pregnancy remained a significant predictor of placental 
FRα mRNA (p=0.0001) and RFC mRNA (p=0.003) after controlling for the gestational age at 
which the blood was collected. There was a non-significant trend for a correlation between cord 
leptin and placental RFC mRNA (r= 0.25, p=0.07). Neither placental PCFT mRNA nor protein 
was significantly associated with maternal or cord leptin.   
Because PCFT may also function as a cellular heme transporter and folate and Fe are 
both essential for erythropoiesis, we examined possible relationships between placental 
expression of PCFT, RFC, and FRα with maternal and cord Fe status. Placental PCFT mRNA 
was negatively associated with cord EPO (r=0.32, p=0.03) and insignificantly correlated with 
cord SF (r=0.28, p=0.053). A significant positive correlation was found between placental PCFT 
protein expression and cord hepcidin (r=0.28, p=0.05). Placental FRα mRNA was positively 
correlated with maternal Hb in late pregnancy (r=0.37, p=0.01) and at delivery (r=0.32, p=0.03). 
RFC expression in the placenta was not related to maternal or neonatal Fe status indicators 
examined.  
Multiple regression models were constructed for each placental folate transporters and 
cord folate concentrations (Table 3.5). Maternal leptin in late gestation was a significant 
predictor of both RFC and FRα in the placenta while cord Fe status variables best captured the 
variations in placental PCFT mRNA and protein expression. A model that included maternal 
serum folate at delivery and placental FRα mRNA expression explained 54% of the variability in 
cord serum folate (p=0.0002).  
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Table 3.5. Multivariate models of placental folate transporters and cord serum folate 
 R2 (Model) β P-value 
Placental RFC    
RFC mRNA (n = 47) 0.24  0.003 
Log maternal leptin in late gestation   0.17 0.03 
Excessive gestational weight gain   0.07 0.08 
RFC protein (n=47) 0.15  0.03 
Log maternal folate in late gestation  -0.20 0.05 
Cigarette smoking   0.14 0.05 
Placental PCFT    
PCFT mRNA (n=47) 0.18  0.01 
Log cord EPO   -0.09 0.03 
Log cord SF   0.08 0.07 
PCFT protein (n=49) 0.12  0.02 
Sqrt cord hepcidin   0.02 0.02 
Placental FRα mRNA (n=47)  0.33  0.0002 
Log maternal leptin in late gestation  0.29 0.0001 
Male infant   0.08 0.07 
Cord serum folate (n=26) 0.54  0.0001 
Log maternal serum folate at delivery  0.53 0.0005 
Sqrt placental FRα mRNA  0.36 0.03 
 
 
Discussion 
In a group of pregnant subjects with a high prevalence of obesity (27%) and excessive 
GWG (69%), there was no evidence for a detrimental effect of obesity or excessive GWG on 
maternal and neonatal folate status or on placental folate transporter expression. We observed 
strong positive associations between maternal leptin and expression of RFC and FRα in the 
placenta and documented for the first time positive correlations between placental transcript 
expression of Rfc and Frα with cord serum folate, which is consistent with a major role of RFC 
and FRα in placental folate transport. In contrast, placental protein/transcript expression of PCFT 
was not related to cord serum folate but was significantly associated with neonatal Fe status, 
which is consistent with a link between PCFT and placental Fe utilization.   
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None of the study participants were folate deficient during pregnancy and the median 
folate concentration of this group was comparable to both US women of child-bearing age (33) 
and to concentrations observed among pregnant women in Australia where folate fortification is 
also mandatory (37). Consistent with the active nature of placental folate transport, cord folate 
concentrations were 1.8-times higher than, and significantly correlated with, maternal serum 
folate at delivery.  
It has been suggested that maternal obesity may limit fetal folate availability and thus 
contribute to increased risk of developmental defects associated with maternal obesity (38). We 
found that neonates born to obese mothers had comparable folate concentrations compared with 
those born to non-obese mothers. This finding is consistent with results presented in two small 
case-control studies (n=30 in each study) that assessed associations between maternal obesity 
and cord folate status (14, 39). Consistent with previous research (14, 39), we also found no 
evidence for inadequate folate supply as a function of maternal obesity as neither dietary folate 
intake nor serum folate levels during pregnancy differed between the obese and non-obese 
groups. However, as suggested by Carter et al. (14), the lack of an association between maternal 
obesity and cord folate at term does not preclude the possibility that maternal obesity may limit 
fetal folate availability early in gestation resulting in developmental defects. Animal models are 
needed to investigate the impact of maternal obesity on fetal folate availability at earlier stages of 
gestation and to examine other potential mechanisms underlying the link between maternal 
obesity and risk of adverse birth outcomes.  
The positive associations between cord serum folate and placental Frα and Rfc are 
consistent with the major role that these two proteins are thought to play in delivering folate to 
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the fetus. In addition, placental transcript levels of Frα and Rfc were highly correlated, which 
may suggest a shared regulatory pathway to facilitate placental folate trafficking.  
Because leptin has been shown to suppress folate transport in human trophoblast BeWo 
cells (18), we hypothesized that placental expression of folate transporters would be negatively 
associated with maternal leptin concentrations. In contrast, a positive association between 
maternal serum leptin and placental FRα and RFC expression was observed, which may reflect 
the role of leptin as an integrating signal that modulates placental nutrient transport as a function 
of maternal nutrient availability (40). The discrepancy between our findings and earlier cell 
culture data may due to the non-physiological, 100-times higher concentration of leptin used to 
elicit alterations in folate transport in the BeWo cell model. Data from the BeWo cell culture 
study also suggested that leptin may impact the Janus-Kinase 2 signaling transduction pathway 
(18). Additional studies are needed to determine the effect of leptin on placental folate transport 
at doses that resemble the physiological concentrations observed during pregnancy.  
Although the role of PCFT in intestinal folate transport is indisputable, the contribution 
of PCFT to placental folate transport is less clear. The extensive co-localization of placental 
PCFT with the major folate transporter FRα in the syncytiotrophoblast suggests a functional 
connection between PCFT and FRα-mediated folate uptake (6). However, unlike FRα and RFC, 
we did not observe a significant association between PCFT expression in the placenta and cord 
serum folate. Instead, our results suggest that PCFT may play a redundant role in placental folate 
transport, which is consistent with the undetectable PCFT-mediated folate transport in human 
syncytiotrophoblast at physiological pH (11) and with the normal phenotype of PCFT knockout 
mice at birth (10) . 
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Because PCFT may function as a cellular heme transporter, we assessed its relationship 
with maternal and neonatal Fe status. Interestingly, placental PCFT was significantly positively 
associated with neonatal Fe status as evidenced by its association with cord hepcidin and EPO, 
which explained 18% and 12% variability in the mRNA and protein expression of placental 
PCFT, respectively. Similar associations were not evident between neonatal Fe status and FRα 
and RFC. The ability to completely correct the anemia phenotype by folate treatment (9, 10, 41) 
and the absence of Fe abnormalities other than anemia in human and animal models of PCFT 
deficiency strongly argue against an essential role of PCFT in systemic Fe homeostasis; 
however, these models were not specifically designed to assess placental and neonatal outcomes 
and thus it remains possible that PCFT may play a role in placental Fe utilization. It is unclear 
whether placental PCFT directly participates in heme uptake and/or intracellular heme 
trafficking as observed in human macrophages (42). The diffuse distribution of PCFT throughout 
the syncytiotrophoblast (6, 14) would support both speculations.  
In summary, in a group of women with normal folate status and high prevalence of 
obesity, pre-pregnancy obesity had no impact on maternal folate levels in late gestation or 
neonatal folate status at birth. Consistent with a major role of FRα and RFC in placental folate 
transport, cord serum folate correlated positively with expression of both transporters in the 
placenta. In contrast, placental PCFT was not related to cord folate but showed a significant 
positive association with cord Fe status, which may suggest a role of PCFT in placental Fe 
transfer to the fetus.  
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CHAPTER 4 
MATERNAL RED BLOOD CELL CATABOLISM AS A SOURCE OF FETAL IRON5 
Introduction 
Data from National Health and Nutrition Examination Survey indicate that the prevalence 
of ID among US children aged 1-2 years has more than doubled over the past decade, increasing 
from 7% in 1999 to 15.9% in 2008 (1). The high prevalence of infant ID raises the concern that 
the birth Fe stores in some infants are inadequate to sustain growth and development over the 
first 6 months of life (2). The existence of critical periods in brain development during early 
infancy and the lack of early Fe screening programs for infants < 1 yr also point to the prenatal 
period as a critical window to minimize the negative impact of infant ID (3).  
A human infant is born with 270 mg Fe, all of which is transported by the placenta from a 
combination of maternal absorption of dietary Fe, liver Fe stores, and RBC Hb Fe recycling (4). 
Relative utilization of these sources in unknown but data in Fe deficient rats suggest that 27% of 
fetal Fe is derived from maternal liver Fe stores and the remaining 73% is obtained from 
maternal Fe absorption and/or RBC Hb catabolism (5). It is estimated that diets with high Fe 
bioavailability contribute 3-4 mg Fe/day into the plasma Fe pool (6), but this amount is not 
sufficient to meet the 8-10 mg of Fe that are shuttled to the fetus daily over the last 4 weeks of 
pregnancy (7). Fe recycling from RBC Fe stores (20 mg Fe/day) provides the largest single Fe 
flux into the circulation (8), and thus may represent a significant Fe source for the fetus. The 
quantitative contribution of maternal RBC Fe to fetal Fe transfer has not been examined in 
humans. Whether placental transfer of this endogenous Fe can be up-regulated during maternal 
                                                             
5 Cao C, Pressman EK, Cooper EM, O’Brien. Results and Discussion to be written and 
manuscript to be submitted to the FASEB Journal in January 2015 
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Fe insufficiency similar to that which is known to occur at the level of the enterocyte for the 
absorption of dietary Fe (9) is unknown. 
Hepcidin is a liver-derived hormone that integrates signals from body Fe stores, 
inflammation, and erythropoietic demand to control systemic Fe trafficking and tissue 
distribution (10). By binding and inducing the subsequent degradation of the Fe channel 
ferroportin, hepcidin decreases Fe entry into the circulation from duodenal Fe absorption, 
macrophage RBC Fe recycling, and hepatic Fe stores. Using a stable Fe isotope technique, we 
previously found that maternal hepcidin was inversely associated with intestinal non-heme Fe 
absorption (11) and placental transfer of dietary Fe (9). However, it is unclear whether placental 
transfer of Fe derived from maternal RBC stores is similarly regulated by maternal hepcidin 
concentrations.  
Using a stable Fe isotope technique, we aimed to: 1) determine the magnitude of maternal 
RBC catabolism and relate this to maternal Fe status during pregnancy, 2) assess the relative 
contributions of maternal dietary Fe absorption in the third trimester of pregnancy and maternal 
RBC catabolism across pregnancy to net placental Fe transfer as measured by isotopic 
enrichment and Fe status in the neonate at birth, and 3) to characterize the role of maternal and 
neonatal hepcidin in determining placental transfer of Fe from the two maternal Fe sources.  
 
Methods 
Subjects 
Pregnant participants (15-35 yrs) were recruited from the University of Rochester 
Midwifery Group and the Rochester Adolescent Maternity Program (RAMP) in Rochester, NY 
between 2012 and 2014. Pregnant volunteers were eligible to participate if they were healthy, 
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carrying a single fetus, and did not smoke cigarettes. Participants were excluded if they had 
gestational diabetes, hematological disorders, hypertension, or malabsorption diseases at the 
entry to the study. The study was approved by the Institutional Review Board of Cornell 
University and the University of Rochester Research Subjects Review Board and informed 
written consent was obtained from all participants. This trial was registered at clinicaltrials.gov 
as NCT01588665. 
Study design and isotope dosing 
Fe isotopes (57Fe at 95% and 58Fe at 93% enrichment) were purchased as metal from 
Trace Sciences International (Richmond Hill, Canada). The two tracers were converted into 
sterile, pyrogen-free solutions of ferrous sulfate using a 2:1 molar ratio of ascorbic acid: Fe 
following the procedure by Kastenmayer (12). Tracer solutions were tested for sterility and 
pyrogenicity (Analytical Research labs, AZ). Fe isotopic composition of the final tracer solutions 
was validated with the use of a ThermoQuest Triton TI Magnetic Sector Thermal Ionization 
Mass Spectrometer (TIMS, ThermoQuest Corporation, Bremen, Germany) and the total Fe 
content of the doses was measured using atomic absorption spectrophotometry (AAnalyst 800; 
PerkinElmer Inc, Waltham, MA). 
This study protocol required five study visits across gestation (Figure 4.1). At the first 
study visit at 15 weeks of gestation, fasting participants were asked to come to the RAMP clinic 
to consume a dose of 15.7 mg 57Fe as ferrous sulfate (total Fe load of 16.6 mg) flavored with 3 
mL of raspberry syrup (Humco, Texarkana, TX) administered orally by syringe. Participants 
were instructed to continue fasting for 2 hours after dosing and were then given a standard lunch 
to take home and consume. Because more than 80% of fetal Fe accumulation occurs over the 
second half of pregnancy in proportion to growing fetal weight (6), placental transfer of absorbed 
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57Fe at gestational week 15 should be minimal (fetal Fe content from early whole body Fe 
analyses is estimated to be 20 mg at week 17 of gestation vs. 273 mg at week 34 of gestation) 
(13) and thus it is reasonable to assume that most of the 57Fe recovered in cord blood is largely 
derived from endogenous maternal RBC Fe catabolism. Two weeks after ingesting the 57Fe dose, 
women returned to the RAMP clinic for a collection of blood samples (10 mL) to determine 
RBC 57Fe incorporation and Fe absorption. Whole blood samples (10 mL) were collected at 
following study visits to monitor changes in RBC 57Fe enrichment that occurred as a 
consequence of RBC catabolism or due to the ~35% increase in RBC mass that occurs after the 
second trimester of gestation (Figure 4.2).  
 
 
Figure 4.1. Study design and sample collection 
 
Maternal body weight was recorded at each study visit (to the 0.1 g) using a calibrated 
scale. Once 57Fe was incorporated into the RBC, the RBC 57Fe content should remain relatively 
constant until the 57Fe enriched RBCs reach the end of the RBC lifespan of 120 days (14, 15), 
corresponding with 34 weeks of gestation (Figure 4.1) or they may also decrease as the RBC 
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mass increases. The fourth study visit occurred at approximately week 34 of gestation. At this 
visit, women ingested a second oral stable Fe isotope dose (1.2 mg 58Fe as ferrous sulfate) 
flavored with 1 mL of raspberry syrup (Humco) followed by 2 mL of a liquid Fe supplement 
(17.6 mg Fe) to provide a similar total Fe load to that obtained from the first stable Fe isotope 
dose. A blood sample was subsequently taken 2 weeks post-dosing to assess absorption of the 
second Fe isotope tracer. Participants were followed until delivery at which time a maternal 
blood sample (10 mL), a cord blood sample (30 mL) and samples of the placental tissue were 
collected.  
 
 
Figure 4.2. Estimated daily Fe requirements across gestation. Adopted from Bothwell (6). 
 
Assessment of Fe status indicators  
Whole blood Hb was measured using the HemoCue Hb 201 system (HemoCue, Brea, 
CA). Maternal anemia was defined as Hb < 11.0 g/dL in the first and third trimesters and Hb < 
10.5 g/dL in the second trimester (16). Because Hb levels are lower in African American than 
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Caucasians with similar Fe status (17), Hb cutoffs for anemia were adjusted downward by 0.8 
g/dL for African American women according to IOM recommendations (18). Neonatal anemia 
was defined as cord Hb concentrations < 13 g/dL (19). Serum was separated on site and shipped 
to Cornell on dry ice for analysis of Fe status indicators. SF and serum sTfR were measured with 
commercially available ELISA kits (Ramco Laboratories, Stafford, TX). TBI was calculated 
using the formula developed by Cook et al. (20): TBI (mg/kg) = – [log (serum sTfR/SF) – 
2.8229]/0.1207. Serum C-reactive protein (CRP), folate, vitamin B12, and erythropoietin (EPO) 
were measured using the Immulite 2000 immunoassay system (Siemens Medical Solutions, 
Malvern, PA). Serum hepcidin was measured using a commercially available Enzyme 
Immunoassay kit (s-1337; Bachem, San Carlos, CA) with a lower detection limit of 0.02 µg/L. 
Determination of RBC isotopic enrichment 
Whole blood samples (0.5 mL) collected at each study visit and cord blood obtained at 
delivery were digested with 4 mL Ultrex nitric acid in a polytetrafluoroethylene beaker. Samples 
were then dried on a hot plate and dissolved in 6N ultrapure hydrochloric acid (JT Baker, 
Phillipsburg, NJ). Iron was extracted with the use of anion exchange chromatography and was 
reconstituted in 3% nitric acid as previously described (9, 21).  
Extracted Fe samples (8 μL) were loaded onto a rhenium filament (ultrapure rhenium 
obtained from H Cross Co, Weehawken, NY) along with 4 μL of silica gel (Sigma-Aldrich Inc, 
St Louis, MO) and 4 μL of phosphoric acid (0.7 N). Isotopic ratios of 57Fe/56Fe (57/56Fe) and 
58Fe/56Fe (58/56Fe) were measured by TIMS and compared to the natural abundance values of 
57/56Fe (0.02317) and 58/56Fe (0.00307) to generate delta percent excess values as previously 
reported (9, 11, 21). Relative SDs obtained averaged 0.026% and 0.24% for 57/56Fe and 58/56Fe, 
respectively. 
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Calculation of Fe absorption and placental Fe transfer 
Fe absorption was calculated using previously described methods assuming that 80% of 
absorbed Fe was incorporated into RBC within two weeks (11, 21, 22). The net amount of 57Fe 
and 58Fe incorporated in maternal RBC was determined by multiplying RBC enrichment of the 
two tracers by the total RBC Fe mass, which was estimated by using a blood volume for 
pregnant women (70 mL/kg), the Fe content of Hb (3.47 mg/g), subject’s Hb value (g/dL), and 
weight (kg) (11, 23) using the following formula: Circulating Fe (mg) = 70 ml/kg × weight (kg) 
× Hb (g/dl) x 0.01 × 3.47 (mg/g). 
 
Figure 4.3. Schematic of in vivo Fe flux of oral stable Fe isotopes 
administerd in the first (57Fe) and third trimester (58Fe) of pregnancy.  
 
Net placental transfer of 57Fe (derived from maternal RBC) and 58Fe (derived from 
maternal diet) was estimated by measuring the total amount of 57Fe and 58Fe in the neonate at 
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birth. Figure 4.3 is the diagram showing the placental transfer of the two oral tracers ingested at 
different time points during pregnancy. Total circulating Fe mass in the neonate was calculated, 
assuming a neonatal blood volume of 80 mL/kg (24, 25) and the Hb Fe content of 3.47 mg/g, 
with the following equation (9, 26): Circulating Fe pool (mg) = 80 mL/kg × birth weight (kg) × 
cord Hb (g/dL) × 3.47 (mg/g) × 0.01. The net amount of 57Fe and 58Fe present in neonatal 
circulation was determined by multiplying the total circulating Fe pool by the percent excess of 
57Fe and 58Fe in cord blood, which reflects the degree to which the natural abundance ratio was 
increased as a result of fetal RBC incorporation of the tracer.  
Statistical analysis 
All statistical analyses were performed using JMP Pro10 (SAS Institute, Cary, NC). 
Difference between placental transfer of maternal endogenous 57Fe and 58Fe from recent 
absorption from the diet was analyzed using paired t-tests. Linear regression analysis was used to 
examine relationships between placental Fe transfer and Fe status indicators. Stepwise regression 
was used to identify significant determinants of placental transfer of Fe from maternal RBC 
(57Fe) and diet (58Fe). Values were presented as Mean ± SD. P-values < 0.05 were considered 
significant.  
 
Preliminary results  
Subject characteristics 
General characteristics of the 16 study participants (15 adults and 1 adolescent) recruited 
to date are shown in Table 4.1. Average age at enrollment was 27.3 ± 4.1 y and more than half 
of the participants (56%) had a parity > 1 at entry into the study. Over 80% of the participants 
reported taking prenatal supplements daily at study enrollment. One subject was hospitalized for 
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deep vein thrombosis at gestational week 26 and was withdrawn from the study. Another subject 
developed preterm premature rupture of the membranes (PROM) at week 33 of gestation and 
therefore did not consume the second isotope dose scheduled at week 34. The 10 participants 
who have completed all study visits had term deliveries (≥ 37 weeks of gestation) and gave birth 
to normal weight infants (between 2,500 – 4,500 g).  
Maternal and neonatal Fe status  
Maternal anemia was evident in 9% of the participants at the first study visit (15 weeks of 
gestation) and was significantly higher at delivery with 27% of women having anemia (Hb < 11 
g/dL). Cord Hb averaged 13.6 ± 2.9 g/dL and 50% (5/10) of the infants were anemic at birth. In 
the six participants with data on SF and sTfR across gestation, SF decreased by more than 50% 
from week 15 to week 36 of gestation (SF: 60.9 vs. 23.7 µg/L, p=0.1). A similar trend was 
evident for TBI across the same interval (8.2 vs. 3.9 mg/kg, p=0.06). Excluding the high cord SF 
concentration (752 µg/L) observed in one neonate that was treated for sepsis at birth, average 
cord SF concentrations were within published normative ranges (40-309 µg/L) for all other 
infants (27).  
Table 4.1. Characteristics of study participants (n=16) 
Subject characteristics Mean ± SD (range) 
Age (y) 27.3 ± 4.1 (17 – 34) 
Parity  1.0 ± 1.2 (0 – 3) 
Pre-pregnancy BMI (kg/m2) 25.1 ± 7.9 (18.0 – 44.6) 
Gestational age at delivery (wk)1 39.2 ± 2.0 (34.7 – 41.4) 
Race (%)  
Caucasian 69 
African American 31 
Ethnicity (%)  
Non-Hispanic  88 
Hispanic  12 
                          1Subjects who have delivered (n=12) 
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Maternal Fe absorption from the 17 mg dose of 57Fe at week 15 of gestation was 11.1 ± 
9.4% (n=12; range 0.8 – 27.6%) and was significantly correlated with serum sTfR (r2=0.53, 
p=0.01) and TBI (r2=0.42, p=0.03) but not with SF or hepcidin. Absorption of the second stable 
Fe isotope administered at week 34 of gestation was 2-times higher than Fe absorption at week 
15 (20.4 ± 11.4 %, p=0.02, n=7).  
Placental transfer of maternal RBC- and diet -derived Fe 
Average maternal enrichment of 57Fe decreased across gestation from 2.6 ± 1.7 % at 
week 17 of gestation to 2.0 ± 1.2% at delivery (n=6, paired t test=0.02). 
 
Figure 4.4. Mean changes in maternal RBC 57Fe enrichment 
across gestation from 6 participants. Error bars represent SEMs. 
 
In the eight neonates with complete isotope data, a total of 0.06 mg of 57Fe and 0.02 mg 
of 58Fe were present in the neonate at birth (Table 4.2).  
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Table 4.2. Placental transfer of oral stable Fe isotopes administered in the first (57Fe) 
and third trimester of pregnancy (58Fe)1 
 57Fe (n=8) 58Fe (n=8) P value 
% excess in cord blood (dose 
adjusted)2 
2.4 ± 1.4 7.1 ± 3.3 0.007 
Total tracer (mg) in cord blood 0.06 ± 0.04 0.02 ± 0.01 0.01 
% of total recovered tracer 
(maternal RBC and neonatal RBC) 
present in neonate at birth3 
5.1 ± 1.7 5.8 ± 2.7 0.4 
1 Values are mean ± SD 
2 Percent excess was adjusted for the natural abundance of isotope administered and 
for small differences in dose received 
3 Quantity of tracer in the neonate as a fraction of total tracer present in the maternal 
RBC and neonatal RBC at delivery 
 
 
The net transfer of 57Fe represented 5.1% of the total 57Fe recovered in the maternal and 
neonatal RBC mass at delivery. The amount of 57Fe in cord blood was positively correlated with 
the amount of 57Fe incorporated in maternal RBC (p=0.003, r2=0.77). In addition, the net transfer 
of 57Fe to the fetus (mg) was significantly inversely associated with cord serum hepcidin 
(p=0.01, r2=0.65), but not with maternal hepcidin (p=0.7). An inverse trend was also observed 
between net transfer of 58Fe and cord hepcidin (p=0.2, r2=0.27).  
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Preliminary conclusions and future plans 
In a novel model of in vivo Fe flux across gestation, we demonstrated that stable Fe 
isotopes can be utilized to trace transfer of Fe to the fetus from the maternal RBC pool. A total of 
16 subjects have been recruited to date. Preliminary results from 8 subjects with complete 
isotopic data have suggested that there is a large inter-subject variation in maternal RBC 57Fe 
enrichment disappearance curves across gestation and it appears that placental Fe transfer is 
more closely related to cord serum hepcidin than maternal hepcidin. Isotopic analyses are on-
going to identify determinants of the slopes of RBC Fe enrichment across gestation.  
To date, 12 of the 16 subjects have completed the study and the 16th subject recruited in 
April 2014 is due in October, 2014. Our study recruiter at the University of Rochester, Melissa 
Miller, will continue assisting with study visit scheduling and sample collection for the 4 
participants who have yet to deliver their infants.  
With regard to laboratory analyses, a total of 91 maternal and cord blood samples have 
been collected and more than half have been analyzed for RBC enrichment and serum Fe status 
indicators (SF and sTfR). More than 60% (24/38) of the serum samples collected from the 
mother at visit 1 and visit 4 and from the neonates at birth have been analyzed for serum 
hepcidin. Our lab manager, Tera Kent, will assist with laboratory analysis for the reminder of the 
study. We anticipate completing all laboratory work 2 months after the last participant has 
completed the study (i.e. by December, 2014) with a goal of submitting this final manuscript by 
January, 2015.   
 
 
 
 134 
References  
1. US Department of Human Services. Healthy people 2020. Washington, DC: US 
Department of Health and Human Services, 2010. 
2. Chaparro CM. Setting the stage for child health and development: prevention of iron 
deficiency in early infancy. J Nutr 2008;138(12):2529-33. 
3. Beard JL. Why Iron Deficiency Is Important in Infant Development. J Nutr 
2008;138(12):2534-6. 
4. Cao C, O'Brien KO. Pregnancy and iron homeostasis: an update. Nutr Rev 
2013;71(1):35-51. 
5. Murray MJ, Stein N. Contribution of maternal rat iron stores to fetal iron in maternal iron 
deficiency and overload. J Nutr 1971;101(11):1583-7. 
6. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin 
Nutr 2000;72(Suppl 1):257S-64S. 
7. Hallberg L. Iron balance in pregnancy and lactation. In: Fomon SJ, Zlotkin S, eds. 
Nutritional anemias. Estados Unidos: Reven Press, 1992:13-28. 
8. Knutson M, Wessling-Resnick M. Iron metabolism in the reticuloendothelial system. Crit 
Rev Biochem Mol Biol 2003;38(1):61-88. 
9. Young MF, Griffin I, Pressman E, McIntyre AW, Cooper E, McNanley T, Harris ZL, 
Westerman M, O'Brien KO. Maternal hepcidin is associated with placental transfer of 
iron derived from dietary heme and nonheme sources. J Nutr 2012;142(1):33-9. 
10. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117(17):4425-33. 
11. Young MF, Griffin I, Pressman E, McIntyre AW, Cooper E, McNanley T, Harris ZL, 
Westerman M, O'Brien KO. Utilization of iron from an animal-based iron source is 
greater than that of ferrous sulfate in pregnant and nonpregnant women. J Nutr 
2010;140(12):2162-6. 
 135 
12. Kastenmayer P, Davidsson L, Galan P, Cherouvrier F, Hercberg S, Hurrell RF. A double 
stable isotope technique for measuring iron absorption in infants. Br J Nutr 
1994;71(3):411-24. 
13. Widdowson EM, Spray CM. Chemical development in utero. Arch Dis Child 
1951;26(127):205-14. 
14. Glader B. Destruction of erythrocytes. In: Wintrobe's clinical hematology. Philadelphia: 
Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009. 
15. Bothwell TH, Charlton RW, Cook JD, Finch CA. Internal iron kinetics. In: Iron 
metabolism in man. Oxford, United Kingdom: Blackwell Scientific Publications, 1979. 
16. Centers for Disease Control and Prevention. Recommendations to prevent and control 
iron deficiency in the United States. MMWR Recomm Rep 1998;47(RR-3):1-36. 
17. Johnson-Spear MA, Yip R. Hemoglobin difference between black and white women with 
comparable iron status: justification for race-specific anemia criteria. Am J Clin Nutr 
1994;60(1):117-21. 
18. Institute of Medicine. Iron Deficiency Anemia: Recommended guidelines for the 
prevention, detection, and management among U.S. children and women of childbearing 
age. Washington DC: National Academy Press, 1993. 
19. Brugnara C. Reference values in infancy and childhood. In: Orkin SH, Nathan DG, eds. 
Nathan & Oski's Hematology of Infancy and Childhood. Philadelphia: Saunders/Elsevier, 
2009:1769–96. 
20. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood 
2003;101(9):3359-64. 
21. Young MF, Glahn RP, Ariza-Nieto M, Inglis J, Olbina G, Westerman M, O'Brien KO. 
Serum hepcidin is significantly associated with iron absorption from food and 
supplemental sources in healthy young women. Am J Clin Nutr 2009;89(2):533-8. 
22. International Atomic Energy Agency. Assessment of iron bioavailability in humans using 
stable iron isotope techniques. In: IAEA Human Health Series. Vienna: IAEA; 2012. 
 136 
23. O'Brien KO, Zavaleta N, Caulfield LE, Yang DX, Abrams SA. Influence of prenatal iron 
and zinc supplements on supplemental iron absorption, red blood cell iron incorporation, 
and iron status in pregnant Peruvian women. Am J Clin Nutr 1999;69(3):509-15. 
24. Mollison PL, Veall N, Cutbush M. Red cell and plasma volume in newborn infants. Arch 
Dis Child 1950;25(123):242-53. 
25. Linderkamp O, Versmold HT, Riegel KP, Betke K. Estimation and prediction of blood 
volume in infants and children. Eur J Pediatr 1977;125(4):227-34. 
26. O'Brien KO, Zavaleta N, Abrams SA, Caulfield LE. Maternal iron status influences iron 
transfer to the fetus during the third trimester of pregnancy. Am J Clin Nutr 
2003;77(4):924-30. 
27. Siddappa AM, Rao R, Long JD, Widness JA, Georgieff MK. The assessment of newborn 
iron stores at birth: a review of the literature and standards for ferritin concentrations. 
Neonatology 2007;92(2):73-82. 
 
 
 
 
 
 
 
 137 
CHAPTER 5 
PRE-PREGNANCY BODY MASS INDEX AND GESTATIONAL WEIGHT GAIN HAVE A 
LIMITED IMPACT ON MATERNAL HEPCIDIN BUT NO SIGNIFICANT IMPACT ON 
MATERNAL OR NEONATAL IRON STATUS6 
Abstract 
Obesity has been linked to suboptimal iron status in non-pregnant populations as a result 
of adiposity-associated inflammation increasing hepcidin production. During gestation, maternal 
obesity may negatively impact neonatal iron status. We aimed to assess the impact of maternal 
obesity and excessive gestational weight gain on maternal and neonatal iron status and to explore 
the possible mediating role of inflammation and estradiol on maternal and neonatal hepcidin. 
This study population included 230 pregnant adolescents (13-18 yrs) enrolled in either a 
longitudinal or a cross-sectional study. Pre-pregnancy BMI (ppBMI) and gestational weight gain 
(GWG) were obtained from medical records. Maternal iron status [hemoglobin, serum iron, 
ferritin, transferrin receptor, total body iron, and hepcidin], inflammation [interleukin-6, leptin] 
and serum estradiol were assessed at mid-gestation (26.2 ± 3.3 wks) in the longitudinal cohort 
and at delivery (39.8 ± 1.3 wks) in both study cohorts. Cord blood was collected in both studies 
and analyzed for iron indicators. Approximately 40% of the adolescents entered pregnancy 
overweight or obese. Multivariate analysis identified ppBMI as a predictor of serum iron at mid-
gestation (β = -0.026, 95%CI: -0.05, -0.007; p=0.009) and serum hepcidin at delivery (β=0.035, 
95%CI: 0.005, 0.06, p=0.02). None of the other maternal iron status indicators were significantly 
associated with ppBMI or GWG. Serum IL-6 was significantly associated with hepcidin at 
                                                             
6 Cao C, Pressman EK, Cooper EM, Guillet R, Westerman M, O’Brien KO. Submitted to 
International Journal of Obesity in June 2014 
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delivery (β=0.23, 95%CI: 0.1, 0.4, p=0.0001) but not at mid-gestation. Neither ppBMI nor GWG 
were significantly associated with neonatal Fe status indicators except for a positive relationship 
between ppBMI and cord Hb (β=0.10, 95%CI: 0.01, 0.2, p=0.03). These results suggest that 
adiposity-related inflammation does not override the iron mediated signals that regulate hepcidin 
production during pregnancy and in this adolescent cohort there is no strong evidence for a 
detrimental effect of maternal obesity and excessive weight gain on iron status in the offspring at 
birth. 
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Introduction 
Approximately 60% of US women of reproductive age are overweight or obese (1) and 
women are gaining excessive weight across pregnancy (2). While excessive calorie intakes are 
common, iron deficiency (ID) remains a public health problem, with 30% of US pregnant 
women having depleted body iron (Fe) in the third trimester (3). 
Epidemiological studies have long noted a link between overweight and low Fe status 
across different age groups (4). Research on the anemia of chronic disease suggests that this 
association may be mediated by an inflammation-associated increase in the cytokine interleukin 
6 (IL-6), which directly stimulates liver production of the Fe regulatory hormone hepcidin (5). 
By inducing the degradation of the Fe exporter ferroportin (6), hepcidin inhibits Fe mobilization 
from intestinal Fe absorption, macrophage Fe recycling, and liver Fe stores, thus limiting Fe 
availability for tissue demands. In addition to IL-6, the adipokine leptin has been shown to 
stimulate hepcidin transcription in vitro and may represent another explanation for the 
association between adiposity and Fe status (7). Recently, estrogen has been shown to suppress 
hepcidin transcription by interacting with an estrogen response element in the hepcidin promoter 
(8). Because there is evidence for lower estrogen levels in obese pregnant women (9), reduced 
estrogen-mediated suppression of hepcidin may be another mechanism by which obesity 
increases hepcidin and negatively affects Fe status. 
In support of the mediating role of inflammation in the obesity-hepcidin link, several 
studies in children and women showed higher circulating IL-6 and hepcidin in obese subjects 
compared with normal weight controls (10-12). It is unclear whether hepcidin responds similarly 
to adiposity-induced inflammation in pregnant women. A recent study by Dao et al. (4) suggests 
this may be the case. In 30 pregnant women with normal or obese pre-pregnancy BMI (ppBMI), 
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serum hepcidin was 2-times higher in those with obesity at entry into pregnancy compared with 
those that had a normal ppBMI. Interestingly, in the 13 women with available cord blood 
samples, ppBMI was inversely associated with cord serum Fe, an observation the authors 
attributed to impaired fetal Fe transfer in the obese mothers. However, serum Fe is not the most 
sensitive marker of Fe status and possible confounders such as dietary Fe intake and race were 
not considered in the analysis. A recent study in 316 pregnant women showed that maternal 
obesity was associated with lower neonatal SF and higher zinc protoporphyrin (13). These 
associations appeared to be largely driven by maternal diabetes as they were no longer 
significant in the non-diabetic mothers (n=234). In addition, this study did not measure hepcidin 
or IL-6/leptin, so it is unclear whether the observed association between maternal obesity and 
neonatal Fe status was mediated by hepcidin or was driven by diabetes-associated alterations in 
Fe homeostasis. Concurrent assessment of inflammation and hepcidin in healthy subjects are 
needed to clarify the relationship between obesity and Fe status in women with uncomplicated 
pregnancies. 
In a large group of pregnant adolescents at risk for ID and obesity, we aimed to: 1) 
evaluate the impact of ppBMI and GWG on serum hepcidin and other Fe status indicators across 
gestation, 2) examine the relationships between IL-6, leptin, and estradiol with hepcidin across 
gestation, and 3) examine the relationships between ppBMI and GWG with neonatal hepcidin 
and Fe status at birth. 
 
Methods 
Study design and subjects 
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A total of 255 pregnant adolescents (13-18 yrs) were enrolled in two USDA-funded 
studies undertaken in Rochester NY between 2005 and 2012. The first study was designed to 
characterize longitudinal changes in maternal bone turnover in relation to fetal bone growth (14-
18) and the second study aimed to examine the cross-sectional relationships between maternal 
and neonatal Fe status and is currently under review (19). Both studies collected maternal and 
cord blood at delivery and the longitudinal study collected an additional maternal blood sample 
at mid-gestation (26.2 ± 3.3 wks). The two study cohorts were recruited using similar eligibility 
criteria (age < 18 yrs, singleton pregnancy, no known medical conditions including diabetes and 
malabsorption diseases) and did not differ in ppBMI, GWG or maternal Fe status at delivery. 
One subject with biologically implausible weight loss from the self-reported pre-pregnancy 
weight to the medically obtained mid-gestation (14 kg) was excluded from all analyses. The final 
study population consisted of 230 pregnant adolescents in whom complete data on ppBMI, 
GWG, and Fe status assessment at mid-gestation (n=144) and/or at delivery (n=207) were 
available. Informed consent was obtained from all study participants and both studies were 
approved by the Institutional Review Boards at the University of Rochester and Cornell 
University.   
Weight gain determinations 
Pre-pregnancy BMI (kg/m2) was calculated using pre-pregnancy weight and height 
recorded in the medical chart. BMI categories were defined in accordance with IOM guidelines 
as follows: underweight: BMI < 18.5; normal weight: BMI 18.5 – 24.9; overweight: BMI 25 – 
29.9; or obese: BMI ≥ 30. In some analyses, we further classified obesity into Class 1 (BMI 30 – 
34.9), Class 2 (BMI 35 – 39.9), and Class 3 (BMI ≥ 40).(20) Due to the small number of 
participants with Class 3 obesity, Class 2 and 3 obesity were collapsed into one group. Total 
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GWG was calculated as the difference between pre-pregnancy weight and weight recorded by 
clinical staff at delivery. Adequate total GWG was defined as a total weight gain of 12.5 – 18 kg 
for underweight women, 11.5 – 16 kg for normal weight women, 7 – 11.5 kg for overweight 
women, and 5 – 9 kg for obese women.(2) For participants in the longitudinal cohort, weight 
data were also available at mid-gestation corresponding to the time when the maternal blood 
samples were obtained. We determined the range of adequate weight gain specific to the 
gestational week at mid-gestation using ppBMI-specific recommendations for first trimester and 
total gestational weight gain according the method by Chmitorz et al.(21) 
Biochemical analyses 
All whole blood samples were assessed for hemoglobin (Hb) by the hospital clinical 
laboratory as previously reported (22). Serum was separated and stored at −80°C prior to 
analysis. Serum ferritin (SF) and soluble transferrin receptor (sTfR) were assessed using ELISA 
kits (Ramco Laboratories, Stafford, TX). Maternal total body iron (TBI) was calculated from SF 
and sTfR using the equation by Cook et al.(23)  
Maternal anemia in the Caucasian adolescents was defined as Hb values < 10.5 g/dL in 
the second trimester, or < 11.0 g/dL in third trimester (24). Because the Hb distribution for 
African Americans is shifted to the left of that for the Caucasians, we adjusted the Hb cutoffs 
downward by 0.8 g/dL to define anemia in African American teens as recommended by IOM for 
black women (25). Specifically, anemia in African American teens was defined as Hb < 9.7 g/dL 
in the second and Hb < 10.2 g/dL in the third trimester. Maternal ID was defined cutoffs 
validated in pregnancy women as either SF < 12 µg/L (26), serum sTfR > 8.5 mg/L (27), or TBI 
< 0 mg/kg (26). Neonatal anemia was defined as cord Hb < 13 g/dL (28). Neonatal total body 
iron (TBI) was calculated using the formula developed in healthy infants (29, 30): TBI (mg) = 
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Hb Fe [body weight (kg) × Hb × 2.74] + storage Fe [21.99  ×  log (SF) -29.04] + functional 
tissue Fe [body weight (kg) × 7 mg/kg].  
Serum erythropoietin (EPO) was measured by the Immulite 2000 immunoassay system 
(Seimens, Los Angeles, CA). Serum hepcidin was measured by Intrinsic LifeSciences (La Jolla, 
CA) using a competitive ELISA with a lower limit of detection of 5 µg/L (31). Hepcidin values 
below the detection limit were assigned a value of 2.5 µg/L for data analysis purposes as 
previously reported (32). Serum Fe was measured by graphic furnace atomic absorption 
spectrophotometry (Perkin Elmer AAnalyst 800, Norwalk, CT) in samples without visual signs 
of hemolysis (81.8% of total available). Serum IL-6 was measured with a multiplex assay kit 
(Millipore, Billerica, MA). Serum C-reactive protein (CRP) was measured in mid-gestation 
samples only using Immulite 2000 immunosystem (Seimens). Serum leptin was analyzed by 
ELISA (Millipore, Billerica, MA). Estradiol was analyzed using ELISA (Alpco Diagnostics, 
Salem, NH).  
Questionnaires about dietary Fe intake  
Using health questionnaire data obtained during the third trimester of pregnancy, 
participants from both studies self-reported the frequency of prenatal supplement use and their 
current smoking status. Dietary Fe intake was estimated by 24-h dietary recall in both studies by 
a registered dietitian using the Nutrition Data System for Research (University of Minnesota, 
Minneapolis, MN). 
Statistical analyses 
Data were analyzed using JMP Pro10 (SAS Institute, Cary, NC). Two adolescents self-
identified as American Indian. Excluding these two subjects did not change any of the study 
results and none of the race-specific analyses differed if these two adolescents were grouped with 
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either the African American or Caucasian cohort. To meet the requirement of statistical 
assumptions and power considerations, data from the two adolescents were included within the 
African American race cohort. Variables with skewed distributions were log-transformed (except 
for cord hepcidin and maternal estradiol which were transformed using square root) before 
analysis. Differences in biochemical measures between the ppBMI and GWG groups were 
assessed by ANOVA and Tukey Post-hoc tests. Bivariate correlations were analyzed by 
Pearson’s correlation. The relationships between ppBMI and GWG with Fe status were also 
analyzed in multivariate models controlling for maternal age, race, gestational age at blood draw, 
and dietary Fe intake. For models of maternal hepcidin at delivery, delivery mode (vaginal and 
cesarean) was also included as a previous study showed differences in maternal hepcidin by 
mode of delivery (33). Data were reported as mean ± SD. P values < 0.05 were considered 
significant.   
 
Results 
Demographic characteristics of the study population (n=230) stratified by ppBMI are 
presented in Table 5.1. Average age of the adolescents at enrollment was 17.2 ± 1.1 yrs and 
about 37.8% entered pregnancy overweight or obese. Among the 41 obese teens, thirteen had 
Class 2 obesity (BMI ≥ 35 kg/m2). A smaller percentage of overweight or obese teens had a 
spontaneous vaginal delivery when compared to the underweight or normal weight teens (82.6% 
vs. 91.3%, p=0.051). More than half of the obese adolescents (58.3%) gained excessive weight 
by mid-gestation and 92.5% exhibited excessive GWG at delivery. Among the 227 adolescents 
with data on glucose tolerance test, one normal weight subject had a confirmed diagnosis of 
gestational diabetes at 30 weeks of gestation. Excluding this subject did not change any of the 
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study results. There were no differences in race, ethnicity, smoking status, prenatal supplement 
use, or daily dietary Fe intake across ppBMI categories.  
Relationships between ppBMI and weight gain with inflammation across gestation 
We examined ppBMI both as a categorical and a continuous variable in relation to 
cytokines and estradiol levels across gestation. At mid-gestation, approximately 40.9% of the 
teens had elevated CRP (> 5 mg/L). Serum leptin, CRP, and IL-6 were more than 2-times higher 
in obese compared with normal weight teens (Table 5.1) and showed significant positive inter-
correlations (p<0.05 for all correlations). At delivery, serum leptin remained elevated in the 
overweight and obese groups but IL-6 in the obese teens no longer differed from the normal 
weight group. Bivariate analyses showed that ppBMI was positively associated with serum leptin 
(r=0.58, p<0.0001), CRP (r=0.50, p<0.0001), and IL-6 (r=0.24, p=0.004) at mid-gestation. 
Serum estradiol at mid-gestation did not differ significantly between ppBMI groups but there 
was a trend for an inverse correlation between ppBMI and estradiol (p=0.1). At delivery, ppBMI 
was correlated with serum leptin (r=0.48, p<0.0001) but not with IL-6 or estradiol.  
We also compared inflammatory markers and estradiol levels between weight gain 
categories. At mid-gestation, serum leptin but not IL-6 was significantly higher in teens who 
gained above the recommended weight gain range compared with those gaining within or below 
the range. At delivery, leptin remained elevated in teens with excessive GWG but there was no 
difference in IL-6 between GWG groups. There was no difference in serum estradiol among 
weight gain categories at mid-gestation or at delivery.  
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Relationships between ppBMI and weight gain with maternal Fe status across gestation 
Maternal Fe status indicators and hepcidin by ppBMI categories are shown in Table 5.2. 
None of the maternal Fe status indicators at mid-gestation or at delivery differed significantly 
among ppBMI categories. Teens gaining lower than recommended GWG had lower hepcidin at 
delivery compared with those who gained within or greater than recommendation. 
 
Table 5.2. Pre-pregnancy BMI and maternal and neonatal Fe status indicators, inflammation 
markers, and estradiol concentrations1 
 Pre-pregnancy BMI 
 Underweight 
< 18.5  
Normal weight 
18.5-24.9 
Overweight 
25.0-29.9 
Obese 
≥ 30 
Maternal      
Mid-gestation     
   Sample size (n) 10 82 28 24 
   Hemoglobin (g/dL) 10.9 ± 1.2 11.1 ± 0.9  11.3 ± 0.8 11.4 ± 0.8 
       Anemia (%) 22.2 8.1 0.0 9.5 
   Serum ferritin (µg/L) 14.8 ± 7.5 22.4 ± 17.8 24.3 ± 16.6  28.4 ± 25.5 
        < 12 (%) 30.0 31.7  17.9 20.8 
   Serum sTfR (mg/L) 5.6 ± 2.5 5.1 ± 3.6 5.2 ± 6.8 4.9 ± 2.2 
        > 8.5 (%) 10.0 6.1 3.6 12.5 
   Total body Fe (mg/kg) 1.5 ± 4.4 3.3 ± 3.7 4.3 ± 3.5 3.7 ± 5.0 
        < 0 (%) 20.0 14.6 10.7 20.8 
   Serum Fe (µg/dL) 94 ± 49a,b 127 ± 87a 97 ± 40a,b 77 ± 32b  
   Serum EPO (mIU/mL) 38.3 ± 34.9 31.7 ± 20.7 30.7 ± 12.0 36.7 ± 24.0  
   Serum hepcidin (µg/L) 18.7 ± 24.6 27.3 ± 25.1 35.6 ± 32.1 29.8 ± 19.3 
        < 5 (%) 10.0 6.2 3.7 0  
   C-reactive protein (µg/L) 2.0 ± 1.1a 4.2 ± 4.4a 10.7 ± 8.7b 9.0 ± 5.3b 
       > 5 (%) 0.0 27.9 66.7 70.0 
   Serum leptin (µg/L) 17.9 ± 8.2a,b 20.3 ± 12.7a 34.4 ± 18.6b  54.9 ± 24.1c  
   Serum IL-6 (µg/L) 1.2 ± 1.2 3.3 ± 8.9 5.1 ± 10.3 7.0 ± 22.0 
   Serum estradiol (pg/mL) 3255 ± 1743 3199 ± 1775 3273 ± 1866  2504 ± 1020 
Delivery     
   Sample size (n) 14 109 43 41 
   Hemoglobin (g/dL) 10.9 ± 1.0  11.6 ± 1.5  11.4 ± 1.3 11.5 ± 1.4 
        Anemia (%) 21.4 20.6 14.6 17.1 
   Serum ferritin (µg/L) 37.6 ± 69.8 30.7 ± 30.2 26.8 ± 30.9 29.9 ± 18.6  
       < 12 (%) 28.6 20.6 25.6 17.1 
   Serum sTfR (mg/L) 6.7 ± 3.6 5.6 ± 2.9 5.1 ± 2.2 5.7 ± 4.4 
       > 8.5 (%) 21.4 12.8 9.3 19.5 
   Total body Fe (mg/kg) 2.6 ± 5.4 3.9 ± 4.1 3.6 ± 3.5 4.4 ± 3.9 
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Table 5.2. (Continued)     
       < 0 (%) 28.6 15.0 14.0 9.8 
   Serum Fe (µg/dL) 88.9 ± 43.4 135.3 ± 149.0 104.4 ± 67.7 107.8 ± 67.7 
   Serum EPO (mIU/mL) 39.8 ± 44.9 33.0 ± 24.7 36.3 ± 31.1 28.8 ± 23.9 
   Serum hepcidin (µg/L) 21.5 ± 18.4 38.5 ± 42.0 42.0 ± 41.6 44.5 ± 33.3 
       < 5 (%) 7.7 13.9 4.7 5.0 
   Serum leptin (µg/L) 23.4 ± 13.9a 29.0 ± 18.6a,b 41.6 ± 23.0b 57.8 ± 23.7b 
   Serum IL-6 (µg/L) 5.4 ± 5.2 10.4 ± 19.5 10.4 ± 14.3 5.8 ± 8.8 
   Serum estradiol (pg/mL) 4713 ± 2162 5688 ± 3086 6895 ± 2881 5446 ± 2376  
Neonatal     
   Sample size (n) 14 101 40 36 
   Hemoglobin (g/dL) 13.4 ± 2.4 14.0 ± 2.8 14.0 ± 2.3  15.5 ± 2.4 
        Anemia (%) 45.5 27.4 18.5 9.5 
   Serum ferritin (µg/L) 198.2 ± 179.0 147.4 ± 94.7 133.3 ± 105.9 144.6 ± 95.5 
       < 76 (%) 21.4 19.2 40.0 25.0 
   Serum sTfR (mg/L) 6.9 ± 2.6 7.9 ± 2.9 9.0 ± 4.2 8.7 ± 4.7  
   Body Fe content (mg)  156.0 ± 34.5a,b 160.2 ± 31.2a 174.8 ± 28.8a,b 184.0 ± 26.6b 
   Serum Fe (µg/dL) 252.2 ± 95.5 221.9 ± 110.0 193.1 ± 60.2 207.0 ± 60.0 
   Serum EPO (mIU/mL) 42.6 ± 35.7 41.0 ± 42.8 194.0 ± 862.1 54.1 ± 55.3 
   Serum hepcidin (µg/L) 73.9 ± 48.5  121.5 ± 84.2 144.9 ± 121.2  123.0 ± 76.4  
  1 Values are mean ± SD, or %; Means in rows with different letters are significantly different 
 
There was no difference in the prevalence of anemia and ID between ppBMI or GWG 
groups. Further dividing obesity categories into Class 1 (ppBMI: 30-35) and Class 2 or above 
(ppBMI ≥ 35) revealed that serum hepcidin at mid-gestation in adolescents with Class 2 and 3 
obesity was 1.5-times higher than the normal weight group (39.6 vs. 27.3 µg/L, p=0.1). Similar 
to hepcidin, SF at mid-gestation was significantly elevated in teens with ppBMI ≥ 35 compared 
with the normal weight teens (46.0 vs. 22.4 µg/L, p=0.02). 
Possible relationships were explored with ppBMI and weight gain as continuous traits in 
relation to Fe status and hepcidin across gestation. There was a weak positive correlation 
between ppBMI and serum hepcidin at mid-gestation (r=0.17, p=0.04; Figure 5.1) but this 
relationship lost significance after controlling for maternal age, race, gestational age at mid-
gestation, weight gain at mid-gestation, and dietary Fe intake (Table 5.3). Serum hepcidin at 
delivery was significantly correlated with ppBMI (r=0.19, p=0.006; Figure 5.1) and ppBMI 
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remained a significant predictor of maternal hepcidin at delivery after adjusting for age, race, 
gestational age at delivery, delivery mode, and dietary Fe intake (Table 5.3). Serum Fe at mid-
gestation was inversely associated with ppBMI both in bivariate analysis (r= -0.21, p=0.02) and 
in the adjusted model (Table 5.3). No relationship was evident between weight gain and 
maternal Fe status except for a trend for a positive correlation between GWG and serum EPO at 
delivery (r=0.12, p=0.08).  
 
 
Figure 5.1. Correlations between ppBMI and serum IL-6 with hepcidin. ppBMI was 
positively associated with A) serum hepcidin at mid-gestation; and B) serum hepcidin at 
delivery. C) Serum IL-6 was insignificantly correlated with hepcidin at mid-gestation but 
was significantly correlated with hepcidin at delivery (D). 
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Table 5.3. Significant effects of pre-pregnancy BMI and weight gain on maternal Fe 
status indicators 
Variables β 95% CI P-value R2 model 
Mid-gestation serum Fe1 (n=123) 0.09 
Pre-pregnancy BMI (kg/m2) -0.026 -0.05,-0.007 0.009  
Weight gain at mid-gestation (kg) -0.005 -0.02,0.01 0.58  
Mid-gestation hepcidin1 (n=141) 0.07 
Pre-pregnancy BMI (kg/m2) 0.026 -0.0004, 0.05 0.054  
Weight gain at mid-gestation (kg) -0.010 -0.04, 0.02 0.49  
Delivery serum hepcidin2 (n=191) 0.06 
Pre-pregnancy BMI (kg/m2) 0.035 0.005, 0.06 0.024  
Total gestational weight gain (kg) 0.0096 -0.01, 0.03 0.38  
1 Adjusted for maternal age, race, gestational age at mid-gestation, and dietary Fe 
intake during pregnancy 
2 Adjusted for maternal age, race, gestational age at delivery, dietary Fe intake during 
pregnancy, and delivery mode 
 
Relationships between hepcidin and IL-6, leptin, and estradiol across gestation  
To explore a possible mediating role of inflammation and estrogen in the relationship 
between ppBMI and hepcidin, we analyzed the relationships between serum IL-6, leptin, and 
estradiol with hepcidin across pregnancy. At mid-gestation, there was a trend for a positive 
correlation between IL-6 and hepcidin (r=0.15, p=0.08; Figure 5.1). Leptin was not associated 
with hepcidin (p=0.9). Serum estradiol was insignificantly inversely correlated with hepcidin (r= 
-0.16, p=0.06). At delivery, neither serum leptin nor estradiol was related to hepcidin. Serum IL-
6 was positively correlated with hepcidin (r=0.27, p=0.0001; Figure 5.1). Excluding subjects 
with undetectable hepcidin at delivery further strengthened the correlation between hepcidin and 
IL-6 (r=0.37, p<0.0001). Serum IL-6 remained a significant predictor of hepcidin in multivariate 
analysis controlling for age, race, gestational age at delivery, and delivery mode (β=0.23, 
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p=0.0001, r2 =0.09). A model that included SF, EPO, and IL-6 at delivery explained 22% of the 
variation in hepcidin at delivery. 
Relations between ppBMI and GWG with neonatal hepcidin and Fe status 
Neonatal Fe status indicators in each maternal ppBMI category are presented in Table 
5.2. Anemia was evident in 24% of the newborns at birth and 25% of the neonates had SF < 76 
µg/L, a cutoff that was previously associated with poor psychomotor performance at 5 years of 
age (34). Infants born to obese mothers had greater body Fe content than those born to normal 
weight mothers (184.0 vs. 160.2 mg, p=0.01). Neonates born to adolescents in higher ppBMI 
categories had higher cord Hb (p for trend=0.03). None of the other neonatal Fe status indicators 
including hepcidin differed among maternal ppBMI groups. With the exception of body Fe 
content, none of the neonatal Fe status indicators showed significance differences between teens 
who gained excess weight compared to those who gained within the normal range.  
Table 5.4. Associations between neonatal Fe status indicators and maternal ppBMI and GWG 
 ppBMI (kg/m2)  GWG (kg) 
Neonatal Fe status1 β 95% CI P  β 95% CI P 
Hb (g/dL) 0.10 0.01, 0.19 0.028  -0.0030 -0.07, 0.06 0.93 
SF (µg/L) -0.011 -0.03, 0.01 0.33  0.0026 -0.01, 0.02 0.76 
Serum sTfR (mg/L) 0.0092 -0.0005, 0.02 0.064  0.0016 -0.006, 0.009 0.67 
Body Fe content (mg) 0.76 -0.05, 1.6 0.065  -0.019 -0.6, 0.6 0.95 
Serum hepcidin (µg/L) 0.036 -0.07, 0.14 0.51  -0.073 -0.15, 0.006 0.070 
Serum Fe (µg/dL) -0.0045 -0.02, 0.010 0.54  -0.0021 -0.01, 0.009 0.70 
Serum EPO (mIU/mL) -0.0024 -0.02, 0.03 0.86  0.0048 -0.01, 0.02 0.61 
1 Adjusted for infant sex, birth weight, and gestational age at delivery 
Multivariate regression was used to assess the influence of ppBMI and GWG on neonatal 
Fe status controlling for infant weight, sex, and gestational age at birth (Table 5.4). Neither 
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ppBMI nor GWG were significantly associated with cord SF, sTfR, serum Fe, EPO, body Fe 
content, or hepcidin. Higher GWG tended to be associated with lower cord hepcidin (β= -0.073, 
p=0.07). Similar to the finding in categorical analysis, ppBMI was a positive predictor of cord 
Hb (β=0.10, p=0.03).  
 
Discussion 
To our knowledge, this is the first study to examine the impact of both maternal ppBMI 
and GWG on hepcidin and inflammatory markers in the mother and her neonate in a large cohort 
of pregnant adolescents across gestation. Concurrent assessment of IL-6, leptin, and estradiol 
provided a unique opportunity to explore possible mediating factors in the relationship between 
obesity and Fe status. We report for the first time different relationships between weight, IL-6, 
and hepcidin at mid-gestation compared to those at delivery. Maternal obesity was associated 
with elevated serum IL-6 but not hepcidin at mid-gestation. Serum IL-6 at delivery was on 
average 2.2-times higher than mid-gestation (9.1 vs. 4.1 µg/L, p<0.0001) and was positively 
correlated with serum hepcidin at delivery. With the exception of serum Fe at mid-gestation, 
maternal obesity and excessive GWG did not negatively impact maternal Fe status during 
pregnancy. None of the neonatal Fe status indicators were adversely impacted by maternal 
obesity and excessive GWG and higher ppBMI was associated with higher cord Hb. SF is the 
most significant determinant of maternal hepcidin both at mid-gestation and delivery. 
Collectively, our results suggest that adiposity-associated inflammation does not override the 
impact of low Fe status in the regulation of hepcidin production during pregnancy and there is 
little evidence for a detrimental effect of maternal obesity and excessive weight gain on Fe status 
in the offspring at birth. 
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Studies in non-pregnant women (n=40) (12) and pregnant adults (n=29) (4) demonstrated 
a 9- and 2-times greater serum hepcidin, respectively, in the obese than normal weight group. In 
our study, serum hepcidin in obese pregnant adolescents was not significantly elevated compared 
with the normal weight group. This discrepancy may reflect differences in degree of adiposity of 
the different study populations. Average BMIs of the obese participants in previous studies were 
above the cutoff for class 2 obesity (BMI ≥ 35) while the majority of obese teens in our study 
had Class 1 obesity. When the obese group in our study was further stratified into different 
classes of obesity, we observed a 50% increase in hepcidin in adolescents with Class 2 and above 
obesity compared with the lean group. Although the difference in hepcidin between the two 
groups did not reach statistical significance, possibly due to small number of teens in the extreme 
obese category, our data are consistent with previous studies that showed higher hepcidin in 
obese individuals with extremely high BMI and support the notion that a certain level of 
adiposity may be necessary to elicit a significant elevation in hepcidin (35, 36). The increase in 
hepcidin in the high BMI group did not appear to be mediated by IL-6 or leptin, as neither was 
associated with hepcidin at mid-gestation and IL-6 was not elevated compared with the normal 
weight adolescents. Interestingly, the most obese adolescents also had the lowest estradiol levels, 
which may have contributed to higher hepcidin in the extreme obese group. This, and the trend 
for an inverse correlation between serum estradiol and hepcidin at mid-gestation, supports the 
cell culture and animal data demonstrating a suppressive effect of estrogen on hepcidin 
transcription (8). It is possible that other hepcidin regulators, such as bone morphogenetic protein 
6 (37), IL-22 (38), and activin B (39), also contributed to the hepcidin increase in adolescents 
with a high degree of obesity. The significance of these potential hepcidin modulators in severely 
obese populations warrants further investigation. 
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A negative association between ppBMI and serum Fe was evident at mid-gestation, 
which is consistent with data in women and female adolescents (40-43). The link between low 
serum Fe and adiposity is often attributed to inflammation-induced increases in hepcidin, but the 
lack of association between hepcidin and serum Fe in our study and others (44-46) does not 
support this explanation. An alternative explanation for obesity-associated hypoferremia has 
been proposed (40, 42) and involves lipocalin-2, an Fe binding protein that is highly expressed in 
adipose tissue (47, 48). Adipose lipocalin-2 increases in obesity (49), and thus may lead to Fe 
sequestration in adipose tissue. Future studies are needed to test this hypothetical role of 
lipocalin-2 and examine lipocalin-2 expression in relation to serum Fe.  
We assessed a potential mediating role of inflammation in the link between weight and 
hepcidin by measuring both IL-6 and leptin, cytokines that have been shown to stimulate 
hepcidin transcription in vitro (5, 7). Consistent with increased inflammation in the obese state 
(50, 51), concentrations of IL-6, leptin, and CRP at mid-gestation were significantly elevated in 
the obese adolescents compared with the lean group. Contrary to the in vitro data, neither IL-6 
nor leptin were correlated with hepcidin at mid-gestation. A positive correlation between IL-6 
and hepcidin has been reported in patients with Hodgkin’s lymphoma (52), end-stage renal 
disease (53), and sepsis (54), but not in healthy pre-menopausal women (12) or pregnant women 
(4, 46). A potent immune-modulatory cytokine, IL-6 is elevated in many diseases and 
inflammatory conditions (55). The absence of a positive relationship between serum IL-6 and 
hepcidin in individuals without severe inflammation may suggest that a threshold level of IL-6 
must be reached to significantly impact hepcidin production. Due to the narrow range of IL-6 
concentrations evident in our population, we were not powered to determine such a threshold. 
Nevertheless, the positive correlation between IL-6 and hepcidin at term when IL-6 was 2.2 
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times-higher than its mid-gestation level, does support a threshold effect of IL-6. Unlike IL-6, 
maternal serum leptin remained unrelated to serum hepcidin at term, which argues against a 
major role of leptin in modulating hepcidin production during pregnancy. More studies are 
needed to examine the impact of inflammatory stimuli on hepcidin in populations with varying 
degrees of inflammation.  
There was no evidence for a negative impact of maternal ppBMI and GWG on neonatal 
Fe status. Consistent with previous findings in adult pregnant women (13), neonates born to 
obese adolescents had higher cord Hb and total body Fe than those born to normal weight 
mothers. This observation may reflect greater birth weight and higher red blood cell mass in 
infants born to mothers with high ppBMI. Similar to the findings in non-diabetic pregnant 
women (13), there was no significant relationship between maternal BMI and cord SF in 
pregnant adolescents. It is unclear why we, and others (13), did not observe an inverse 
relationship between maternal BMI and cord serum Fe as reported previously in 13 healthy 
pregnant women (4). More studies that undertake a comprehensive assessment of maternal and 
neonatal Fe status are needed to clarify the impact of maternal weight on neonatal Fe status in 
pregnant populations. 
In this large cohort of healthy pregnant adolescents, maternal obesity and GWG had a 
limited impact on maternal and neonatal Fe status. Maternal IL-6 increased from mid-gestation 
to delivery and was positively associated hepcidin at delivery but not at mid-gestation. Maternal 
IL-6 had no impact on neonatal hepcidin. Our results suggest that low-grade inflammation during 
pregnancy does not override the suppressive effect of Fe depletion on hepcidin, supporting the 
notion that hepcidin expression is driven by the strength of each individual regulator under 
conditions of opposing stimuli. 
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CHAPTER 6 
CONCLUSIONS 
This doctoral research examined the novel hypothesis that heme Fe is a quantitatively 
important Fe source during pregnancy. Findings from this study have provided new insight into 
mechanisms by which heme and non-heme Fe are transported across the duodenum and the 
placenta, the two gateway tissues for Fe delivery to the mother and her fetus during pregnancy. 
Novel experimental approaches were used to investigate various aspects of Fe utilization in 
pregnancy including placental heme Fe transporter expression, intestinal Fe absorption and 
placental Fe transport, the role of hepcidin in regulating cellular Fe transport, as well as the 
impact of maternal obesity and inflammation on Fe homeostasis across pregnancy. To address 
these questions, four research projects were undertaken and discussed in detail in Chapters three 
through six. The major findings from each project are summarized below followed by 
suggestions for future research.  
The first research project was a stable Fe isotope study in rats designed to compare the 
impact of on duodenal absorption of heme and non-heme Fe. The use of animals allowed us to 
explore the cellular mechanisms responsible for reduced duodenal Fe absorption in response to 
hepcidin up-regulation and to further trace the tissue distribution of Fe derived from the two 
different Fe sources that were ingested. As expected, Fe overload significantly elevated liver 
hepcidin expression. Hepcidin more potently down-regulated non-heme absorption than heme Fe 
absorption in rats. In contrast to the classic inhibitory effect of hepcidin on the basolateral Fe 
exporter FPN which has been described in macrophages, hepcidin had no impact of duodenal 
FPN but was negatively associated with the apical Fe transporter DMT1. This observation is 
consistent with emerging literature suggesting that apical Fe uptake, not basolateral Fe export, is 
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the primary target of hepcidin in the duodenum. Another important and novel finding of this 
study was the differential distribution of absorbed heme and non-heme Fe between erythroid and 
Fe storage tissues. A significantly greater proportion of absorbed heme Fe was recovered in the 
spleen compared to that observed for non-heme Fe, suggesting that some heme may be exported 
into the circulation in a distinct non-heme Fe form (i.e. as intact heme Fe). Finally, we showed 
that heme Fe absorption was less efficient than non-heme Fe absorption in rats, while the reserve 
is true in humans. This raises important questions regarding the choice of appropriate animal 
models for characterization of heme Fe absorption. Although rat studies offer important insights 
on the mechanistic aspects of heme Fe absorption, species differences must be considered when 
making inferences from these observations to human Fe physiology.  
In the second project, we generated novel data on placental expression of two cellular 
heme transporters, the heme-Hx receptor LRP1 and the heme/folate transporter PCFT, in relation 
to maternal and neonatal Fe status. It is believed that the placenta relies primarily on the uptake 
of non-heme Fe from the maternal circulation to meet placental and fetal Fe demands. However, 
the abundant expression of several recently identified cellular heme transporters in the human 
placenta suggests that the placenta may be able to utilize heme Fe sources. In pregnant 
adolescents at risk for ID, we observed an inverse association between placental LRP1 
expression and cord hepcidin, which may reflect a compensatory up-regulation of placental 
LRP1 when fetal Fe demands are high. While correlations do not imply causality, this 
observation is consistent with a role of LRP1 in placental Fe transport. In support of this 
speculation, LRP1 was found to be positively associated with expression of the heme exporter 
FLVCR1 in the placenta, which may suggest a coordination of placental heme Fe transport. In 
the second study under this aim, we assessed placental expression of PCFT, the major intestinal 
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folate transporter that is known to have a low affinity for heme in the enterocyte, in relation to 
maternal and neonatal folate and Fe status and to explore its relationships to the two established 
placental folate transporters, FRα and RFC, in the same pregnant adolescent cohort. Unlike FRα 
and RFC, which were strongly correlated with cord folate concentrations, PCFT in the placenta 
was not related to cord serum folate, which is consistent with its undetectable folate transport 
activity at neutral pH in vitro. Together these findings argue against a major role of PCFT in 
placental folate delivery to the fetus. In addition, we found a positive association between PCFT 
and cord Fe status. These data may suggest a greater involvement of PCFT in placental heme Fe 
utilization compared with folate transport. These unique findings regarding placental LRP1 and 
PCFT provide initial evidence for a possible role of these transporters in placental Fe transport. 
Further mechanistic studies are needed to elucidate the exact functions of these transporters in 
placental heme utilization and to delineate the molecular mechanisms involved in the apical 
uptake, intracellular trafficking, and catabolic degradation of heme in the placenta. Studies are 
underway in our lab to assess all known heme and non-heme Fe transporters in the human 
placenta to identify the best predictors of cord Fe status and to examine the relative difference in 
heme and non-heme transporters in relation to maternal and neonatal Fe status and hepcidin 
concentrations.  
The third research project utilized stable Fe isotope techniques to intrinsically label 
maternal Hb early in gestation and assess the relative contribution of the maternal RBC pool to 
neonatal RBC enrichment at birth. Determinants on endogenous Fe transfer to the fetus were 
compared and contrasted to transfer of dietary non-heme Fe to the fetus using a second stable Fe 
isotope administered late in the third trimester of pregnancy. This study tested the hypothesis that 
maternal Fe in the circulating RBC pool is a major source of fetal Fe and examined the 
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determinants of placental transfer of these two Fe sources. Findings from this study will provide 
valuable insight on the role of the maternal RBC Fe mass early in gestation and its ability to 
provide Fe in support of fetal Fe demands.  
My final research project was a secondary data analysis that examined possible 
relationships between maternal obesity and inflammation with maternal and neonatal Fe status in 
a cohort of 230 pregnant adolescents with a high prevalence of obesity and excessive gestational 
weight gain. Many epidemiological studies in non-pregnant populations have observed an 
association between obesity and ID and this association is thought to be mediated in part by 
inflammation-induced increases in hepcidin which inhibits Fe absorption and Fe mobilization 
from Fe stores. It is unclear whether a similar relationship between obesity and Fe status occurs 
during pregnancy and if maternal inflammation affects hepcidin and Fe homeostasis in the 
mother and her neonate at birth. In the 230 healthy pregnant adolescents studied, pre-pregnancy 
obesity and excessive gestational weight gain did not negatively impact neonatal Fe status. In 
contrast, maternal obesity was associated with a significantly higher neonatal Hb concentration 
at birth. Contrary to the potent stimulatory effect of the pro-inflammatory cytokine IL-6 on 
hepcidin observed in vitro, maternal IL-6 was not related to hepcidin during pregnancy but this 
association became evident at delivery likely due to delivery mediated changes in inflammation. 
Our data provide little evidence for a detrimental effect of maternal Class 1 and 2 obesity or 
excessive gestational weight gain on Fe status in the offspring at birth and suggest that the low-
grade inflammation observed during pregnancy in this age group did not override the impact of 
low Fe stores on the regulation of maternal hepcidin. The differential relationships between IL-6 
and hepcidin during pregnancy and at delivery are consistent with the growing literature 
indicating a threshold effect of IL-6 on hepcidin. More studies are needed to examine the impact 
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of inflammatory cytokines on hepcidin in populations with varying degrees of inflammation and 
ID/Fe sufficiency.  
Fe homeostasis during pregnancy is maintained through the coordinated regulation of 
different organ systems to ensure adequate Fe supply for both the mother and her fetus. This 
doctoral research addressed various important aspects of this complex system as illustrated in 
Figure 6.1. that include: 1) duodenal absorption of dietary heme and non-heme Fe and the role 
of hepcidin in regulating Fe absorption, 2) placental heme Fe transporters and their relationships 
to neonatal Fe status, 3) placental transfer of maternal Fe derived endogenously from Hb stores 
and exogenously from dietary Fe intake, and 4) the impact of maternal obesity and inflammation 
on maternal and neonatal hepcidin and Fe status.  
 
Figure 6.1. Schematic of heme and non-heme Fe flux among different organ systems during 
pregnancy with the placement of the four specific aims of this research. Solid black lines 
represent non-heme Fe flux and the dotted black lines represent heme Fe flux. The white 
arrows represent hypotheses tested in this research. The directionality of significant 
relationships are indicated by “+” and “–” signs. Arrows crossed with a black line indicate 
null relationships. 
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Results from this research underscore the need for additional mechanistic research to: 1) 
elucidate the molecular mechanisms responsible for the differential effect of hepcidin on heme 
and non-heme Fe absorption, 2) characterize heme transport activity and cellular locations of the 
heme Fe transporters in the placenta and identify heme Fe sources in the maternal circulation that 
are available for placental uptake, 3) investigate the magnitude of intravascular RBC destruction 
during pregnancy and examine the extent to which placental macrophages participate in RBC 
catabolism and Hb recycling, and 4) identify additional factors affecting hepcidin production 
during pregnancy as serum ferritin and inflammation together only account for 20% of the 
variation in maternal hepcidin at delivery. Polymorphisms in genes involved in Fe homeostasis 
such as HFE may be major contributors to the large variability in hepcidin and Fe status among 
individuals. Similar to Fe status and hepcidin, Fe absorption also vary greatly among individuals 
and hepcidin and Fe stores only capture 30% of the variation in Fe absorption. To explore 
possible genetic determinants of Fe status and Fe absorption, I participated in a collaborative 
project in Dr. Zhenglong Gu’s laboratory that explored the possible impact of HFE 
polymorphisms on Fe status and Fe absorption. Dr. Gu’s group has previously identified a HFE 
haplotype that appeared to be under positive selection in East Asia and the subsequent isotope 
study in young Asian females found greater Fe absorption in the homozygous carriers of this 
haplotype compared to individuals of the control genotype with similar Fe status, supporting a 
role of genetic variation in determining Fe absorption and implicating natural selection of 
efficient Fe utilization as a driving force of these genetic changes. It is also highly likely that 
gene-gene and gene-nutrient interactions also play a role in regulation of hepcidin production 
and Fe status. The rapid progress in the understanding of how hepcidin orchestrates whole body 
Fe metabolism and how hepcidin levels can be altered by peptide-based agonists and antagonists 
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promises new hepcidin-targeted therapies for common Fe disorders including Fe-restricted 
anemia in inflammatory diseases and the Fe overload seen in diseases such as hemochromatosis 
and beta-thalassemia. In addition to systemic Fe homeostasis and transport, emerging data have 
brought attention to intracellular Fe metabolism and suggested a central role of the 
mitochondrion in modulating cellular Fe uptake and intracellular Fe trafficking in response to Fe 
demands of other organelles. Impaired mitochondrial Fe homeostasis has been implicated in the 
pathophysiology of neurodegenerative diseases, cardiomyopathy, and RBC disorders, which 
strongly supports the mitochondrial-origin-of-disease hypothesis and opens the possibility of 
new treatment targets. Knowledge on mitochondrial Fe-processing pathways and the 
communication between intracellular organelles will add a new dimension to the understanding 
of Fe metabolism and revolutionize the investigation of Fe-related diseases.  
From a public health perspective, this research supports the Dietary Guidelines for 
Americans 2010 recommendation for pregnant women to include more heme Fe sources in their 
diet as heme Fe absorption is less impacted by Fe status and hepcidin. More studies are needed to 
evaluate the effectiveness, cost, and possible side-effects of heme-based Fe supplementation in 
pregnancy. In addition, we revealed the previously unappreciated role of maternal RBC mass as 
an Fe source for the fetus and emphasizes the need to establish an adequate RBC mass prior to 
pregnancy in support of an adequate fetal Fe endowment at birth. 
 
